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7General introduction
Adapted from 
Jihan Harki, Eric T.T.L. Tjwa and Désirée van Noord, Functional 
testing in the diagnosis of chronic mesenteric ischemia, Mesenteric 
Vascular Disease: Current Therapy. New York, Springer, 2015:63-77
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Chronic gastrointestinal ischemia
Chronic gastrointestinal ischemia (CGI) results from insufficient 
blood supply to the stomach, small intestine and colon. In most 
cases this is caused by stenosis of the supplying arteries with lack 
of sufficient collateral circulation. Most often the stenosis is due to 
atherosclerosis 1, but other non-occlusive causes are also known 2,3. 
Three direct branches of the abdominal aorta are responsible for 
the arterial blood supply of the gastrointestinal tract: the celiac 
artery (CA), the superior mesenteric artery (SMA) and the inferior 
mesenteric artery (IMA). 
CGI is a diagnostic challenge. Currently, there is no single 
test with high sensitivity and specificity to diagnose or exclude this 
condition. Chronic abdominal pain is a common symptom in the 
population, as are stenoses of the mesenteric arteries. Development 
of mucosal perfusion assessment techniques may be of additional 
diagnostic value in identifying and grading the severity of mesen-
teric ischemia. These functional tests may help to select patients 
who will benefit from treatment by revascularization. Until recently 
it was thought that CGI could only occur in the presence of mini-
mal two occluded mesenteric arteries, but studies on diagnostic 
strategies including functional tests have shown that a significant 
stenosis of a single artery with insufficient collateral circulation can 
also lead to clinically relevant mesenteric ischemia 4,5. 
Therefore, a diagnostic approach combining assessment of 
clinical symptoms, radiological imaging of the mesenteric arter-
ies and functional testing is recommended in the work-up of CGI 
suspected patients 6. 
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Diagnosis of CGI
The current established approach for diagnosing CGI is based on 
three main components. The first includes assessment of medical 
history, clinical symptoms and physical examination. The second 
component concerns radiological imaging of the mesenteric arter-
ies and the third aims at detection of mucosal ischemia by means of 
a functional test 6,7. All patients and procedures will be discussed in 
a dedicated multidisciplinary team consisting of a vascular surgeon, 
intervention radiologist and gastroenterologist, all specialized in 
CGI, leading to a final expert-based consensus diagnosis 6,8,9.
The diagnosis CGI is made if patient fulfils 2 of the 3 following 
criteria 9:
1 Distinctive clinical presentation including presence of post-
prandial pain and otherwise unexplained weight loss of >5% of the 
normal body weight.
2 Significant stenosis of >70% of at least one of the mesenteric 
arteries demonstrated by radiological evaluation.
3 Mucosal ischemia detected by tonometry or visible light 
spectroscopy (VLS). 
A definitive diagnosis of CGI is made after persistent relief 
of symptoms on follow-up after treatment. This is not the ideal 
gold standard, however it is currently the most reliable way to 
establish CGI. 
Visible light spectroscopy
Background
Functional tests such as gastric exercise tonometry (GET) and 
24-hour tonometry are both accurate for the detection of CGI 1,4,10,11. 
Unfortunately, the wider use of tonometry is hampered by its 
cumbersome and invasive nature, therefore the need for a better, 
more patient-friendly test remained. This led to the development of 
VLS. VLS, also known as reflectance spectrophotometry, enables 
direct measurement of the adequacy of mucosal perfusion 12. It is 
a relatively new technique that non-invasively measures capillary 
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hemoglobin oxygen saturation using white light delivered by a 
fiberoptic probe during endoscopy. The marked difference in the 
absorption spectra of oxygenated and deoxygenated hemoglobin 
makes direct measurement of the percent saturation of the mucosal 
hemoglobin possible. Using real-time signaling, artifacts as those 
caused by scattering can also be eliminated 12. Connected to a 
device, continuous display of the mucosal oxygen saturation on a 
screen is possible 9,12. 
VLS has been used for evaluation of intensive care patients, 
assessment of anastomotic strength in esophageal and colorectal 
anastomoses and to determine microvascular perfusion during 
reconstructive surgery 13-15. It can also increase endoscopic detec-
tion of mesenteric tumors 16.
Furthermore, VLS appears to be of great value as a new and 
less invasive diagnostic tool in patients suspected of CGI 9. Since the 
measured oxygen saturation measurements reflect the adequacy of 
mucosal perfusion, events that decrease the delivery of oxygen to 
the mesenteric mucosa (i.e. mesenteric artery stenosis) will result 
in lower mucosal hemoglobin oxygen saturations 9. VLS can easily 
be incorporated in diagnostic strategies as endoscopy is often 
performed early in the diagnostic work-up of these patients with 
abdominal pain.
Procedure
VLS is performed during upper endoscopy under conscious 
sedation 9,12. Patients are not allowed to drink or eat before the 
procedure. Butylscopalamin is admitted intravenously before the 
start of VLS measurements in order to prevent luminal spasms and 
optimize the readings. Peripheral oxygen saturation and heart rate 
are continuously monitored and to minimize the effect of confound-
ing factors of concomitant cardiopulmonary diseases peripheral 
saturation should be above 94%. If necessary, oxygen (FiO2 21%) 
can be administered. 
The VLS measurements are performed using a fiberoptic 
catheter-based oximeter that can be passed through the endoscope. 
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After irrigation of the target area to remove bile remnants, point-
measurements of the oxygen saturation are performed at three 
locations: antrum of the stomach, duodenal bulb and descending 
duodenum. The probe is positioned approximately 1-5 mm above 
the mucosa  1. Once a stable reading is obtained with less than 
5% variation in read-out as seen on the display, the actual measure-
ment can be performed. Three repeated readings will be taken of 
each location. The average of the three readings per location will be 
regarded as the most accurate reflection of mucosal oxygen satura-
tion of that specific location. 
Based on the cut-off values determined in a large cohort 
study in CGI suspected patients, measurements are positive for 
ischemia when the measured saturation is:
∙  < 63% in the antrum and/or, 
∙  < 62% in the duodenal bulb and/or,
∙  < 58% in the descending duodenum 9.
 1 Mucosal oxygen saturation using VLS. The probe is placed  
  1-5mm directly above the mucosa of the stomach and  
  duodenum
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Diagnostic value of VLS 
VLS is a validated diagnostic method to correctly detect CGI with a 
sensitivity and specificity of 90% and 60% respectively 9. The high 
sensitivity and low specificity are the consequence of the estab-
lished cut-off values for each of the specific sites of the mesenteric 
tract as calculated by van Noord et al 9. These cut-off values were 
based on a trainee data set of patients diagnosed with CGI using 
mesenteric tonometry and were additionally validated in a confir-
mation cohort. 
With these cut-off values, the ability to distinguish patients 
with CGI from those without is the highest and no patients with CGI 
were missed, as earlier studies have shown that undiagnosed and 
untreated patients with ischemia have higher morbidity and mortal-
ity rates 1,7. However, the higher sensitivity is at the expense of the 
specificity resulting in higher rate of false-negatives.
After successful intervention, improved VLS measurements 
can be observed in patients with CGI 9. Among the patients with re-
lief of symptoms one year after intervention, 80% showed improved 
or even normalization of the oxygen saturation measurements by 
VLS measurements. At the same time, in all patients with persis-
tent symptoms after intervention no improvement in the oxygen 
saturation measurements was observed 9. Furthermore, selection 
for treatment based on standardized diagnostic work-up including 
radiological imaging and oxygen saturation measurements by VLS 
accommodates for a sustained response in 70% of the patients with 
the clinical suspicion of CGI 17.
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Chronic gastrointestinal ischemia and 
liver injury
Hypoxic liver injury in an acute setting of cardiac, circulatory or 
respiratory failure, also known as hypoxic or ischemic hepatitis, 
is caused by insufficient oxygen uptake by hepatocytes and is 
usually defined as a sharp increase in serum aminotransferases 
(ALT) up to 20 times the upper limit of normal due to centrilobular 
hepatocyte necrosis in the absence of other potential causes of 
hepatitis 18. It occurs in up to 20% of critically ill patients with low 
cardiac output and has a high 30-day mortality rate of 50% 19. It is 
unknown whether hypoxic liver injury only pertains to the acute or 
also to the chronic setting. Chronically compromised mesenteric 
arterial flow is hallmark of CGI 6. The main cause of CGI is significant 
stenosis (≥70%) at the level of the origin of the mesenteric vascula-
ture (CA and/or SMA) due to atherosclerosis, but also non-occlusive 
mesenteric ischemia (NOMI) due to cardiac forward failure may 
be observed. It is not known to what degree liver injury occurs in 
patients with CGI.
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Chronic gastrointestinal ischemia and portal 
vein thrombosis 
Portal vein thrombosis (PVT) is a infrequent vascular disorder 
caused by deposition of blood clot in the extra-hepatic portal 
vein. Etiological factors include systemic and local prothrombotic 
factors such as portal vein stasis in the presence of liver cirrhosis. 
PVT can be classified as either acute or chronic, depending on the 
presence of a portal cavernoma 20,21. A feared complication of PVT 
is gastrointestinal ischemia. Gastrointestinal ischemia can result 
in intestinal infarction, a life-threatening complication that often 
requires immediate surgical intervention 22. Treatment of acute PVT 
therefore aims at vascular recanalization, preventing the occurrence 
of gastrointestinal ischemia and portal hypertension 20. The actual 
prevalence of gastrointestinal ischemia in patients with PVT is 
unknown. Studies, mainly conducted in patients with acute PVT, 
report prevalences of intestinal infarction of 2%-32%, with mortality 
rates of 0%-20% 21,23-27. Regarding patients with chronic PVT, studies 
report conflicting results. As patients with chronic PVT often have 
an extensive venous collateral circulation, it is assumed that gas-
trointestinal ischemia is less likely to occur 22. However, in a large 
prospective study in splanchnic vein thrombosis, 26% of patients 
presented with intestinal infarction. In nearly half of these patients a 
portal cavernoma was detected, suggesting gastrointestinal isch-
emia is also a frequent complication in chronic PVT 24. 
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Vascular diseases and the liver
Portal hypertension is defined as an increase in porto-systemic 
pressure gradient in any portion of the portal venous system. A 
major cause of portal hypertension is liver cirrhosis. A severe 
complication of portal hypertension is gastroesophageal variceal 
bleeding (GEVB). There is a high chance of rebleeding in these 
patients, which is associated with high morbidity and mortality 28,29. 
Therefore, management should be directed at the prevention of 
rebleeding. Currently, the secondary prevention of GEVB is endo-
scopic treatment with variceal ligation (EVL) for esophageal varices 
and N-butyl cyanoacrylate injection for gastric varices, in combina-
tion with β-blocker therapy. When this fails, transjugular intrahe-
patic portosystemic shunt (TIPS) placement is the recommended as 
the second-line therapy 30. Recent studies have shown that TIPS is 
more effective in reducing the risk recurrent variceal bleeding, but 
is associated with a higher risk of hepatic encephalopathy and does 
not improve survival 31,32. 
However, next to clinical effectiveness, it is important to 
evaluate costs in order to fully determine which treatment is more 
superior as a secondary prevention therapy for variceal rebleeding. 
In these times when healthcare is getting increasingly expensive 
and more focus is on economic viability of new treatments, cost 
studies provide insight into the distribution of costs and thus cost 
reducing measures. 
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Aims and outline
The aim of this thesis is to explore various aspects and diagnostic 
methods for the detection of CGI, by means of functional testing us-
ing VLS, a prediction model for CGI, and hypoxia-inducible factor-1α 
(HIF-1α) as a marker for CGI. This is followed by studies of CGI due 
to portal vein thrombosis and CGI induced liver injury. Furthermore, 
treatment of other vascular diseases of the gastrointestinal tract 
such as variceal bleeding, are discussed. 
In the standard work-up for patients suspected of CGI, muco-
sal oxygen saturation measurements using VLS are performed in 
fasting conditions. However, detection of CGI using VLS could be 
optimized using food as provocation. It is known that patients with 
CGI with a 70% to 99% stenosis of the superior mesentery artery 
have significantly lower increase in postprandial peak systolic 
velocity 33. Due to this lack of postprandial increase in the splanchnic 
blood flow, not enough oxygen can be delivered to provide for the 
metabolic demand of the gastrointestinal tract and consequently 
resulting in gastrointestinal mucosal ischemia. Therefore, stimula-
tion with food with a high caloric content will lead to an increased 
metabolic demand of the gastrointestinal tract and subsequently 
require a higher blood flow which cannot be met in patients with 
gastrointestinal ischemia and could result in different, possibly 
lower oxygenation saturation measurements of the gastrointestinal 
tract using VLS. In chapter 2 the predictive value and the diagnostic 
ability of postprandial mucosal saturation measurements using VLS 
is described. Furthermore, several studies have shown that micro-
circulatory alterations are related to hemodynamic changes which 
have been reported to impair intestinal perfusion 34-36. In these 
patients, the sublingual capillary perfusion seems well correlated 
to the hypoxic state of the gastric mucosa 37. In chapter 3 we study 
the association between sublingual microcirculatory alterations, as 
triggered by luminal feeding stimulation, and chronic hemodynamic 
changes such as in patients with CGI. 
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The role of clinical symptoms alone in the diagnosis of CGI is 
limited 10,38. The combination of postprandial pain, weight loss and 
presence of an abdominal bruit is known as the ‘classical’ triad of 
CGI. This is however only present in 16-21% of patients and has 
limited predictive value for diagnosing CGI 10,39,40. In chapter 4 we 
present a prediction model for CGI, based on the combination 
of medical history, symptoms and radiological evaluation of the 
mesenteric arteries. 
Currently, histological examination of biopsy material plays 
no definitive role in the diagnosis of CGI. A histological pathogno-
monic marker for CGI would be of great value as a non-invasive 
diagnostic method. HIF-1α is a significant intracellular regulator of 
oxygen hemostasis and is expressed in cells under low oxygen ten-
sion 41. Expression of HIF-1α in gastric or intestinal tissue may thus 
identify patients with CGI. In chapter 5 we performed a pilot study 
to investigate the expression of HIF-1α in chronic ischemic tissue by 
immunohistochemistry. 
Hypoxic liver injury occurs in up to 20% of critically ill patients 
in an acute setting of cardiac, circulatory or respiratory failure 19. It 
is unknown whether hypoxic liver injury only pertains to the acute 
or also to the chronic setting. In chapter 6 we aimed to determine 
the incidence of hypoxic hepatitis in a well-defined cohort of CGI 
patients. 
Gastrointestinal ischemia is a feared complication of PVT. In 
chapter 7 we describe the clinical presentation and characteristics 
of gastrointestinal ischemia in patients with PVT. 
Gastroesophageal variceal bleeding (GEVB) is a severe 
complication of portal hypertension. There is a high chance of 
rebleeding in these patients, which is associated with severe mor-
bidity and mortality. In chapter 8 we focus on the quality of life and 
cost-effectiveness of treatment with EVL and TIPS in patients with 
GEVB.
Finally, in chapter 9 and chapter 10 the conclusions of this 
thesis and suggestions for further research are discussed. 
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Abstract
Background
Chronic gastrointestinal ischemia (CGI) is 
the result of decreased mucosal perfu-
sion, in most cases due to atherosclerotic 
stenosis of the supplying gastrointestinal 
arteries. Visible light spectroscopy (VLS) 
enables direct measurement of mucosal 
oxygenation saturation during upper 
endoscopy. No data is available on the 
hemodynamic changes using VLS in 
patients with CGI after intake of food. In 
this proof of concept study, we aimed to 
investigate the effect of food administra-
tion on VLS measurements in patients 
with CGI and healthy controls. 
Methods
Consecutive patients with the diagnosis 
of CGI and healthy controls were pro-
spectively included between September 
2014 and August 2015. All patients 
received the standard work-up for CGI, 
consisting of assessment of medical his-
tory and symptoms, radiological imaging 
of the gastrointestinal arteries, and VLS 
measurements. VLS measurements in 
postprandial state were compared to VLS 
measurements in fasting state. 
Results
We performed 168 VLS measurements 
in 12 patients with CGI (median age 63.2 
(IQR 48.8-70.4) years, 67% male) and 16 
controls (32.9 (IQR 27.7-39.8.2) years, 44% 
male). There was no significant increase 
between postprandial and baseline VLS 
measurements in CGI patients (baseline 
antrum median 58.5 (IQR 53.5-59.0) vs 
postprandial antrum median 57.5 (IQR 
54.0-60.8), p=0.25 ; baseline duodenal 
bulb median 53.0 (IQR 48.8-54.0) vs post-
prandial duodenal bulb median 53.5 (IQR 
50.3-56.8), p=0.89; baseline descending 
duodenum median 49.5 (IQR 45.3-52.8) 
vs postprandial descending duodenum 
median 54.0 (IQR 47.3-57.8), p=0.33 , 
respectively). In the healthy controls, 
there was a trend towards higher VLS 
measurements in the postprandial state.
Conclusion
This is the first comparative prospec-
tive study showing the hemodynamic 
changes in patients with CGI and healthy 
controls after stimulation with food using 
VLS. We found no difference in VLS 
measurements before and after caloric 
challenge in patients with CGI, however 
there was a trend in increase in VLS 
measurements in the healthy controls. 
The current results show insufficient 
discrimination between patients with CGI 
and healthy controls.
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Introduction
Chronic gastrointestinal ischemia (CGI) results from insufficient 
blood supply to the gastrointestinal tract, in most cases caused by 
atherosclerotic stenosis of the supplying arteries 1.
The diagnosis of CGI remains a challenging quest. This is 
firstly because the role of clinical symptoms alone in the diagnosis 
of CGI is limited 2,3. Furthermore, there is no single test with high 
sensitivity and specificity to diagnose or exclude this condition. 
Currently, a diagnostic approach combining assessment of clinical 
symptoms, radiological imaging of the gastrointestinal arteries and 
functional testing is recommended in the work-up of patients with 
the clinical suspicion of CGI 1. Functional tests, such as tonometry 
and visible light spectroscopy (VLS), have been reported to be 
reliable tests in establishing gastrointestinal mucosal ischemia 3,9-11. 
VLS enables direct measurement of mucosal haemoglobin oxygen 
saturations during upper endoscopy 4. It is a validated diagnostic 
method and has a sensitivity of 90% for the detection of CGI 5. 
Currently, VLS measurements are performed in a fasting 
state during endoscopy. However, studies have shown that patients 
with CGI may have less increase in splanchnic blood flow after oral 
caloric stimulation compared to healthy subjects leading to mucosal 
ischemia of the gastrointestinal tract. Consequently, this leads to 
the presence of postprandial pain, a typical presenting symptom 
for CGI 3,6-9. Therefore, the hypothesis rises that mucosal ischemia 
only occurs postprandially, in response to an increased metabolic 
demand, or exercise related, indicating a time-dependent relation. 
Consequently, patients with CGI with less impaired mesenteric 
blood flow could thus show low-normal or even normal mucosal 
saturation measurements in this fasting situation and can therefore 
be missed using VLS. 
In this proof of concept study, we aimed to investigate the 
effect of food administration on mucosal oxygenation measured by 
VLS in patients with CGI and healthy controls. Assuming mucosal 
ischemia occurs when metabolic demand exceeds the oxygen 
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supply during postprandial state, we hypothesize that VLS mea-
surements after stimulation with food results in different, possibly 
lower VLS measurements in patients with CGI compared to healthy 
subjects.
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Methods
 
Study population
Patients with the diagnosis of CGI were prospectively and con-
secutively included between September 2014 to August 2015. All 
patients received the recommended work-up of CGI consisting of 
thorough assessment of medical history and clinical symptoms, 
radiological imaging using computed tomography (CT)- angiogra-
phy, or in case of contra-indications magnetic resonance (MR)- angi-
ography, and functional testing by VLS. All patients and assessment 
results were discussed in a multidisciplinary team consisting of 
vascular surgeons, intervention radiologists and gastroenterolo-
gists, all experienced in the management of CGI. This yielded a 
final expert-based consensus diagnosis in each case. The diagnosis 
CGI was established if a patient fulfilled two of the three following 
criteria: (a) distinctive clinical presentation including presence of 
postprandial pain and otherwise unexplained weight loss of >5% of 
the normal body weight, (b) significant stenosis of >50% of at least 
one of the mesenteric arteries, and (c) functional signs of mucosal 
ischemia demonstrated by VLS. In case of one-vessel disease, 
three of the above criteria has to be fulfilled for the diagnosis of 
CGI Mucosal ischemia by VLS was defined as mucosal oxygen 
saturation <58%, <62%, or <63% for measurements in the duode-
num, duodenal bulb and the antrum of the stomach respectively. 
The definitive diagnosis of CGI was made after sustained relief of 
symptoms during follow-up in treated patients. 
Non-smoking healthy subjects with patent gastrointestinal 
arteries as determined by abdominal duplex ultrasound, no gastro-
intestinal complains, and unremarkable medical history were asked 
to participate in our study on voluntary basis. 
Patients with history of gastric (bypass) surgery, cardiac 
arrhythmias or cardiac conduction disease, or who were unable to 
give informed consent were excluded from the study. Approval for 
the study was obtained from the Institutional Review Board of the 
Erasmus MC University Medical Centre Rotterdam, the Netherlands.
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VLS measurements
We performed mucosal oxygen saturation measurement with VLS 
in CGI suspected patients and healthy volunteers at baseline (stan-
dard care) and after stimulation with luminal feeding. 
In standard fashion patients receive midazolam 2.5-5 mg intrave-
nously and combined with fentanyl 0.05 mg for sedation. To prevent 
luminal spasms butylscopalamine 20 mg is admitted intravenously 
before the start of VLS measurements. As to minimize the effect 
of confounding factors of cardiopulmonary diseases we aim to 
keep peripheral oxygen saturation >95% by administering oxygen 
intra-nasally to every patient and systemic oxygen saturation is 
monitored by pulse oximetry. 
The baseline VLS measurements were performed during upper 
endoscopy using a fiberoptic catheter-based oximeter (T-Stat 303 
Microvascular Oximeter, Spectros, Portola Valley, California, USA), 
which can be passed through the accessory channel of the endo-
scope. Measurements of the oxygen saturation were performed at 
three sites in the stomach and duodenum: antrum of the stomach, 
descending duodenum and duodenal bulb. After irrigation of the 
target area and positioning the probe approximately 1-5 mm above 
the mucosa, three repeated readings were taken of different areas 
of each location once a stable reading is obtained with less than 
5% variation in panel read-out. The average of the three readings 
per location is regarded as the actual measurement of that specific 
location. 
Subsequently, a feeding tube was endoscopically placed in the 
antrum. Over the feeding tube, patients were given 300 ml (= 450 
kcal) compound liquid food (Nutrison Energy ®, Nutricia Koninklijke 
Numico N.V., WTC Schiphol, the Netherlands), a solution of car-
bohydrates, protein and fat with a low volume and a high caloric 
content. Patients were seated in upright position while the receiving 
the liquid compound food and they were monitored extensively.
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Simultaneous to the luminal feeding stimulation, patients received 
erythromycin 250 mg in order to improve motility and clear gastric 
contents more rapidly. 
The postprandial VLS measurements were performed 60 minutes 
after the baseline VLS measurements and were done the same 
fashion as described previously. In case of liquid food remnants 
in the stomach, these were thoroughly removed by irrigation and 
suction first before performing the VLS measurements.
Statistical analysis
Baseline characteristics were calculated using descriptive statistics. 
Data were expressed as mean and standard deviation (SD), median 
and interquartile range (IQR), or count and percentage (%), when 
appropriate. Mann-Whitney test was applied to calculate the dif-
ferences in baseline and postprandial VLS measurements between 
patients with CGI and healthy volunteers. Wilcoxon signed rank 
test was performed to study the differences between baseline and 
postprandial VLS measurements in CGI patients and in healthy 
volunteers.
Statistical analysis was performed using SPSS 21.0 program (SPSS 
Inc., Chicago, IL, USA). A p-value of <0.01 was considered signifi-
cant in order to correct for multiple endpoints (antrum, duodenal 
bulb and descending duodenum). 
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Results 
 
Patient characteristics 
During the study period, 49 consecutive patients with the clinical 
suspicion of CGI were eligible for the study. Informed consent was 
obtained from 31 (63%) patients. Reasons for non-participation 
were mostly poor condition of the patient or anxiety to undergo 
multiple upper endoscopies. Three (6%) patients failed to complete 
this work-up, leaving a total of 28 (57%) patients. The results of the 
diagnostic work-up of 28 patients in the study were discussed in a 
multidisciplinary expert panel. A consensus diagnosis of CGI was 
made in 16/28 (57%) patients and in 12/28 (43%) patients CGI was 
ruled out (see  1, flowchart of study). 
During follow-up (median 3.0 (IQR 1-6) months), two patients 
were lost to follow-up and in two patients the diagnosis of Non-
Occlusive Mesenteric Ischemia (NOMI) had to be rejected due to 
an alternative diagnosis, leaving a total of 12 patients with CGI 
(11 patients with occlusive CGI and one patient with NOMI). 
Intervention was offered to all 11 patients with occlusive 
ischemia, which consisted of endovascular treatment for seven 
patients with atherosclerotic stenosis of the gastrointestinal arter-
ies and surgical treatment for four patients diagnosed with Celiac 
Artery Compression Syndrome (CACS). The patient diagnosed with 
NOMI received vasodilatory medication. All patients had sustained 
relief of symptoms after symptoms. Thus, in total 12 patients were 
diagnosed with a definitive diagnosis of CGI. For characteristics of 
patients and volunteers see  1. 
Baseline and postprandial VLS measurements 
The baseline VLS measurements in patients with CGI were below 
the established cut-off values for that specific site in the gastroin-
testinal tract, indicating mucosal ischemia: gastric antrum median 
58.5 (IQR 53.5-59.0), duodenal bulb median 53.0 (IQR 48.8-54.0), and 
descending duodenum median 49.5 (IQR 45.3-52.8). In the controls, 
these values were significantly higher in the gastric antrum (median 
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61.0 (IQR 59.3-63.0); p=0.007) and in the duodenal bulb 54.0 (IQR 
49.0-56.0); p=0.003), but not in the descending duodenum (median 
54.0 (IQR 49.0-56.0); p=0.04)  2. 
Postprandial VLS measurements showed a significant differ-
ence in only the measurements in the duodenal bulb (median 53.5 
(IQR 50.3-56.8) for CGI patients vs median 59.5 (IQR 54.8-61.5) for 
the controls, p=0.004)  3.
Despite a trend to an increase in VLS measurements after 
stimulation with food, there was no significant increase between 
postprandial and baseline VLS measurements in patients with 
CGI (baseline antrum median 58.5 (IQR 53.5-59.0) vs postprandial 
antrum median 57.5 (IQR 54.0-60.8), p=0.25; baseline duodenal bulb 
median 53.0 (IQR 48.8-54.0) vs postprandial duodenal bulb median 
53.5 (IQR 50.3-56.8), p=0.89; baseline descending duodenum 
median 49.5 (IQR 45.3-52.8) vs postprandial descending duodenum 
median 54.0 (IQR 47.3-57.8), p=0.33, respectively). In the healthy 
controls, a trend was observed towards higher postprandial VLS 
measurements in the descending duodenum (baseline descending 
duodenum median 58.0 (IQR 54.0-62.8) vs postprandial descend-
ing duodenum median 59.5 (IQR 54.8-61.5), p=0.03), but not in 
the antrum and duodenal bulb (baseline antrum median 61.0 (IQR 
59.3-63.0) vs postprandial antrum median 63.0 (IQR 58.5-65.0), 
p=0.57, and baseline duodenal bulb median 54.0 (IQR 49.0-56.0) vs 
postprandial duodenal bulb median 56.0 (IQR 52.8-59.5), p=0.93, 
respectively).
There was no difference in ∆ VLS after food stimulation 
between patients with CGI and controls (p=0.66 for the antrum, 
p=0.94 for the duodenal bulb, and p=0.98 for the descending 
duodenum, respectively)  4. 
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 1 Flowchart of study
suspicion of CGI
(n=49)
consensus diagnosis non-CGI
(n=12)
informed consent
(n =31)
complete work-up of CGI + postprandial 
VLS measurements
(n = 28)
multidisciplinary expert panel
consensus diagnosis of CGI
n=16
definitive diagnosis of CGI
n=12
no informed consent
(n=18)
failed to complete total work-up
(n=3)
exclusion
lost to follow-up (n=2)
no sustained response after treatment (n=2)
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 1 Baseline characteristics of CGI patients and controls
CGI
(n=12)
controls
(n=16) p-value e
age (mean, SD) 63.2 (48.8-70.4) 32.9 (27.7-39.8) 0.001
gender
male
female
8 (67)
4 (33)
7 (44)
9 (56)
0.2
BMI (kg/m2) 24.2 (21.5-28.3) 23.0 (20.7-24.9) 0.2
symptomatology
abdominal pain
postprandial pain
exercise-induced pain
weight loss 
weight loss (kg/months) a
diarrhea
nausea 
duration of symptoms (months) a
10 (83)
9 (75)
4 (33)
7 (58)
2.0 (1.1-3.0)
2 (17)
5 (42)
10.0 (6.0-21.0)
0
0
0
0
0
0
0
0
<0.001
<0.001
0.013
<0.001
<0.001
0.09
0.004
0.004
cardiovascular comorbidity
history of CVD
hypertension
DM type II
hypercholesterolemia
family history of CVD
smoking d
pack years a
alcohol use
alcohol (U/day) b
8 (67)
7 (58)
3 (25)
6 (50)
5 (42)
10 (83)
162 (0-356)
6 (50)
0 (0-1.8)
0
1 (6)
0
0
3 (19)
0
0
11 (69)
0.5 (0-1.0)
<0.001
0.003
0.03
0.001
0.1
0.04
<0.001
0.3
<0.001
mesenteric artery stenosis c
no stenosis
single artery stenosis
multi artery stenosis
1 (8)
4 (33)
7 (58)
16
0
0
<0.001
<0.001
<0.001
values represent number and percentage (%) of patients unless otherwise specified
a median, interquartile range (IQR)
b median, range
c stenosis of the mesenteric arteries is defined as >70% lumen reduction on CT- or 
MR-angiography
d includes present and former smokers
e p-value <0.01 was considered significant
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 2 Baseline VLS measurements in patients with CGI and  
  healthy controls             CGI   controls
  
  antrum duodenal bulb descending duodenum
VLS measurements performed at three locations in the gastrointestinal tract for both patients and 
controls in the fasting state. VLS measurements were significantly decreased for patients with 
CGI compared to the controls in the gastric antrum and duodenal bulb, but not in the descending 
duodenum. Boxes represent medians with interquartile range, whiskers extend to the most and 
least extreme scores respectively.
 3 Postprandial VLS measurements in patients with CGI and  
  healthy controls             CGI   controls
  
  antrum duodenal bulb descending duodenum
VLS measurements performed at three locations in the gastrointestinal tract for both patients 
and controls in the postprandial state. VLS measurements were significantly decreased for 
patients with CGI compared to the controls in the duodenal bulb, but not in the gastric antrum and 
descending duodenum. Boxes represent medians with interquartile range, whiskers extend to the 
most and least extreme scores respectively.
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 4 Difference (∆) between postprandial VLS measurements and 
  baseline VLS measurements per location in the gastrointestinal
  tract in patients with CGI and in healthy controls
  CGI   controls
  
  antrum duodenal bulb descending duodenum
VLS measurements performed at three locations in the gastrointestinal tract for both patients 
and controls. ∆ VLS was calculated as postprandial VLS minus baseline VLS. In both the patients 
as well as in the controls, there was no significant difference between postprandial and baseline 
VLS measurements in all locations of the gastrointestinal tract. Boxes represent medians 
with interquartile range, whiskers extend to the most and least extreme scores respectively. 
P-value <0.01 was considered significant.
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Discussion
In this proof of concept study, we aimed to investigate the effect 
of caloric challenge on VLS measurements in patients with CGI 
and healthy controls. We found that there is no significant increase 
or decrease in VLS measurements after stimulation with food in 
patients with CGI whereas in healthy controls VLS measurements in 
the duodenal bulb rose significantly after food stimulation. 
Currently VLS measurements are validated only in a fasting 
state. Measurements for the postprandial state have not been 
investigated and its diagnostic discriminatory potential to correctly 
identify those with CGI from healthy controls, and ultimately pa-
tients with abdominal complaints that are not caused by gastroin-
testinal ischemia, has not been assessed. Our hypothesis was that, 
contrary to healthy volunteers, metabolic demand in patients with 
CGI exceeds mucosal oxygen supply when calorically challenged. 
The ability to maintain or increase postprandial mucosal oxygen-
ation might therefore offer a more sensitive means to diagnose 
patients with gastrointestinal ischemia. We found that there is no 
significant decrease in VLS measurements after stimulation with 
food in patients with CGI. However, in line with our hypothesis, 
we did observe higher VLS measurements in healthy controls 
suggestive of a physiological hyperemic response induced by food 
stimulation 1,10,11. 
To our knowledge, this is the first study which quantitatively 
assesses gastrointestinal ischemia in the postprandial state using 
VLS. VLS measures capillary hemoglobin oxygen saturation and 
enables to objectively and quantitatively determine the presence 
and extent of gastrointestinal mucosal ischemia. It is a validated 
diagnostic method and has a sensitivity of 90% and specificity of 
60% for the detection of CGI and has established cut-off values for 
each of the specific sites of the gastrointestinal tract, which are 
previously calculated by van Noord et al 5. 
Although our original hypothesis was confirmed from a 
(patho)physiological point of view, showing a statistically signifi-
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cant difference in postprandial duodenal bulb VSL measurements 
between patients with CGI and healthy volunteers, the numerical 
overlap is considerable making postprandial measurements not yet 
suitable for clinical use. For this, several issues need to be taken 
into consideration.
In this proof-of-concept study we tested a limited number of 
individuals. Inclusion of more patients and controls may increase 
the power to statistically differentiate between both groups, for 
example also by measurements of the antrum and duodenum.
VLS measurements in patients with CGI sometimes show 
substantial variation. Therefore, the average of three repeated mea-
surements of each location is regarded as the most accurate reflec-
tion of the mucosal oxygen saturation of that location 5. In addition, 
VLS is limited to point measurements. Mucosal ischemia might be 
patchy and could therefore be missed or underestimated. In addi-
tion, VLS measurements may be further hampered by food rem-
nants. In case of liquid food remnants in the stomach, these were 
thoroughly removed by irrigation and suction before performing 
the VLS measurements. Simultaneous to luminal feeding, patients 
received erythromycin 250 mg in order to improve motility and 
clear gastric contents more rapidly. Other events that may hamper 
the VLS measurements are luminal spasms and bile acid remnants. 
Therefore, butylscopolamine was administered intravenously prior 
to the start of VLS measurements and the VLS measurements were 
performed after irrigation of the target area. 
Studies have shown that the increase in abdominal discom-
fort in patients with CGI occurs after 15-30 minutes after digestion 
of food and can persist for one to three hours 2,10,12,13. In our study, 
repeated VLS measurements were performed during this time 
range, that is after 60 minutes after caloric stimulation. This time 
period was chosen in order to minimize the effect of food remnants 
in the stomach and consequently to optimize the patient safety e.g. 
to reduce the risk of aspiration during the second upper endoscopy. 
However, it might be that the time point of the repeated VLS mea-
surements were not optimally aligned with the time point at which 
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metabolic demands are maximal and hence mucosal oxygen supply 
most severely challenged. Therefore choosing a different time point 
for postprandial VLS measurements might enhance its discrimina-
tory capacity.
This is the first study describing the hemodynamic changes in 
patients with CGI after stimulation with food using VLS. We found 
that there is no significant increase or decrease in VLS measure-
ments after stimulation with food in patients with CGI whereas 
in healthy controls VLS measurements in the duodenal bulb rose 
significantly after food stimulation. Although these observations 
seem to confirm our initial hypothesis that indeed the physiological 
hyperemic response induced by food stimulation is impaired in 
patients with CGI, it currently provides to little discriminatory power 
for clinical use. Modifications of the VLS assessment protocol, in 
particular the timing of postprandial measurements, may improve 
its applicability. 
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Abstract
Background
Chronic gastrointestinal ischemia (CGI) 
is the result of insufficient blood supply 
to the gastrointestinal tract. The majority 
of CGI patients has systemic disorders 
of the circulatory system including 
hypertension, diabetes and other cardio-
vascular risk factors. Studies in patients 
with acute gastrointestinal ischemia, 
found a correlation between intestinal 
ischemia and sublingual microcircula-
tory alterations. However, little is known 
about the microcirculatory alterations 
in patients with CGI. We hypothesize 
that patients with CGI may suffer of 
systemic microcirculation disturbances. 
We further hypothesized that sublingual 
microcirculation is responsive to enteral 
caloric challenges and as such provides a 
means to indirectly assess the intestinal 
microcirculation. 
Methods
Consecutive patients with CGI were pro-
spectively included between September 
2014 and August 2015. All patients 
received the standard work-up for CGI, 
consisting of assessment of medical his-
tory and symptoms, radiological imaging 
of the gastrointestinal arteries, and 
endoscopic visible light spectroscopy 
(VLS) for assessment of gastroduodenal 
mucosal oxygen saturation. The sub-
lingual microcirculation was evaluated 
before (T0) and 20 minutes after enteral 
feeding 1. Total vessel density (TVD (mm/
mm2)), perfused vessel density (PVD 
(mm/mm2), proportion of perfused ves-
sels (PPV (%)), microvascular flow index 
(MFI (AU)) were assessed. 
Results
We included 12 consecutive patients with 
CGI. After caloric challenge, a significant 
increase in the PVD of the small (PVDs) 
vessels and all vessels (PVDa), and in the 
PPV of the small vessels (PPVs) was ob-
served (PVDs median 16.3 (IQR 13.3-22.1) 
mm/mm2 vs 19.9 (IQR 14.2-26.2) mm/
mm2, p=0.008; PVDa median 19.1 (IQR 
16.2-23.6) mm/mm2 vs 22.2 (16.5-28.9) 
mm/mm2, p=0.02; PPVs median 84.8% 
(IQR 75.3-90.4) vs 91.0% (80.1-93.8), 
p=0.01). 
Conclusion
Patients with CGI show significant 
alterations in the sublingual microcircula-
tion after stimulation with food. This 
non-invasive tool may offer differential 
diagnostic opportunities to diagnose 
patients with CGI.
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Introduction
Chronic gastrointestinal ischemia (CGI) is the result of insufficient 
blood supply to the stomach, small intestine and colon leading to 
decreased mucosal perfusion and oxygenation. In most cases this 
is caused by stenosis of the supplying arteries due to atheroscle-
rosis, chronic heart failure and pulmonary conditions can further 
contribute or predominate (so-called non-occlusive chronic isch-
emia (NOMI)) 2.
It is believed that patients with CGI have a lack of postprandial 
increase in the splanchnic blood flow after ingestion of food caus-
ing a misbalance between sufficient oxygen delivery and metabolic 
demand 3. Hence the postprandial discomfort many CGI patients 
experience after ingestion of food 3. Until recently it was thought 
that CGI could only occur in the presence of minimal two occluded 
mesenteric arteries, but studies have shown that a significant 
stenosis of a single artery can also lead to clinically relevant gastro-
intestinal ischemia 4,5. In these patients with single-vessel CGI, the 
occurrence of symptoms is thought to be related to insufficient col-
lateral circulation 2. Another underlying cause might be that patients 
with CGI have microcirculatory alterations associated with systemic 
disorders of the circulatory system. The majority of patients with 
CGI is known with hypertension, diabetes and other cardiovascular 
risk factors 6. Therefore, microvascular pathology in this patient 
group is very likely and might explain why single-vessel stenosis 
can lead to clinical symptoms even in presence of sufficient col-
lateral circulation. 
However, there is little insight regarding the microcirculatory 
alterations in patients with CGI. Several studies, mainly investigat-
ing patients in hemodynamic shock, found a correlation between 
intestinal ischemia and sublingual microcirculatory alterations 7-9. 
These alterations consisted of decreased microvessel density and 
erythrocyte velocity which were similar in both the sublingual 
and gut regions. Furthermore, the sublingual capillary perfusion 
seemed well correlated to the hypoxic state of the gastric mucosa 
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in these patients 9-11. This may be expected since the gastrointestinal 
tract and the sublingual microcirculation share a common embryo-
genic origin 7. 
No studies have been performed to investigate the relation-
ship between sublingual microcirculation and hemodynamic 
changes such as in patients with CGI. Based on these findings 
we formulated the hypothesis patients with CGI may also exhibit 
microcirculatory alterations. We hypothesize that sublingual micro-
circulation is responsive to enteral caloric challenges and as such 
provides a means to indirectly assess the intestinal microcircula-
tion. Assessment of the sublingual microcirculation may provide a 
non-invasive diagnostic opportunity since it may ultimately provide 
a non-invasive tool to diagnose or refute the diagnosis of CGI in a 
more patient friendly way.
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Methods
Study population
Patients with confirmed CGI were prospectively included between 
September 2014 and August 2015. All patients received the recom-
mended work-up of CGI consisting of thorough assessment of 
medical history and clinical symptoms, radiological imaging of the 
mesenteric arteries using computed tomography (CT)- angiography, 
or in case of contra-indications magnetic resonance (MR)- angi-
ography. Gastroduodenal mucosal oxygen saturation was further 
functionally tested by VLS. Patients work-up were discussed in a 
multidisciplinary team consisting of vascular surgeons, intervention 
radiologists and gastroenterologists, all experienced in the manage-
ment of CGI. This yielded a final expert-based consensus diagnosis. 
A diagnosis CGI was made if a patient fulfilled two of the three 
following criteria:
1 distinctive clinical presentation including presence of post-
prandial pain and otherwise unexplained weight loss of >5% of the 
normal body weight;
2 significant stenosis of >50% of at least one of the mesenteric 
arteries;
3 functional signs of mucosal ischemia demonstrated by VLS. 
Mucosal ischemia by VLS was defined as mucosal oxygen 
saturation < 58%, <62%, or <63% for measurements in the duode-
num, duodenal bulb and the stomach, respectively. The diagnosis 
CGI was established if a patient fulfilled two of the three following 
criteria:
1 distinctive clinical presentation including presence of post-
prandial pain and otherwise unexplained weight loss of >5% of the 
normal body weight;
2 significant stenosis of >50% of at least one of the mesenteric 
arteries;
3 functional signs of mucosal ischemia demonstrated by VLS. 
Mucosal ischemia by VLS was defined as mucosal oxygen 
saturation < 58%, <62%, or <63% for measurements in the duode-
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num, duodenal bulb and the antrum of the stomach respectively 
based on previous assessments in patients and healthy controls. 
A definitive diagnosis of CGI was made after sustained relief of 
symptoms during follow-up in patients after appropriate treatment, 
which includes revascularization in patients with stenotic CGI and 
vasodilatory medication in patients with NOMI . 
Informed consent was obtained from all patients. Approval 
for the study was obtained from the Institutional Review Board 
of the Erasmus MC University Medical Centre Rotterdam, The 
Netherlands. 
Assessment of microcirculation
We measured the sublingual microcirculation using a Cytocam-
IDF device  1 12. The measurement was performed both before 
(T0) and 20 minutes after enteral feeding (T1). Patients received 
enteral feeding through an endoscopically placed feeding tube 
in the antrum. Over the feeding tube, patients were given 300 ml 
compound liquid food (Nutrison Energy ®, Nutricia Advanced 
Medical Nutrition, Zoetermeer, the Netherlands), a solution of 
carbohydrates, protein and fat with a low volume and a high caloric 
content (= 450 kcal). At each time point, microcirculation was filmed 
in three different locations on the sublingual mucosa for a minimum 
of 2 seconds per sequence as previous described 13. Great care was 
taken to clear saliva before image acquisition. Film sequences were 
repeatedly taken until three sequences of good quality. The quality 
of the images were assessed using the Massey score for micro-
circulation image quality 14. Video-image analysis was performed 
blindly by one independent researcher according to protocol using 
Automated Vascular Analysis (AVA) 3.0 15. The following parameters 
were obtained: total vessel density (TVD (mm/mm2), perfused 
vessel density (PVD (mm/mm2), proportion of perfused vessels (PPV 
(%)), and microvascular flow index (MFI (AU)), respectively, of small 
vessels and all vessels.
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Statistical analysis
Baseline characteristics were calculated using descriptive statistics. 
Data were expressed as median and interquartile range (IQR), or 
count and percentage (%), when appropriate. Wilcoxon signed rank 
test was performed to study the differences between baseline and 
postprandial parameters of the microcirculation in CGI patients. 
Statistical analysis was performed using SPSS 21.0 program 
(SPSS Inc., Chicago, IL, USA). A two-sided p-value of <0.05 was 
considered significant. 
 1 The Cytocam-IDF captures the sublingual microcirculation
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 1 Baseline characteristics of CGI patients and controls
CGI
n=12
age (mean, SD) 63.2 (48.8-70.4)
gender
male
female
8 (67)
4 (33)
BMI (kg/m2) 24.2 (21.5-28.3)
symptomatology
abdominal pain
postprandial pain
exercise-induced pain
weight loss 
weight loss (kg/months) a
diarrhea
nausea 
duration of symptoms (months) a
10 (83)
9 (75)
4 (33)
7 (58)
2.0 (1.1-3.0)
2 (17)
5 (42)
10.0 (6.0-21.0)
cardiovascular comorbidity
history of CVD
hypertension
DM type II
hypercholesterolemia
family history of CVD
smoking d
pack years a
alcohol use
alcohol (U/day) b
8 (67)
7 (58)
3 (25)
6 (50)
5 (42)
10 (83)
162 (0-356)
6 (50)
0 (0-1.8)
mesenteric artery stenosis c
no stenosis
single artery stenosis
multi artery stenosis
1 (8)
4 (33)
7 (58)
VLS measurement
antrum
duodenal bulb
descending duodenum
58.5 (53.5-59.0)
53.0 (48.8-54.0)
49.5 (45.3-52.8)
values represent number and percentage (%) of patients unless otherwise specified
a median, interquartile range (IQR)
b median, range
c stenosis of the mesenteric arteries is defined as >70% lumen reduction on CT- or 
MR-angiography
d includes present and former smokers
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Results
Patient characteristics 
During the study period, 49 consecutive patients with the clinical 
suspicion of CGI were eligible for the study. Informed consent was 
received from 31 (63%) patients. Reasons for non-participation were 
mostly poor condition of the patient or anxiety to undergo multiple 
investigations. Three (6%) patients failed to complete this work-up, 
leaving a total of 28 (57%) participants in the study. The results of 
the diagnostic work-up of the 28 patients in the study were dis-
cussed in a multidisciplinary expert panel. A consensus diagnosis 
of CGI was made in 16/28 (57%) patients whereas in 12/28 (43%) 
patients CGI was ruled out. 
During follow-up (median 3.0 (IQR 1-6) months), two patients 
were lost to follow-up and in two patients the diagnosis of NOMI 
had to be adjusted leaving a total of 12 patients with CGI (11 pa-
tients with occlusive CGI and one patients with NOMI  1). 
Sublingual microcirculation
Absolute data and ranges for the microvascular variables of all 
patients are provided in  2. 
The PVD of the small vessels and all vessels significantly 
increased after caloric challenge (T1) compared to baseline (T0) 
(PVDs median 16.3 (IQR 13.3-22.1) mm/mm2 vs 19.9 (IQR 14.2-26.2) 
mm/mm2, p=0.008; PVDa median 19.1 (IQR 16.2-23.6) mm/mm2 vs 
22.2 (16.5-28.9) mm/mm2, p=0.02)  3  2. Furthermore, there is a 
significant increase in the PPV of the small vessels after caloric chal-
lenge (median 84.8% (IQR 75.3-90.4) vs 91.0% (80.1-93.8), p=0.01). 
This did not pertain to the PPV of all vessels (median 85.4% (IQR 
79.8-91.5) vs 90.4% (IQR 81.4-94.4), p=0.05)  3. In addition, there 
was a trend towards significance in the increase in TVD of the small 
vessels after caloric challenge (median 20.8 (IQR 17.6-23.8) mm/mm2 
vs 22.4 (IQR 17.8-32.2) mm/mm2, p=0.09). 
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 2 Individual patient data of sublingual microcirculation
microcirculation
patient time point a TVDs TVDa PVDs PVDa PPVs PPVa MFIs MFIa
1 0
1
19,13
18,76
24,22
21,81
17,19
16,29
22,25
19,24
90,50
86,48
92,27
87,66
2,83
3,00
2,94
2,84
2 0
1
15,36
13,87
18,00
15,01
13,58
13,32
16,17
14,46
87,58
95,97
89,20
96,17
3,00
3,00
2,61
2,90
3 0
1
17,64
17,51
21,08
21,93
13,27
14,33
16,71
17,95
75,34
82,80
79,35
83,28
2,67
2,50
2,56
2,80
4 0
1
23,95
34,90
25,18
38,03
21,78
32,31
23,01
35,44
91,44
92,92
91,78
93,46
3,00
3,00
2,97
3,00
5 0
1
23,45
25,42
25,04
28,44
22,25
24,96
23,84
27,98
94,80
98,05
95,20
98,36
3,00
3,00
3,00
3,00
6 0
1
20,54
19,90
24,13
23,94
10,82
12,58
13,43
16,21
52,52
62,63
55,79
66,41
1,58
2,33
1,94
2,58
7 0
1
21,11
16,50
23,87
18,31
15,35
15,47
17,00
17,26
73,64
92,81
72,98
93,74
2,75
3,00
2,50
2,94
8 0
1
31,68
34,45
34,26
35,76
28,80
31,09
31,37
32,20
89,98
90,40
90,70
90,08
3,00
3,00
3,00
2,93
9 0
1
11,88
18,52
15,65
20,77
8,98
14,21
12,75
16,10
75,25
77,20
81,11
78,16
2,83
2,89
2,70
2,49
10 0
1
23,66
27,78
25,68
27,78
19,24
25,43
21,25
25,24
81,95
91,57
83,09
90,79
2,67
3,00
2,89
2,89
11 0
1
28,70
33,67
31,06
36,33
22,72
26,51
25,08
29,17
79,47
79,22
81,06
80,79
2,75
2,58
2,75
2,82
12 0
1
17,56
24,85
19,01
27,32
15,12
23,42
16,26
25,88
88,39
94,11
87,66
94,62
3,00
3,00
2,85
3,00
a time point 0 is at baseline before caloric challenge, time point 1 is after caloric challenge
513 Patients with chronic gastro intestinal ischemia have an altered  
 sublingual microcirculation
 3 Difference in sublingual microcirculatory parameters before  
  and after caloric challenge
CGI (n=12)
microcirculation time point a median (IQR) p-value b
TVDs 0
1
20.8 (17.6-23.8)
22.4 (17.8-32.2) 0.09
TVDa 0
1
24.2 (19.5-25.6)
25.6 (21.0-33.9) 0.18
PVDs 0
1
16.3 (13.3-22.1)
19.9 (14.2-26.2) 0.008
PVDa 0
1
19.1 (16.2-23.6)
22.2 (16.5-28.9) 0.02
PPVs 0
1
84.8 (75.3-90.4)
91.0 (80.1-93.8) 0.01
PPVa 0
1
85.4 (79.8-91.5)
90.4 (81.4-94.4) 0.05
MFIs 0
1
2.8 (2.7-3.0)
3.0 (2.7-3.0) 0.17
MFIa 0
1
2.8 (2.6-3.0)
2.9 (2.8-3.0) 0.14
a time point 0 is at baseline before caloric challenge, time point 1 is after caloric challenge 
b p-value <0.05 was considered significant
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 2 Perfused vessel density of the small vessels (PVDs) in mm/mm2
  of all patients at baseline (T0) and after caloric challenge (T1)
  
 3 Proportion of perfused vessels of the small vessels (PPVs) 
  in mm/mm2 of all patients at baseline (T0) and after caloric 
  challenge (T1)
  
boxes represent medians with interquartile range, whiskers extent to the most and least extreme 
scores respectively.
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Discussion
In this proof of concept study, we aimed to investigate the sublin-
gual microcirculation of CGI patients during fasting and caloric chal-
lenge. We found that patients with CGI have a significant increase 
in the perfused vessel density and proportion of perfused vessels 
after stimulation with food.
Studies in patients with CGI have focused on macrovascular 
alterations 16-18. It is believed that patients with CGI have a lack of 
postprandial increase in the splanchnic blood flow after ingestion 
of food leading to insufficient oxygen delivery to provide for the 
metabolic demand of the gastrointestinal tract in the presence of 
insufficient collateral circulation 3. Another underlying cause might 
be that patients with CGI have microcirculatory alterations associ-
ated with systemic disorders of the circulatory system and that this 
also attributes to the presence of clinical symptoms 6. Therefore, mi-
crovascular pathology in this patient group is very likely and might 
explain why single-vessel stenosis can lead to clinical symptoms 
even in presence of sufficient collateral circulation. We therefore 
hypothesized that patients with CGI may also exhibit microcircula-
tory alterations. We hypothesize that sublingual microcirculation 
is responsive to enteral caloric challenges and as such provides a 
means to indirectly assess the intestinal microcirculation. 
Our study shows that patients with CGI have a significant 
increase in the microvascular parameters after a caloric challenge 
and thus have a hyperaemic response to ingestion of food with a 
high caloric composition. In addition, we have reason to assume 
that patients with CGI may have impaired sublingual microcircula-
tion compared to healthy volunteers. A previous study investigated 
the sublingual microvessel density and flow in healthy volunteers 19. 
The investigators observed a mean PPV for the small vessels of 
94.0%, whereas the PPV of small vessels in healthy volunteers is 
100% 20. In our study, the median PPV for the small vessels was 
considerably lower (84.8%). Therefore, it might be that patients with 
CGI have a poor microcirculation to begin with, despite the increase 
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in microcirculatory parameters after a caloric challenge. Further 
studies with the inclusion of more patients and healthy controls us-
ing the current protocol are needed to further illustrate this matter. 
Our study has limitations. Patients with CGI were under con-
scious sedation with intravenous midazolam and fentanyl at time of 
the second sublingual microcirculatory measurements after caloric 
challenge but not during the baseline sublingual measurements. A 
recent study showed that the sublingual microcirculation in patients 
with shock was greater after the infusion of midazolam 21. In this 
study, the proportion of perfused vessels was significantly greater 
after infusion of midazolam (PPV median 96.4% (IQR 93.7-97.6) vs 
92.7% (88.3-94.7), p<.005). Therefore, the hyperaemic response in 
our patients after a caloric challenge might partly be caused by the 
effect of midazolam.
To our knowledge, this is the first study to investigate the 
sublingual microcirculation in patients with CGI. Patients with CGI 
might have a worse microcirculation to begin with compared to 
healthy controls. Furthermore, we found that patients with CGI have 
a significant increase in the perfused vessel density and proportion 
of perfused vessels after stimulation with food and thus have a 
hyperaemic response to ingestion of food. This study provides us 
more insight in the relationship between the microcirculation and 
hemodynamic changes in the gastrointestinal tract. These findings 
may lead to development of non-invasive, rapid, and less-burden-
some diagnostic methods for the detection of CGI. We believe it 
would be interesting to assess the diagnostic ability of sublingual 
measurements of the microcirculation in patients with the diagnosis 
of CGI and to compare it to the current diagnostic modalities such 
as VLS. Future studies with more patients and healthy are needed 
to increase the generalizability of our findings and to provide more 
discriminatory power for clinical use. 
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Abstract
Background
No golden diagnostic standard is avail-
able to diagnose Chronic Gastrointestinal 
Ischemia (CGI). We aimed to establish an 
accurate prediction model for CGI, based 
on clinical symptoms and radiological 
evaluation of the mesenteric arteries.
Methods
We prospectively included consecutive 
patients with clinical suspicion of CGI in 
a tertiary referral center. Predictors for 
CGI were obtained by comparing clini-
cal parameters to the diagnosis of CGI. 
Multivariable logistic regression was 
used to combine the strongest predictors 
in a model. A score chart based on the 
prediction model was provided to calcu-
late the risk of CGI.
Results
CGI was present in 171/436 (39%) 
patients (67 (54-74) years; 27% male). 
Strongest predictors for CGI were in-
creasing age (OR1.24, 95%CI 0.88-1.73), 
female gender (OR1.86, 95%CI 1.18-2.95), 
weight loss (OR1.87, 95% CI1.18-2.97), 
nausea (OR1.27, 95%CI 0.82-1.98), 
concomitant cardiovascular disease 
(OR2.15, 95%CI 1.35-3.44), and positive 
family history for cardiovascular disease 
(OR1.36, 95%CI 0.87-2.12). Duration of 
symptoms >12 months (OR0.90, 95%CI 
0.82-0.99) and use of analgetics (OR0.80, 
95%CI 0.45-1.44 for opioid use and 
OR0.41, 95%CI 0.19-0.87 for non-opioid 
use) lowered the risk of having CGI. A 
model based on clinical symptoms alone 
showed limited discriminative ability for 
diagnosing CGI (c-statistic 0.62). Adding 
radiological imaging of the mesenteric 
arteries improved the discriminative 
ability (c-statistic 0.76). 
Conclusion
Clinical symptoms alone are insufficient 
to predict the risk of CGI. Radiological 
evaluation of the mesenteric arteries is 
essential. This tool may be useful for 
clinicians to assess the risk of CGI and to 
decide whether further diagnostic work-
up for CGI is needed.
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Introduction
Chronic gastrointestinal ischemia (CGI) is the result of decreased 
mucosal perfusion, in most cases caused by atherosclerotic steno-
sis of the supplying arteries 1. In some cases, hypoperfusion and/
or hypo-oxygenation is due to underlying cardiac or pulmonary 
disease. The diagnosis of CGI is a clinical challenge. This is firstly 
because patients with CGI may present with a variety of symptoms. 
Furthermore, there is no single, accurate test to diagnose or exclude 
CGI. The role of clinical symptoms alone in the diagnosis of CGI is 
limited 2,3. The combination of postprandial pain, weight loss and 
presence of an abdominal bruit is known as the ‘classical’ triad of 
CGI. This is however only present in 16-21% of patients and has 
limited predictive value for diagnosing CGI 3-5. Studies to identify 
predictive symptoms and risk stratification methods have been 
based on relatively small cohorts of selected patients. The current 
models thus only rendered modest discriminative capacity 2,3. Even 
though larger cohorts would allow further specification, it is unlikely 
that this will raise the predictive probability of a model based on 
symptoms alone. 
This supports the current diagnostic approach that combines 
assessment of clinical symptoms with radiological imaging of the 
gastrointestinal arteries and functional testing by tonometry or 
visible light spectroscopy (VLS) 6. This seemingly simple approach 
is however limited by a number of challenges. Functional testing 
is not widely available, and is furthermore burdensome and costly. 
The use of the more patient-friendly and less cumbersome VLS 
technique also has its limitations. VLS has a sensitivity of 90% for 
the detection of CGI 7. However, this is at the loss of specificity, 
which ranges around 60%. Random abdominal imaging, especially 
in the elderly, frequently reveals mesenteric artery stenosis in 
variable degrees. This is often an incidental finding with uncertain 
clinical relevance when typical symptoms of CGI are lacking. 
A more accurate CGI prediction model is needed. This should 
take the finite availability of functional tests in general hospitals into 
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account 2,3. We therefore aimed to establish a prediction model for 
CGI, based on the combination of medical history, symptoms and 
radiological evaluation of the mesenteric arteries. For that purpose, 
we used a large cohort of patients in order to identify low, interme-
diate and high-risk patients for CGI. 
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Methods
Study population
Consecutive patients with a clinical suspicion of CGI referred to a 
tertiary care center were prospectively included in the study cohort 
between November 2006 to March 2013. Suspicion for CGI was 
defined upon discretion of the referring physician based on pres-
ence of one or more of the following criteria: 
1 presence of postprandial abdominal pain
2 otherwise unexplained weight loss (>5% of normal body weight)
3 significant stenosis of >50% of at least one of the gastro-
intestinal arteries on radiological evaluation 3. 
In all patients, upper endoscopy, colonoscopy and radiologi-
cal imaging had not revealed an alternative diagnosis. The standard 
CGI work-up included assessment of medical history and symptoms 
by a structured questionnaire. This was followed by radiological 
imaging by CT- or MR-angiography. The latter was done in case of 
contra-indications for CT-angiography, in particular contrast allergy 
or renal failure. Finally, patients were functionally assessed by gas-
trointestinal tonometry or VLS. Approval for the study was obtained 
from the Institutional Review Board of the Erasmus MC University 
Medical Centre Rotterdam, the Netherlands.
Consensus diagnosis and definitive diagnosis of CGI
All patients and assessment results were discussed in a multi-
disciplinary team consisting of vascular surgeons, intervention 
radiologists and gastroenterologists, all experienced in the manage-
ment of CGI. This yielded a final expert-based consensus diagnosis 
in each case. 
A diagnosis CGI was established if a patient fulfilled two of 
the three following criteria:
1 distinctive clinical presentation including presence of post-
prandial pain and otherwise unexplained weight loss of >5% of the 
normal body weight
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2 significant stenosis of >50% of at least one of the mesenteric 
arteries
3 functional signs of mucosal ischemia demonstrated by 
tonometry or VLS. 
Pathological tonometry findings were defined as gastric 
or jejunal PCO2 above respectively 12.0, 13.6, or 10.6 kPa after 
breakfast, dinner, or compound solution meal, respectively 8. 
Mucosal ischemia by VLS was defined as mucosal oxygen satura-
tion < 58%, <62%, or <63% for measurements in the duodenum, 
duodenal bulb and the antrum of the stomach respectively. After 
reaching a consensus diagnosis, CGI patients were sub-classified 
as having occlusive disease CGI (≥ 1 stenotic mesenteric artery) or 
non-occlusive mesenteric ischemia (NOMI). Patients with occlusive 
CGI were eligible for endovascular or surgical revascularization. In 
patients with NOMI, vasodilatory therapy was considered 9,10. Upon 
either treatment, all patients received standard follow-up consisting 
of scheduled visits at the outpatient clinic. The definitive diagnosis 
of CGI was made after sustained relief of symptoms during follow-
up in treated patients. 
Questionnaire 
All patients were asked to complete a standardized questionnaire 
prior to their first visit to our outpatient clinic. The questionnaire 
was specifically designed for collection of relevant medical and 
family history, abdominal symptoms, and medication use 1,3. 
Medical history findings that were considered relevant for CGI 
assessment included a history of cardiovascular (both coronary and 
peripheral) arterial disease. Family history findings that were con-
sidered relevant included a known history of first-degree relatives 
with cardiovascular arterial disease. Participants were asked for the 
presence of gastrointestinal symptoms in general and of symptoms 
specific for CGI such as postprandial and exercise-related pain. 
Severity of these symptoms was assessed on a 5-point Likert-type 
scale (0 = no pain; 1 = pain, but no interference with Activities of 
Daily Living (ADL); 2 = pain, with small impairment of ADL; 3 = pain, 
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with major impairment of ADL, 4 = pain, with complete impairment 
of ADL). 
Statistical analysis 
Baseline characteristics were calculated using descriptive statistics. 
Data were expressed as mean and standard deviation (SD), median 
and interquartile range (IQR) or count and percentage (%), when 
appropriate. Missing observations were imputed multiple times 
using the R-software. The imputation model used all the variables 
that we considered as potential predictors and the diagnosis CGI. 
Univariable and multivariable associations of the candidate predic-
tors for CGI were assessed using logistic regression analysis. The 
associations were estimated as Odds Ratios (OR). For the univari-
able analysis the OR for the following variables were studied: age, 
gender, presence of postprandial pain and exercise-induced pain 
(both yes/no, Likert-scale) weight loss per month defined as total 
amount of weight loss divided by the period (in months) in which 
the weight loss occurred, diarrhea (yes/no), nausea (yes/no) and 
duration of symptoms in months, smoking (yes/no, pack years (py)), 
use of alcohol in units, use of analgetics (yes/no), use of anti-
thrombotics (yes/no), concomitant cardiovascular disease (yes/no), 
hypercholesterolemia (yes/no), diabetes mellitus (DM) type II (yes/
no) and hypertension (yes/no). For continuous variables, the OR was 
calculated for the interquartile range (IQR). In all these categorical 
variables, absence of variable was used as reference category. 
For the multivariate analysis, we developed two models: 
model A (clinical model), solely based on clinical parameters ob-
tained from medical history and questionnaire, and model B, based 
on clinical parameters plus mesenteric artery imaging. 
In agreement with the rule of thumb to use no more than one 
variable per ten outcomes in the less frequent outcome category, 
we considered no more than 17 variables for the clinical model 
A. Based on literature and clinical knowledge, we chose clinical 
symptoms of CGI and risk factors for atherosclerosis but also use of 
analgetics and antithrombotic therapy. 
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Variable selection was performed using backward stepwise selec-
tion using a liberal p-value of 0.20 in order to increase the power 
of selecting true predictors and to exclude variables with small 
effects 11. The discriminative ability of the model was estimated with 
a measure of concordance, the c-statistic. The c-statistic is identical 
to the area under the receiver operating characteristic (ROC) curve 
for dichotomous outcomes, and indicates to what extent patients 
with CGI can be distinguished from patients without CGI 12. We used 
bootstrapping to assess and correct for optimism 11,13.
Based on the multivariable analysis for model A and model B, 
we developed a score chart based on the original regression 
coefficients 14.
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Results
Patient characteristics
During the study period 443 consecutive patients with the clinical 
suspicion of CGI received the protocolized work-up. Seven patients 
failed to complete this work-up and were excluded from analysis, 
leaving a total of 436 patients in the study  1. The median age of 
the referred population was 61 (IQR 50-72) years, and 151 (35%) 
patients were male  1. 
Forty-two percent of the total population had a history of 
cardiovascular disease. Analgetics, including opioids, and non-
opioids and over-the-counter drugs, were used in 25% of patients. 
Antithrombotics were used by 50% of patients, with platelet 
aggregation inhibitors being mostly used (39%) followed by oral 
anticoagulants (10%)  1. 
Clinical symptoms
The most commonly reported symptoms were presence of abdomi-
nal pain (83%), postprandial pain (79%), and exercise-induced pain 
(76%). Presence of these symptoms was similar between patients 
with CGI and without CGI. Weight loss (median 1.6 (IQR 0.8-3.5) kg/
month) was present in 286 (66%) patients and was more prevalent 
in patients with CGI compared to patients with non-CGI (75% vs 
61%; median weight loss 1.8 (IQR 1.0-3.7) vs 1.6 (IQR 0.8-3.3) kg/
month). A significant stenosis of at least 1 mesenteric artery was 
present in 195 (45%) patients and was present in 123 (72%) patients 
with CGI compared to 72 (27%) patients with non-CGI. Fifty-five 
patients were diagnosed with CGI based on single-vessel arterial 
stenotic disease. Stenosis of the CA was present in 43 (78%) pa-
tients. Mucosal ischemia was detected in 37 (86%) of these patients 
with CA stenosis. Stenosis of the SMA was present in 12 (22%) 
patients. In only one patient of this group mucosal ischemia was not 
detected by means of functional testing. Multi-vessel disease was 
present in 66 patients (46 patients with concomitant stenosis of the 
68 Vascular diseases of the gastrointestinal tract
 1 Flowchart of study
Suspicion of CGI (N=443)
Standard work-up:
∙  Medical history and physical examination
∙  Radiological imaging: US, CT- or MR-A 
 and/or diagnostic DSA
∙  Functional test: tonometry or VLS
+ Questionnaire
Multidisciplinary expert panel (n=436)
Consensus diagnosis CGI (n=229)
Occlusive ischemia (n=139)
∙  Single vessel (n=72)
∙  Two vessel (n=67)
NOMI (n=90)
Definitive diagnosis CGI (n=171)
Occlusive ischemia (n=121)
∙  Single vessel (n=55)
∙  Two vessel (n=66)
NOMI (n=50)
Patient
with
bowel
ischemia
(n=1)
Definitive diagnosis non-CGI (n=265)
Patent mesenteric arteries (n=184)
Stenosis, no ischemia (n=70)
Ischemic colitis (n=11)
Management
Occlusive ischemia
Intervention (n=127)
PTA and/or stentplacement (n=94)
Surgical (release) (n=27)
Both (n=6)
Conservative (n=12)
Follow-up
Occlusive ischemia
Sustained response on endovascular 
intervention (n=78)
Sustained response on surgical intervention (n=78)
Conservative therapy, ongoing symptoms (n=11)
No response on intervention (n=13)
No significant stenosis during intervention (n=5)
Conservative therapy, self-limiting (n=1)
NOMI
Vasodilatative therapy (n=81)
Conservative (n=9)
NOMI
Sustained response on 
vasodilatative therapy (n=45)
Conservative therapy, ongoing 
symptoms (n=5)
No response on vasodilatative 
therapy (n=36)
Conservative therapy, self-limiting 
symptoms (n=4)
Consensus diagnosis non-CGI (n=207)
Patent mesenteric arteries (n=140)
Stenosis, no ischemia (n=56)
Ischemic colitis (n=11)
Excluded:
failure to com plete standard work-up (n=7)
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CA and SMA, and 20 patients with concomitant stenosis of the CA, 
SMA and inferior mesenteric artery (IMA), respectively). 
Management of patients with CGI
The results of the diagnostic work-up of the 436 included patients 
in the study were discussed in a multidisciplinary expert panel. A 
consensus diagnosis of CGI was made in 229 (53%) patients and 
in 207 (47%) patients CGI was excluded. As listed in  1, 208/229 
patients with the consensus diagnosis of CGI were eligible for 
treatment. Intervention was offered to 127 patients with occlusive 
ischemia, of whom 94 patients received angioplasty and/or stenting 
of the mesenteric arteries, and 27 patients were treated surgically. 
A further six patients were treated surgically after endovascular 
treatment had failed. The remaining twelve patients were unfit for 
intervention and received conservative therapy. During follow-up of 
these patients, 109 patients with occlusive CGI had sustained relief 
of symptoms after treatment. Of these patients, 19/109 had reste-
nosis during follow-up. Stent revision was successful in 10/17 and 
surgical bypass in five patients. Despite multiple attempts for by-
passes and relaparatomies for bowel resection, three patients died 
of acute-on-chronic ischemia. In one patient with instentstenosis, 
surgical treatment was not possible. He was treated conservatively 
and died of ischemia-related causes. Fourteen patients who were 
diagnosed with occlusive CGI, died of non-ischemia related causes 
during follow-up. Eleven patients with occlusive CGI who were not 
eligible for treatment, had ongoing symptoms during follow-up. 
Furthermore, one of these 11 patients died of acute-on-chronic 
ischemia. This patient was admitted for sudden, severe abdominal 
pain. Bowel resection was performed, however this was not suc-
cessful and this patient died during admission. 
NOMI patients received medical treatment with vasodilative 
therapy (n=81) or a expectative approach (n=9)  1. The first line 
therapy for patients with NOMI consists of isosorbide dinitrate 20 
or 40mg od. The first line therapy is ceased in case of side effects 
or no clinical improvement after four weeks, and is replaced by 
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 1 Patient characteristics for the total group and subgroups  
  according to definitive diagnosis of CGI/non-CGI
observed
(n)
total population
(n=436)
CGI
(n=171 (39))
non-CGI
(n=265 (61))
age (years) a  436 61 (50-72) 67 (54-74) 58 (45-71)
sex
male
female
436
151 (35)
285 (65)
47 (27)
124 (73)
104 (39)
161 (61)
postprandial pain 
no pain
pain, no hindrance in ADL 
pain, small impairment ADL
pain, major impairment ADL
pain, complete impairment ADL
exercise-induced pain
no pain
pain, no hindrance in ADL 
pain, small impairment ADL
pain, major impairment ADL
pain, complete impairment ADL
BMI (kg/m2) a
weight loss
weight loss (kg/month) a 
diarrhea
nausea
duration of symptoms (months) a
427
415
424
431
271
416
429
420
92 (22)
79 (19)
141 (33)
77 (18)
38 (9)
99 (24)
70 (17)
134 (32)
84 (20)
28 (7)
22.4 (19.5-25.9)
286 (66)
1.6 (0.8-3.5)
111 (37)
141 (33)
12.0 (6.0-36.0)
33 (20)
29 (17)
55 (33)
32 (19)
19 (11)
39 (24)
20 (13)
58 (36)
28 (18)
15 (9)
21.5 (18.6-25.0)
126 (75)
1.8 (1.0-3.7)
39 (24)
66 (47)
12 (6.0-26.0)
59 (23)
50 (19)
86 (33)
45 (17)
19 (7)
60 (24)
50 (20)
76 (30)
56 (22)
13 (5)
20.8 (18.8-23.6)
160 (61)
1.6 (0.8-3.3)
72 (28)
75 (29)
12 (6.0-24.0)
cardiovascular disease
hypertension
DM type II
hypercholesterolemia
436
436
436
434
185 (42)
232 (53)
63 (14)
171 (39)
93 (54)
108 (63)
29 (17)
80 (16)
92 (35)
124 (47)
34 (13)
91 (35)
family history CVD
smoking 
smoking (pack years) a
alcohol 
alcohol (U/day) b
425
433
393
280 (66)
317 (73)
11 (0-26)
161 (41)
0 (0-30)
119 (71)
133 (78)
13 (2-26)
65 (42)
0 (0-10)
161 (63)
184 (70)
10 (0-25)
96 (40)
0 (0-24)
analgetics
none
opioids
non-opioids
antithrombotics
none
platelet aggregration inhibitors
oral anticoagulants
both
435
436
326 (75)
64 (15)
45 (10)
216 (50)
169 (39)
45 (10)
6 (1)
134 (78)
26 (15)
11 (6)
66 (39)
82 (48)
20 (12)
3 (2)
192(73)
38 (14)
34 (13)
150 (57)
87 (33)
25 (9)
3 (1)
mesenteric artery stenosis
no stenosis
single artery stenosis
multi artery stenosis
436
241 (55)
122 (28)
73 (17)
48 (28)
57 (33)
66 (39)
193 (73)
65 (25)
7 (2)
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observed
(n)
total population
(n=436)
CGI
(n=171 (39))
non-CGI
(n=265 (61))
functional mucosal ischemia c
present
absent
 409
317 (73)
92 (21)
152 (89)
14 (8)
165 (62)
78 (29)
endoscopic mucosal appearance d
normal
edema
erythema
erosion
ulceration
428
282 (66)
3 (1)
64 (15)
58 (14)
21 (5)
108 (64)
1 (1)
19 (11)
29 (17)
12 (7)
174 (67)
2 (1)
45 (17)
29 (11)
9 (4)
a median, interquartile range (IQR) 
b median, range
c functional mucosal ischemia as detected by functional testing using tonometry or VLS
d endoscopic (morphological) appearance of the gastric mucosal during upper GI endoscopy
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second-line treatment consisting of ketanserin 20mg or 40 mg 
od. Clinical response was defined as complete or partial relief of 
the major persisting symptoms. The etiologies of the NOMI were 
mostly of cardiac origin, however there were also patients with 
pulmonary pathology (3 patients with chronic obstructive disease), 
two patients with vasospasms of the mesenteric arteries and one 
patient with a low-flow state based on chronic kidney insufficiency. 
Five patients with NOMI were treated conservatively. Four of the 
five patients had ongoing symptoms and one patient died of cardiac 
failure during follow-up. Of the 45 patients with NOMI and a sus-
tained response on vasodilatative therapy, four patients eventually 
received percutaneous transluminal coronary angioplasty (PTCA) 
or coronary artery bypass procedure during follow-up as the final 
treatment of their complains. One patient was eligible for PTCA, 
however after two unsuccessful attempts it was decided to omit 
this. Two patients died of terminal heart failure during follow-up. 
At follow-up (median 5.6 (IQR 1.4-18.6) months), sustained 
relief of symptoms was achieved in 78/94 patients endovascularly 
treated and in 31/33 patients surgically treated. A sustained re-
sponse was observed in 45/81 (56%) patients with NOMI. During fol-
low up, five (2%) patients with the consensus diagnosis CGI became 
free of symptoms without any treatment and were classified as 
definitive diagnosis non-CGI. One patient with the consensus diag-
nosis of non-CGI was hospitalized with ischemia-related morbidity 
during follow-up and was therefore reclassified as CGI patient. 
Thus, from the 436 included patients, 171 (39%) were definitely 
diagnosed with CGI of whom 121 (71%) patients with occlusive CGI 
and 50 (29%) patients with NOMI (see supplementary  1 for patient 
characteristics of the groups).
Management of patients with non-CGI
Among the patients in whom CGI was ruled out, 140 (68%) had 
patent mesenteric arteries, 51 (25%) patients had a single-vessel 
stenosis, and 5 (2%) patients had multi-vessel stenosis. In the 
patients with patent mesenteric arteries, 59 patients had normal 
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oxygen saturation levels. Sixty-six patients had signs of local hy-
posaturation but a diagnosis of CGI was rejected based on atypical 
symptomatology in combination with patent arteries. In the remain-
ing patients, functional testing was not performed due to a known 
history of (partial) gastrectomy or due to atypical symptomatology 
in combination with patent arteries. In the 51 patients with a single-
vessel stenosis, functional testing showed normal mucosal oxygen 
saturation in ten patients. Functional testing was not performed in 
five patients due to a history of gastrectomy in combination with an 
atypical symptomatology. In 36 patients with single-vessel stenosis, 
functional testing showed hypo-oxygenation. However, these 
patients had a very atypical symptomatology. In the patients with 
multi-vessel mesenteric stenosis, functional testing showed normal 
mucosal oxygen saturation in one patient in combination with an 
atypical symptomatology. Four patients had atypical symptomatol-
ogy and hypo-oxygenation on functional testing. In these patients, 
CGI was ruled out due to an alternative diagnosis. The alternative 
diagnosis for non-CGI patients was in most cases presence of ma-
lignancy with or without metastases, inflammatory bowel disease, 
or (chronic) pancreatitis. Five patients were classified as non-CGI 
after an initial consensus diagnosis of CGI, but were however not 
eligible for treatment and were thus treated conservatively. During 
follow-up the symptoms were self-limiting, which in return made 
the diagnosis of CGI very unlikely in these patients. 
Prediction model for CGI 
In the univariate regression analysis, clinical parameters showing 
strong association with CGI were increasing age (OR 1.61, 95% CI 
1.21-2.16), female gender (OR 1.70, 95% CI 1.12-2.58), weight loss (OR 
1.91, 95% CI 1.24-2.92), nausea (OR 1.65, 95% CI 1.10-2.49), duration 
of symptoms (OR 0.88, 95% CI 0.80-0.99), presence of concomitant 
cardiovascular disease (OR 2.24, 95% CI 1.51-3.32), hypertension 
(OR 1.95, 95% CI 1.32-2.89), hypercholesterolemia (OR 1.68, 95% 
CI 1.13-2.48), smoking (OR 1.36, 95% CI 1.01-1.84) and use of non-
opioid analgetics (OR 0.47, 95% CI 0.23-0.95)  2.
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 2 Predictors for CGI
univariable analysis
OR [95% CI] a
model A
OR [95% CI] a
model B
OR [95% CI] a
age (years) a 1.61 [1.21-2.16] 1.24 [0.88-1.73] 0.99 [0.68-1.43]
female gender 1.70 [1.12-2.58] 1.86 [1.18-2.95] 1.30 [0.76-2.21]
postprandial pain 
no pain
pain, no hindrance in ADL 
pain, small impairment ADL
pain, major impairment ADL
pain, complete impairment ADL
exercise-induced pain
no pain
pain, no hindrance in ADL 
pain, small impairment ADL
pain, major impairment ADL
pain, complete impairment ADL
BMI (kg/m2) a
weight loss
weight loss (kg/month) a 
diarrhea
nausea
duration of symptoms (months) a
reference
0.99 [0.53-1.84]
1.09 [0.63-1.87]
1.25 [0.67-2.32]
1.86 [0.87-4.00]
reference
0.65 [0.34-1.25]
1.17 [0.69-1.99]
0.81 [0.44-1.49]
1.78 [0.72-4.39]
0.98 [0.77-1.26]
1.91 [1.24-2.92]
0.99 [0.85-1.14]
0.79 [0.49-1.26]
1.65 [1.10-2.49]
0.88 [0.80-0.98]
1.87 [1.18-2.97]
1.27 [0.82-1.98]
0.90 [0.82-0.99]
1.72 [0.02-2.90]
1.78 [1.07-2.95]
0.90 [0.81-1.00]
cardiovascular disease
hypertension
DM type II
hypercholesterolemia
2.24 [1.51-3.32]
1.95 [1.32-2.89]
1.38 [0.81-2.38]
1.68 [1.13-2.48]
2.15 [1.35-3.44] 1.55 [0.90-2.69]
family history CVD
smoking 
smoking (pack years) a
alcohol 
alcohol (U/day) b
1.44 [0.95-2.19]
1.49 [0.95-2.32]
1.36 [1.01-1.84]
1.06 [0.71-1.59]
1.03 [0.90-1.19]
1.36 [0.87-2.12] 1.39 [0.84-2.31]
analgetics
none
opioids
non-opioids
antithrombotics
none
platelet aggregration inhibitors
oral anticoagulants
both
reference
0.99 [0.57-1.70]
0.47 [0.23-0.95]
reference
2.14 [1.41-3.25]
1.82 [0.94-3.50]
2.27 [0.45-11.56]
0.80 [0.45-1.44]
0.41 [0.19-0.87]
0.71 [0.35-1.41]
0.60 [0.27-1.36]
mesenteric artery stenosis
no stenosis
single artery stenosis
multi artery stenosis
reference
3.53 [2.19-5.68]
37.91 [16.35-87.89]
reference
3.56 [2.15-5.92]
34.60 [14.15-84.63]
c-statistic of model 0.62 0.76
a values represent Odds Ratio [95% Confidence Interval]
b for continuous variables, values represent OR [95% CI] for interquartile range (IQR)
c concordance statistic, equivalent to area under the receiver operating characteristic (ROC) 
curve, after internal validation
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In the multivariable logistic regression analysis using backward 
stepwise selection, age, female gender, weight loss, nausea, 
concomitant cardiovascular disease and positive family history 
for cardiovascular disease were the strongest predictors for CGI. 
Duration of symptoms >12 months and use of analgetics were 
adversely associated with CGI. Note that some 95% confidence 
intervals cross one, which is the result of the liberal p-value of 0.20 
used to select the predictors. Combining the predictors in model A 
showed a c-statistic of 0.62. The model adding radiological imag-
ing to assess the patency of the mesenteric arteries (no stenosis, 
single- or two-vessel arterial stenotic disease) to the self-reported 
clinical parameters (Model B) improved the discriminative ability of 
the model, with a c-statistic of 0.76 after optimism correction. For 
the false positive and false negative rates based on Model B see 
supplementary  2.
Based on Model A and B, a score chart was developed for 
predicting CGI  3. Based on the total score, risks of having CGI are 
categorized  4a. A total score of -4 to 1 points indicates a predicted 
risk of 18% of having CGI, 2-7 points to 32% and 8 points or more to 
an absolute risk 50% of having CGI. As an example, a 65-year old 
(1 point) female (3 points) with no history of cardiovascular disease 
(0 points) and weight loss of 4 kg since 3 months (3 point), but who 
uses analgetics including over-the-counter medication (-4 points), 
has a total score of 3 points, indicating a low risk of having CGI. 
The prediction model including radiological evaluation of the 
mesentery arteries allows further distinction of patients in having 
low (0%-17% absolute risk of CGI), intermediate (18%-38%) or high 
risk (>70%) of CGI  4b. 
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 3 Score chart for the prediction of CGI based on questionnaire
predictors scoring points
age
< 60 years
≥ 60 years
0
1
sex
male
female
0
3
cardiovascular disease
no 
yes
0
1
family history of 
cardiovascular disease 
no
yes 
0
1
weight loss
no
yes
0
3
 4 Prediction model for CGI: model A with self-reported clinical  
  variables and model B with self-reported clinical variables and 
  radiological evaluation of the mesenteric arteries and the  
  absolute risk (%) for CGI
model A
total score absolute risk
−4-1
2-7
8+
18%
32%
 50%
predictors scoring points
nausea
no 
yes
0
1
duration of symptoms
≤ 12 months
> 12 months
1
0
use of analgetics
none
opioids
non-opioids
0
-1
-4
mesenteric artery stenosis
no stenosis
single artery stenosis
multi artery stenosis
0
6
10
model B
total score absolute risk
−4-1
2-7
8+
18%
32%
 50%
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Discussion
We present a prediction model to identify patients with CGI based 
on a large prospective study. Our study shows that advanced age, 
female gender, presence of nausea and weight loss, recent onset 
of symptoms, concomitant cardiovascular disease, positive family 
history for cardiovascular disease, and no use of analgetics are 
predictors for CGI. However, medical history and clinical symptoms 
alone are only moderately predictive of the risk of CGI and includ-
ing radiological evaluation of the mesenteric arteries in the model 
considerably improves the accuracy of risk assessment of CGI. 
Therefore, we established a model based on clinical symptoms and 
radiological evaluation of the mesenteric arteries to identify low, 
intermediate and high-risk patients for CGI.
There is an unmet need for widely accepted criteria for the 
diagnosis of CGI 15-17. Until now, evaluation for CGI is in particular 
reserved for patients who report specific clinical symptoms. This 
may however result in underdiagnosis, continuation of testing 
for other conditions, and delay of appropriate treatment 18-20. This 
large prospective study shows that medical history and clinical 
symptoms alone are only moderately predictive of the risk of CGI. 
Including radiological evaluation of the mesenteric arteries in the 
model considerably improved the accuracy of risk assessment of 
CGI. We established a model based on these variables to identify 
low, intermediate and high-risk patients for CGI. The strengths 
of this model are its high performance for predicting the risk of 
CGI constructed on the largest patient population diagnosed with 
CGI. Furthermore, it also applies to patients with non-occlusive 
mesenteric ischemia NOMI, a disease entity that has not earlier 
been included 21-23. As patients with NOMI still have the same symp-
tomatology, the model is designed to identify them as risk-patients, 
urging the clinician not to refrain from further investigation. A next 
step could then be the performance of functional testing such as 
gastric tonometry of VLS. 
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In this study, patients with a clinical suspicion of CGI referred for 
further evaluation to a tertiary center were included. All patients, 
also non-CGI patients, received the same work-up which makes 
this an unique cohort suitable for developing a prediction model. In 
line with earlier studies, our study shows that ‘classical’ symptoms 
such as postprandial pain and presence of weight loss are the 
most prevalent symptoms in patients with CGI but also in non-CGI 
patients 1-3,24. As a consequence, postprandial abdominal pain is a 
weak clinical predictor for CGI. However, this finding may be con-
founded by selection. Our data corroborate with earlier reports that 
a cardiovascular risk profile predisposes for CGI and earlier onset of 
symptoms 1,2,19,25. 
Our study confirms that the diagnostic value of clinical vari-
ables alone in the diagnosis of CGI is limited (c-statistic 0.62) 26. This 
is similar to previous models (c-statistics of 0.60-0.62) assessing 
only these clinical variables 2,3. Combining clinical variables with 
presence of mesenteric arterial stenosis in a second model allows 
discriminating more accurately between patients with and without 
CGI (c-statistic of 0.76). Based on this, we have developed a simple 
score chart that takes into account the limited availability of func-
tional tests in most hospitals 8,27,28. This score may be used in clinical 
decision making. This could allow a wait-and-see policy in patients 
with a low score 2. In patients with intermediate and high score a 
more aggressive approach (including vascular intervention) may be 
advocated 29,30. 
A possible limitation of this study regards incorporation 
bias 31. All test results such as reported symptoms, imaging of 
mesenteric vasculature, and mucosal saturation levels were consid-
ered to establish the diagnosis of CGI. This may have led to overes-
timation of the accuracy of the studied variables for the prediction 
model for CGI 32,33. This illustrates the necessity for prospective, ex-
ternal validation of our model in a new cohort of patients. However, 
this is expected to be difficult as large well-defined cohorts are 
lacking and will also be limited by the absence of a golden standard 
for CGI. Another limitation concerns the duration of follow-up after 
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reaching the consensus diagnosis. The consensus diagnosis of CGI 
was changed into non-CGI in 46 subjects, as treatment of CGI did 
not result in a sustained response 3,24,34,35. Also, most patients with 
a consensus diagnosis of non-CGI were discharged from follow-up 
but were instructed to report when ischemic complications had 
occurred 1,34. This may have resulted in underdiagnosis of CGI in 
follow-up. Nevertheless, we believe this will not affect the predic-
tion model as we expect this to occur at a low rate 3,34.
In conclusion, our study confirms that clinical symptoms 
alone are insufficient to predict the risk of CGI. Radiological evalu-
ation of the mesenteric arteries improves predictions substantially. 
We present a prediction model based on clinical variables and 
radiological imaging of the mesenteric arteries with acceptable 
accuracy. This may be a useful tool for clinicians to assess the risk 
of CGI and to decide whether further diagnostic work-up and treat-
ment is indicated.
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 s1 Patient characteristics of patients with CGI according to  
  occlusive CGI and NOMI
observed
n
total population
n=171 (100%)
CGI
n=121 (71%)
non-CGI
n=50 (29%)
age (years) a  121 67 (54-74) 63 (54-74) 60 (52-72)
sex
male
female
121
47 (27)
124 (73)
25 (21)
96 (79)
22 (44)
28 (56)
postprandial pain 
no pain
pain, no hindrance in ADL 
pain, small impairment ADL
pain, major impairment ADL
pain, complete impairment ADL
exercise-induced pain
no pain
pain, no hindrance in ADL 
pain, small impairment ADL
pain, major impairment ADL
pain, complete impairment ADL
BMI (kg/m2) a
weight loss
weight loss (kg/month) a 
diarrhea
nausea
duration of symptoms (months) a
119
112
116
119
83
112
119
118
33 (20)
29 (17)
55 (33)
32 (19)
19 (11)
39 (24)
20 (13)
58 (36)
28 (18)
15 (9)
21.5 (18.6-25.0)
126 (75)
1.8 (1.0-3.7)
39 (24)
66 (47)
12 (6.0-26.0)
22 (19)
18 (15)
47 (40)
24 (20)
8 (7)
27 (24)
14 (13)
40 (36)
23 (21)
8 (7)
22.2 (19.5-25.1)
88 (74)
1.6 (0.8-3.6)
26 (23)
45 (38)
12 (5.6-24.0)
11 (22)
11 (22)
8 (16)
8 (16)
11 (22)
12 (25)
6 (13)
18 (38)
5 (10)
7 (15)
22.5 (18.5-27.8)
38 (76)
1.9 (1.0-5.6)
13 (26)
21 (42)
12 (5.5-39.0)
cardiovascular disease
hypertension
DM type II
hypercholesterolemia
121
121
121
121
93 (54)
108 (63)
29 (17)
80 (16)
56 (46)
79 (65)
20 (17)
58 (48)
28 (56)
29 (58)
9 (18)
22 (44)
family history CVD
smoking 
smoking (pack years) a
alcohol 
alcohol (U/day) b
118
121
118
110
118
119 (71)
133 (78)
13 (2-26)
65 (42)
0 (0-10)
83 (70)
96 (79)
15 (3-28)
48 (44)
0 (0-2)
36 (72)
37 (74)
15 (0-31)
17 (38)
0 (0-2)
analgetics
none
opioids
non-opioids
antithrombotics
none
platelet aggregration inhibitors
oral anticoagulants
both
112
112
134 (78)
26 (15)
11 (6)
66 (39)
82 (48)
20 (12)
3 (2)
95 (79)
19 (16)
7 (6)
46 (38)
58 (48)
16 (13)
1 (1)
39 (78)
7 (14)
4 (8)
20 (40)
24 (48)
4 (8)
2 (4)
values represent number and percentage (%) of patients.  
a median, interquartile range (IQR)
b median, range
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 s2 False positive and false negative rates for the diagnosis of CGI 
  according to Model B
CGI + CGI − total PPV
−4-7 points CGI + 25 133 158 0.16
8-13 points CGI + 50 102 152 0.33
>14 points 96 30 126 0.76
total 171 265 436
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Abstract
Background
Chronic gastrointestinal ischemia (CGI) is 
the result of decreased mucosal perfu-
sion. Typical histological characteristics 
are lacking which hampers its early 
diagnosis. Hypoxia-inducible factor-1α 
(HIF-1α) is expressed under acute hy-
poxia. We investigated HIF-1α expression 
in chronic ischemic and inflammatory 
conditions of the human gastrointestinal 
(GI)-tract.
Materials and methods
Immunohistochemical expression of HIF-
1α was analyzed in 61 patients, including 
patients with CGI, Helicobacter pylori-
gastritis, ischemic colitis (IC), infectious 
colitis, inflammatory bowel disease 
(IBD) and 22 controls. HIF-1α expression 
in > 10% of the cells was regarded as 
positive staining, and expression < 10% 
of the cells was considered as negative 
staining. 
Results 
In the upper GI-tract, HIF-1α expression 
was found in 5/20 CGI-patients, but not 
in controls (p=0.08). The sensitivity 
and specificity of HIF-1α expression for 
diagnosing CGI was 25% and 84%. In the 
lower GI-tract, in HIF-1α was expressed 
in all patients with IC, infectious colitis 
and in majority of IBD-patients. This was 
also in 7/12 controls. The sensitivity and 
specificity of HIF-1α for diagnosing IC 
was 100% and 51%. HIF-1α expression 
was more observed in patients with 
inflammation on histology (p=0.02) in the 
lower GI-tract. 
Conclusions 
HIF-1α is expressed in acute and chronic 
ischemic tissue, but also in normal colon 
tissue and inflammatory disorders.
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Introduction
Chronic gastrointestinal ischemia (CGI) is characterized by a broad 
range of clinical symptoms including chronic abdominal pain and 
weight loss and is the result of decreased mucosal perfusion by 
the gastrointestinal vasculature. The majority of patients with CGI 
is only diagnosed after extensive evaluation, often over prolonged 
periods, but it may be fatal when not timely recognized 1,2.
Currently, there is no single test with high sensitivity and 
specificity to diagnose or exclude CGI. A diagnostic approach com-
bining assessment of clinical symptoms, radiological imaging of 
the gastrointestinal arteries and functional testing by tonometry or 
spectroscopy, is currently performed in the work-up of CGI suspect-
ed patients 3. At present, a definitive diagnosis of CGI can only be 
made after persistent relief of symptoms on follow-up after treat-
ment. Histology does not seem to play a major role in the diagnosis 
of CGI 4. Markers for acute ischemia such as lactate dehydrogenase 
(LDH), leukocyte counts, C-reactive protein (CRP), and D-dimer have 
limited value for diagnosing CGI 5-8. Against the lack of specificity 
of symptoms and diagnostic tests, further research is needed to 
assess typical histology for CGI. 
Hypoxia-inducible factor-1α (HIF-1α) is expressed in acute 
ischemia 9. HIF-1α is a significant intracellular regulator of oxygen 
hemostasis and is expressed in cells under low oxygen tension 10. 
It may exert a tissue-protective effect under these circumstances 
by upregulation of cytoprotective genes that help to control 
metabolism, enhance oxygen delivery, and angiogenesis 11-13. 
Immunohistochemical staining revealed presence of HIF-1α in 
several organs, including the gastrointestinal (GI)-tract, under 
hypoxic conditions 14,15. Expression of HIF-1α in gastric or intestinal 
tissue may thus identify patients with CGI. To address this issue, we 
performed a pilot study to investigate the expression of HIF-1α in 
chronic ischemic tissue by immunohistochemistry.
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Materials and methods
Study design
A histological study in which the immunohistochemical expression 
of HIF-1α was analyzed in 61 patients and 22 controls. This study 
was approved by the Institutional Review Board of the Erasmus MC 
University Medical Centre and adherent to Good Clinical Practice.
Participants and controls 
Immunohistochemical expression of HIF-1α in the gastrointestinal 
tract was analyzed in the upper or lower GI tract of 61 patients and 
22 controls. These included 20 patients with CGI, nine patients 
with H. pylori-gastritis, nine patients with ischemic colitis (IC), five 
patients with infectious colitis and 18 patients with inflammatory 
bowel disease (IBD). All patients underwent either upper endoscopy 
with paired gastric and duodenal biopsies or colonoscopy with 
biopsy sampling. 
Consecutive patients with CGI were selected. Diagnosis of 
CGI was based on clinical history, presence of mucosal ischemia 
assessed by functional testing, and/or significant stenosis of ≥1 
gastrointestinal artery. Patients with H. pylori-gastritis and infec-
tious colitis were randomly selected from the hospital database. 
Presence of H. pylori-gastritis was confirmed by histology. 
Infectious colitis was confirmed by means of stool culture and 
histology confirmation: Clostridium difficile (n=3), Campylobacter 
jejuni (n=1), and Escherichia coli (0157 strain) (n=1). Patients with IC 
were selected when clinical presentation, course of the disease, and 
the endoscopic appearance indicated ischemia and this was con-
firmed by histology. Patients with IBD consisted of 9 patients with 
M. Crohn, and 9 with ulcerative colitis. Tissue samples for patients 
with ulcerative colitis were collected during endoscopy due to 
complains (n=5), and surveillance (n=3), or were resection specimen 
(n=1). For patients with M. Crohn, biopsy-sampling occurred during 
endoscopy due to complains (n=4), surveillance (n=4) and in one 
patient during surgery (n=1). 
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Twenty-two subjects served as the control group in the study, 
and were unmatched. For the upper GI-tract, consecutive patients 
with unexplained abdominal symptoms (n=10) requiring upper 
endoscopy were selected. In these patients CGI, H. pylori- gastritis 
and other pathology was excluded. For the lower GI-tract, tissue 
samples were collected during double balloon enteroscopy due to 
gastrointestinal bleeding (n=6) and unexplained abdominal symp-
toms (n=6). 
Endoscopy
Upper GI endoscopy was performed in all patients with CGI, 
H. pylori-gastritis and 10 controls. Colonoscopy with biopsy sam-
pling was performed in all other patients. Prior to biopsy sampling, 
the endoscopic appearance was evaluated by grading into: no 
inflammation, presence of oedema and erythema, ulceration, or 
necrosis. Biopsy sampling was performed according to a standard-
ized protocol during endoscopy. Biopsies from the upper GI-tract 
included a biopsy from the descending duodenum, and one from 
the greater curvature of the antrum within 2-3 cm from the pylorus 
or corpus. 
Histology
Presence of inflammation was systemically scored for the upper 
and lower GI-tract. Gastric biopsies of patients with CGI were 
scored by the Houston-updated Sydney System 16. In biopsies of 
the lower GI-tract, the presence of inflammation was scored by the 
6 grade classification system by Geboes et al. 17 All scoring was 
performed by an expert GI pathologist (KB), blinded for the patient 
characteristics.
Immunohistochemistry
Formaldehyde-fixed, paraffin-embedded tissue samples were cut 
and prepared according to protocol. Antigen retrieval was achieved 
as was previously described 18. After an overnight incubation with 
mouse monoclonal antibody against human HIF-1α (1:10 for upper 
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GI tract and 1:200 respectively for colon samples; BD Transductions 
Laboratories, Sparks, Maryland, USA), binding of the primary anti-
body was visualized with the Novocastra Polymer Detection System 
(Novocastra Laboratories Ltd., New castle, United Kingdom). 
Peroxidase activity was developed with DAB (BD Pharmingen, 
Transductions Laboratories, Sparks MD, U.S.A.). Between each step 
the slides were washed in phosphate buffered saline. Finally, after 
rinsing with deionized water, the slides were counterstained with 
hematoxylin, and dehydrated before being mounted. Ductal-type 
breast cancer cell lines served as positive controls, and negative 
controls were achieved by omitting the primary antibody 19. To test 
the specificity of the primary antibody, hepatocytes were stained 
for HIF-1α expression, as these cells are known for not express-
ing HIF-1α 20. All slides were scored by the same pathologist (KB), 
blinded for the results of the clinical work-up. The slide order 
was randomized, minimizing the risk of bias as much as possible. 
Immunohistochemical staining of HIF-1α expression was evaluated 
as previously described 21. Staining in the nuclei and cytoplasma of 
the cells was evaluated. The number of positive cells was assessed 
in all optical fields at magnification x200, and the mean value of all 
fields was used to obtain the final score. Stain intensity and stain 
pattern was assessed. Expression > 10% of the cells was regarded 
as positive staining, and expression < 10% of the cells was regarded 
as negative staining. The overall staining intensity was graded on a 
4-point system by Allred et al. 22 
Statistical analysis
Baseline characteristics were calculated using descriptive statistics. 
Differences in presence of HIF-1α expression and inflammation were 
assessed using Kruskal-Wallis or Mann-Whitney test. Differences in 
presence of inflammation according presence of HIF-1α expression 
was assessed using Mann-Whitney test. Statistical analysis was 
performed using the SPSS 21.0 program (SPSS Inc., Chicago, IL, 
USA). A p-value of <0.05 was considered statistically significant.
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Results
Patients characteristics
Immunohistochemical expression of HIF-1α in the gastrointestinal 
tract was analyzed in 61 patients and 22 controls. These included 
20 patients with CGI, nine patients with H. pylori-gastritis, nine 
patients with ischemic colitis (IC), 18 patients with inflammatory 
bowel disease (IBD) and five patients with infectious colitis. Ten 
controls served for the upper GI-tract and 12 controls for the lower 
GI-tract respectively. Characteristics of patients and controls are 
summarized in  1a and  1b. 
 1a Patients characteristics according to localization in the GI-tract
upper GI-tract
n=39
lower GI-tract 
n=44
age (mean, SD) 61.6 (16.1) 51 (18)
gender
male
female
17 (44%)
22 (56%)
22 (50%)
22 (50%)
diagnosis 
ischemia a
infection b
inflammation c
controls
20 (51%)
9 (23%)
n.a.
10 (26%)
9 (21%)
5 (11%)
18 (41%)
12 (27%)
endoscopic appearance
normal
edema/ erythema
ulceration
necrosis
15 (38%)
12 (31%)
12(31%)
0 (0%)
15 (34%)
8 (18%)
11 (25%)
10 (23%)
values represent number and percentage (%) of patients
a chronic gastrointestinal ischemia and/or ischemic colitis
b H. pylori-gastritis and/or infectious colitis
c inflammatory bowel disease
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Endoscopy
Overall, endoscopic pathological findings were found in 24 (61%) 
and 29 (66%) patients of the upper and lower GI-tract group. The en-
doscopic appearance of patients with CGI did not differ significantly 
from patients with H. pylori-gastritis and the controls. Interestingly, 
the majority of patients with CGI had no or only mild inflammation 
on endoscopy and in 50% of patients the endoscopic appearance 
was completely normal. In patients with H. pylori-gastritis, ulcer-
ation (44%) was mostly seen on endoscopy. The endoscopic ap-
pearance of the controls was normal in 3 (30%) subjects. However, 
mild erythema and edema was observed in 50% of the healthy 
subjects. 
 1b Clinical characteristics of patients: upper and lower GI-tract
CGI 
n=20
H. pylori-gastritis
n=9
controls upper GI
n=10
IC
n=9
UC
n=9
 IBD  CD
n=9
infectious colitis
n=5
controls lower GI
n=12
inflammatory parameters
CRP, mg/l a
leukocytes, × 109/l a
2.0 (1.0-4.0)
6.8 (5.8-10.1)
1.0 (1.0-3.0)
7.9 (6.5-8.4)
1.0 (1.0-3.0)
5.7 (4.9-7.1)
72 (40-175)
11.7 (8.4-13.4)
2 (1-47)
8.1 (5.2-15.0)
17 (4-37)
9.0 (7.4-9.6)
66 (38-480)
10.9 (10.2-27)
1 (1-6)
5.3 (4.9-7.3)
mesenteric arterial stenosis b
absent
single-vessel
multi-vessel
unknown
1 (5%)
6 (30%)
13 (65%)
–
–
–
–
9 (100%)
9 (90%)
–
1 (10%)
–
2 (22%)
–
1 (11%)
6 (66%)
–
–
–
18 (100%)
1 (20%)
–
–
4 (80%)
2 (17%)
1 (8%)
–
9 (75%)
medication
immunesuppressives 
anti-inflammatory drugs 
antacids 
3 (15%)
11 (55%)
16 (80%)
3 (33%)
4 (44%)
3 (33%)
–
2 (20%)
7 (70%)
–
4 (44%)
7 (78%)
7 (78%)
6 (67%)
1 (11%)
6 (67%)
6 (67%)
1 (11%)
2 (40%)
2 (40%)
2 (40%)
4 (40%)
5 (46%)
9 (90%)
smoking habit
current
former 
never
unknown
4 (20%)
9 (45%)
7 (35%)
–
1 (11%)
–
4 (44%)
4 (44%)
2 (22%)
4 (44%)
3 (33%)
–
2 (33%)
1 (17%)
2 (33%)
1 (17%)
1 (11%)
–
6 (66%)
2 (22%)
1 (11%)
1 (11%)
1 (11%)
6 (66%)
–
–
2 (40%)
3 (60%)
5 (42%)
1 (8%)
1 (8%)
5 (42%)
values represent number and percentage (%) of patients
a median, interquartile range (IQR)
b mesenteric arterial stenosis defined as significant stenosis ≥ 50%
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In all IC patients abnormal findings were present on endoscopy. 
Ulceration was present in most of the patients with IC (n=67%). All 
patients with infectious colitis had pathologic endoscopic appear-
ance, either presence of erythema and edema (n=2/5) or even 
necrosis (n=3/5). The majority of patients with IBD had abnormal 
findings on endoscopy, varying from presence of erythema to 
necrosis. However, in 5 patients no signs of inflammation were 
observed in the colon on endoscopy. In the majority of the controls 
(83%), no abnormalities were seen in the colon on endoscopy. 
Endoscopy
Overall, endoscopic pathological findings were found in 24 (61%) 
and 29 (66%) patients of the upper and lower GI-tract group. The en-
doscopic appearance of patients with CGI did not differ significantly 
from patients with H. pylori-gastritis and the controls. Interestingly, 
the majority of patients with CGI had no or only mild inflammation 
on endoscopy and in 50% of patients the endoscopic appearance 
was completely normal. In patients with H. pylori-gastritis, ulcer-
ation (44%) was mostly seen on endoscopy. The endoscopic ap-
pearance of the controls was normal in 3 (30%) subjects. However, 
mild erythema and edema was observed in 50% of the healthy 
subjects. 
 1b Clinical characteristics of patients: upper and lower GI-tract
CGI 
n=20
H. pylori-gastritis
n=9
controls upper GI
n=10
IC
n=9
UC
n=9
 IBD  CD
n=9
infectious colitis
n=5
controls lower GI
n=12
inflammatory parameters
CRP, mg/l a
leukocytes, × 109/l a
2.0 (1.0-4.0)
6.8 (5.8-10.1)
1.0 (1.0-3.0)
7.9 (6.5-8.4)
1.0 (1.0-3.0)
5.7 (4.9-7.1)
72 (40-175)
11.7 (8.4-13.4)
2 (1-47)
8.1 (5.2-15.0)
17 (4-37)
9.0 (7.4-9.6)
66 (38-480)
10.9 (10.2-27)
1 (1-6)
5.3 (4.9-7.3)
mesenteric arterial stenosis b
absent
single-vessel
multi-vessel
unknown
1 (5%)
6 (30%)
13 (65%)
–
–
–
–
9 (100%)
9 (90%)
–
1 (10%)
–
2 (22%)
–
1 (11%)
6 (66%)
–
–
–
18 (100%)
1 (20%)
–
–
4 (80%)
2 (17%)
1 (8%)
–
9 (75%)
medication
immunesuppressives 
anti-inflammatory drugs 
antacids 
3 (15%)
11 (55%)
16 (80%)
3 (33%)
4 (44%)
3 (33%)
–
2 (20%)
7 (70%)
–
4 (44%)
7 (78%)
7 (78%)
6 (67%)
1 (11%)
6 (67%)
6 (67%)
1 (11%)
2 (40%)
2 (40%)
2 (40%)
4 (40%)
5 (46%)
9 (90%)
smoking habit
current
former 
never
unknown
4 (20%)
9 (45%)
7 (35%)
–
1 (11%)
–
4 (44%)
4 (44%)
2 (22%)
4 (44%)
3 (33%)
–
2 (33%)
1 (17%)
2 (33%)
1 (17%)
1 (11%)
–
6 (66%)
2 (22%)
1 (11%)
1 (11%)
1 (11%)
6 (66%)
–
–
2 (40%)
3 (60%)
5 (42%)
1 (8%)
1 (8%)
5 (42%)
values represent number and percentage (%) of patients
a median, interquartile range (IQR)
b mesenteric arterial stenosis defined as significant stenosis ≥ 50%
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 1 Serial sections of gastrointestinal tract tissue analyzed for 
  expression of HIF-1α by immunohistochemistry
 
a  normal stomach mucosa      b  chronic gastrointestinal ischemia
magnification 400 ×        magnification 400 ×
 
c  normal colon mucosa       d  ischemic colitis
magnification 400 ×        magnification 200 ×
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Expression of HIF-1α 
Expression of HIF-1α was found in 5 out of 20 (25%) patients with 
CGI. HIF-1α expression was not present in the controls  1a,b. 
Expression of HIF-1α did not significantly differ between these 
groups   2. 
Expression of HIF-1α was more present in the lower GI-tract. 
In all patients with IC, and infectious colitis HIF-1α was upregulated 
 1c. Presence of HIF-1α was also seen in majority of IBD patients 
(67%). This was also in 7 out of 12 controls  1d. 
Assessing the diagnostic performance of HIF-1α expression 
for the diagnosis of gastrointestinal ischemia, the sensitivity and 
specificity of HIF-1α were 25% and 84%. The sensitivity of HIF-1α for 
indicating presence of IC is 100%, with a specificity of 51%. 
 2 Expression of HIF-1α in the GI-tract
HIF-1α + P-value
upper GI-tract
CGI
H. pylori-gastritis
controls
5 (25%)
3 (33%)
0
0.65
0.08
lower GI-tract
IC
infectious colitis
IBD
controls
9 (100%)
5 (100%)
12 (67%)
7 (58%)
0.48
0.05
0.03 a
values represent number and percentage (%) of patients
a p -value < 0.05 was considered significant
96 Vascular diseases of the gastrointestinal tract
 3a Inflammation in the upper GI-tract according to diagnosis and 
  expression of HIF-1α
no
inflammation
mild-moderate 
inflammation
moderate-severe 
inflammation
CGI
H. pylori-gastritis
controls
13 (65%)
0
5 (50%)
7 (35%)
4 (44%)
5 (50%)
0
5 (56%)
0
HIF-1α present
HIF-1α absent
2 (11%)
16 (89%)
4 (25%)
12 (75%)
2 (40%)
3 (60%)
values represent number and percentage (%) of patients
a p -value < 0.05 was considered significant. Inflammation was scored as no inflammation 
(Sydney grade 0), mild to moderate (Sydney grade I-II) and moderate to severe inflammation 
(Sydney grade III-IV). Sydney grading was performed as previously published 16.
 3b Inflammation in the upper GI-tract according to diagnosis and 
  expression of HIF-1α
no
inflammation
chronic
inflammation
acute
inflammation
crypt
destruction
IC
infectious colitis 
IBD
controls
1 (11%)
0
3 (17%)
10 (83%)
1 (11%)
2 (40%)
3 (17%)
2 (17%)
1 (11%)
0
1 (5%)
0
6 (67%)
3 (60%)
11 (61%)
0
HIF-1α present
HIF-1α absent
9 (64%) a
5 (36%)
3 (38%) a
5 (62%)
2 (100%) a
0
19 (95%) a
1 (5%)
values represent number and percentage (%) of patients
a p-value  < 0.05 was considered significant. Inflammation was scored as no inflammation 
(Geboes grade 0), chronic (Geboes grade 1), acute (Geboes grade 2-3) and crypt destruction 
(Geboes grade 4-5). Scoring of inflammation in IBD as previously published 17.
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Presence of inflammation 
In 65% of patients with CGI histologic examination showed no sign 
of inflammation (grade 0 of the Sydney Classification Score). In the 
remaining patients (n=7), mild to moderate inflammation (Sydney 
grade I-II) was observed. Mild to severe inflammation (Sydney 
grade III-IV) was present in all patients with H. pylori-gastritis. 
Remarkably, in 50% of the controls mild to moderate inflammation 
(Sydney grade I-II) could be observed on histology  3a. 
In the lower GI-tract, majority (68%) of patients showed some 
degree of inflammation on histology  3b. In all but one patient of 
the IC-group inflammation was present on histology. In 67% (n=6) 
of these patients ulceration and crypt destruction was present. This 
was comparable to the IBD and infectious colitis group, in which 
ulceration and crypt destruction was present in 61% (n=11) and 60% 
(n=3), respectively. In 83% (n=10) of the healthy subjects no abnor-
malities were observed on histology. 
Inflammation and HIF-1α expression
HIF-1α expression was more frequently observed in 53% of patients 
with any degree of inflammation on histology in the upper GI-tract, 
and in 73% of patients in the lower GI-tract  3a. The sensitivity and 
specificity of HIF-1α for indicating presence of inflammation is 29% 
and 89% respectively, in the upper GI-tract, compared to 80% and 
36% for the lower GI-tract respectively. In the lower GI-tract, HIF-1α 
expression was significantly more observed in patients with inflam-
mation on histology (p=0.02)  3b.
98 Vascular diseases of the gastrointestinal tract
Discussion
Only limited studies are performed to investigate the role of HIF-1α 
in the gastrointestinal tract, with most of them focusing solely 
on ischemia-reperfusion injury or neoplasia, but none in CGI 23,24. 
The present study demonstrates the presence of HIF-1α in chronic 
ischemic and inflammatory diseases of the gastrointestinal tract. 
We performed a pilot study to investigate the expression of 
HIF-1α in chronic ischemic tissue in order to identify patients with 
CGI. Our results show that HIF-1α is present in ischemic tissue, but 
cannot differentiate between ischemic, inflammatory diseases and 
controls. Furthermore, there is a weak correlation between HIF-1α 
expression and presence of inflammation seen on histology. 
HIF1-α is markedly expressed in acute gastric ischemia, but 
expression of HIF-1α in chronic ischemic tissue of the GI-tract has 
not been described before 25. In this study, patients with acute co-
lonic ischemia and chronic gastric ischemia were included. It would 
have been ideal to include chronic colitis, being a long-term compli-
cation after an episode of acute ischemic colitis, but its incidence is 
very low and therefore rare 26. Hence, to evaluate the expression of 
HIF-1α in ischemic tissue, we opted to explore its expression under 
both acute and chronic hypoxic conditions in the two most encoun-
tered forms of gastrointestinal ischemia. 
This study demonstrates that HIF-1α is a marker for ischemia, 
showing high sensitivity for correctly identifying patients with 
IC, but poor sensitivity for diagnosing CGI. The difference in the 
expression of HIF-1α between these disease entities could be at-
tributed to several variables. 
First, the cellular responses involving HIF-1α appear to be 
different in acute and chronic conditions of hypoxia. Prolonged 
periods of hypoxia, such as in CGI, activate feedback mechanisms 
that decrease HIF-1α, such as enhanced protein kinase B (Akt) 
phosphorylation and consequent glycogen synthase kinase 3B 
(GSK3B), or forkhead transcription factor (FOX)04 activation. 
Second, upregulation of prolyl hydroxylase domains 27, encoding for 
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enzymes involved in HIF1-α hydroxylation, seem to be responsible 
for decrease of HIF-1α under chronic hypoxia. This is in contrast to 
their downregulation during short term hypoxic periods 28,29. 
Furthermore, exposure to hypoxia elicits tissue inflammation 
by activation of genes encoding pro-inflammatory molecules. In 
case of acute hypoxia, such as in IC, it can be hypothesized that 
the pro-inflammatory reaction is more severe compared to chronic 
exposure to hypoxia. 
Indeed, presence of inflammation might attribute to the 
enhanced expression of HIF-1α 30. Expression of HIF-1α was present 
in all patients with ischemic colitis and infectious colitis, and was 
also significantly more present in patients with H. pylori-gastritis 
compared to CGI and healthy subjects. We found that patients with 
enhanced expression of HIF-1α also showed more inflammation 
on histology. In line with this, patients with expression of HIF-1α 
showed significantly more inflammation on histology in the lower 
GI-tract. Multiple factors associated with inflammation can cause 
limited oxygen availability, such as vasoconstriction, edema, and 
vasculitis with HIF-1α expression as result 31,32. Also, inflammatory 
cells at the site of inflammation enhance the local oxygen consump-
tion leading to hypoxic conditions 33. Studies have detected im-
munoreactive HIF-1α in human macrophages. Bacterial exposure in-
duces the production of NO and TNF-α production by macrophages, 
which not only generate inflammation, but also further stabilize 
HIF-1α in myeloid cells in the infectious focus 34. This could also 
explain why in patients with infectious colitis, as well as gastritis, 
and in patients with IBD, expression of HIF-1α is present, even under 
normoxia. This is in line with earlier studies concerning expression 
of HIF-1α in colonic and infected upper GI-tract tissue 35-37.
A possible limitation of the study is the use of HIF-1α-
modifying drugs during time of endoscopy and biopsy sampling. 
Use of non-steroidal anti-inflammatory drugs (NSAID) and proton 
pump-inhibitors (PPI) results in under expression of HIF-1α through 
upregulation of the von Hippel-Lindau factor (pVHL) which enhanc-
es degradation of HIF-1α, and by inhibition of angiogenesis 38-40. As 
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not all patients could be stratified for (on-demand) PPI and NSAID 
use, this may have introduced a bias. Furthermore, the study is 
limited by the small sample population limiting the ability to detect 
significant differences between patients with chronic ischemia, 
controls and patients with inflammation. Further research using a 
larger sample size is needed. 
In addition, it would be preferred to conduct a second inde-
pendent technique such as western blot analysis or polymerase 
chain reaction (PCR) to corroborate our immunohistochemical 
findings. Demonstrating stable HIF-1α by such techniques is chal-
lenging because the ubiquitination of HIF-1α is a dynamic process 
and HIF-1α is a short-lived protein. As a solution, deubiquitination 
through pVHL-interacting protein deubiquitinating enzyme-2 (VDU2) 
could be considered. However, this required careful attention as 
it may result in artefacts 41. Given the extent of these and possible 
other confounders, we believe performing these additional tech-
niques is beyond the scope of this pilot study. 
 The results in our study confirm previous studies showing 
no expression of HIF-1α in normal tissue of the upper GI-tract 40,42. 
Concerning the expression of HIF-1α in normal colon tissue, differ-
ent results are demonstrated ranging from no expression to 90% 
expression in samples of normal colon 15,35. In our study, HIF-1α 
expression in the colon was present in 57% of the healthy subjects. 
It is suggested that HIF-1α may play a role in the physiology of 
normal colon tissue. Due to the anaerobic environment in the lumen 
of the colon, capillaries in the surface regions of the colon epithe-
lium are unable to provide for the oxygen demand of the tissue. As 
a result, these hypoxic areas may induce HIF-1α in order to promote 
angiogenesis and glycolysis 15. 
Our study shows that HIF-1α identifies ischemia. However, 
no significant difference between patients with CGI and controls 
could be seen. HIF-1α has a high sensitivity for correctly identifying 
patients with IC; however, it cannot differentiate between ischemia 
and inflammation. 
1015 Hypoxia-inducible factor 1-α in chronic gastrointestinal ischemia
In conclusion, this study shows that HIF-1α is expressed in ischemic 
tissue, but also in normal colon tissue, and various inflammatory 
disorders. Therefore, the value of HIF-1α as a marker for ischemia 
remains to be further investigated.
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Introduction
Hypoxic liver injury in an acute setting of cardiac, circulatory or 
respiratory failure, also known as hypoxic or ischemic hepatitis, is 
caused by insufficient oxygen uptake by hepatocytes and is usually 
defined as a sharp increase in serum aminotransferases (ALT) up to 
20 times the upper limit of normal due to centrilobular hepatocyte 
necrosis in the absence of other potential causes of hepatitis 1. It 
occurs in up to 20% of critically ill patients with low cardiac output 
and has a high 30-day mortality rate of 50% 2. It is unknown whether 
hypoxic liver injury only pertains to the acute or also to the chronic 
setting. Chronically compromised mesenteric arterial flow is hall-
mark of a disease entity known as chronic gastrointestinal ischemia 
(CGI) 3. The main cause of CGI is significant stenosis (≥70%) at the 
level of the origin of the mesenteric vasculature (celiac artery (CA) 
and/or superior mesenteric artery (SMA)) due to atherosclerosis, 
but also non-occlusive mesenteric ischemia (NOMI) due to cardiac 
forward failure may be observed. The incidence of CGI is estimated 
at 13/100.000 person-years and may progress in the vast majority 
from asymptomatic to symptoms of abdominal pain and malnutri-
tion, with some progressing to visceral infarction and death within 6 
years 4. It is not known to what degree liver injury occurs in CGI. We 
aimed to observe the extend of liver injury in a well-defined cohort 
of CGI patients.
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Methods
We performed a retrospective observational study of 156 consecu-
tive patients diagnosed with CGI between November 2006 and 
March 2013. All patients received a standard CGI work-up includ-
ing assessment of clinical symptoms and lifestyle parameters, 
laboratory tests, radiological imaging (abdominal ultrasound 
and/or computed tomography angiography (CT-A) and validated 
gastroduodenal mucosal saturation measurements 5. We excluded 
patients with known liver disease. Liver injury was defined as ALT 
>1x upper limit of normal (ULN), corrected for gender. 
Baseline characteristics were calculated using descriptive sta-
tistics. Data were expressed as mean and standard deviation (SD), 
median and interquartile range (IQR) or count and percentage (%), 
when appropriate. Logistic regression analysis was used to assess 
associations between potential risk factors and presence of liver in-
jury. The associations were estimated as Odds Ratios (OR) with 95% 
confidence interval (CI). Statistical analysis was performed using 
the SPSS 21.0 program (SPSS Inc., Chicago, IL, USA). A two-sided 
p-value of <0.05 was considered statistically significant.
The study was approved by the institutional reviewing board 
of the Erasmus MC University Medical Centre, Rotterdam, the 
Netherlands.
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Results
In total, 156 patients were eligible for inclusion (median age 64.1 
(IQR 53.1-73.6) years; 74% female, median ALT 0.49x ULN (IQR 
0.36-0.67) and 90% had gastro-intestinal mucosal ischemia  1). 
Radiological imaging did not reveal any considerable liver abnor-
malities. Stenotic CGI was present in 107 (69%) patients and NOMI 
in 49 (31%) patients. 
Elevated ALT >1x ULN was present at baseline in 15 (11%) pa-
tients (10 stenotic CGI; five NOMI). Mucosal ischemia was detected 
in 12 of these patients. None had an ALT level more than 3x ULN. 
Elevated ALT >1x ULN was not significantly associated with pres-
ence of mucosal ischemia, significant stenosis of the CA, SMA, or 
both CA and SMA. Neither was there an association between ALT 
>1x ULN and presence of known predisposed conditions of steatotic 
liver injury such as body mass index (BMI), alcohol consumption 
and diabetes mellitus (DM) type II, nor between ALT >1x ULN and 
increasing age  2. Twelve of these 15 patients received treatment 
(endovascular, surgical or medical treatment according to cause of 
CGI). At follow-up (median 17.6 months), only 2 of these patients 
kept ALT >1x ULN (mean 75 IU/ml). Both patients were diagnosed 
with NOMI and were irresponsive to treatment.
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 1 Baseline characteristics
total population
(n=156)
ALT <1x ULN a
(n=141)
ALT >1x ULN a
(n=15)
age (years) b 64.1 (53.1-73.6) 64.2 (52.9-73.7) 61.8 (57.6-72.4)
sex
male
female
40 (26)
116 (74)
37 (26)
104 (74)
3 (20)
12 (80)
BMI (kg/m2) b 22.4 (19.4-25.9) 22.5 (19.5-26.0) 21.6 (18.7-25.8)
duration of symptoms (months) b 12 (6.0-25.5) 12 (6-24) 24 (6.0-78)
alcohol (U/day) c
increased alcohol intake d
0 (0-20)
37 (24)
0 (0-20)
35 (25)
0 (0-5)
2 (13)
DM type II 26 (16) 24 (17) 2 (13)
diagnosis
NOMI
stenotic CGI
49 (31)
107 (69)
44 (31)
97 (69)
5 (33)
10 (67) 
mesenteric artery stenosis
no stenosis
single artery stenosis
multi artery stenosis
47 (30)
52 (33)
67 (37)
42 (30)
47 (33)
52 (37)
5 (33)
5 (33)
5 (33)
mucosal ischemia
present
absent
not performed
141 (90)
13 (8)
2 (1)
129 (92)
10 (7)
2 (1)
12 (80)
3 (20)
0
values represent number and percentage (%) of patients
a ALT >1x ULN, corrected for gender (33 U/l for females, 44 U/l for males)
b median (interquartile range (IQR))
c median (range)
d increased alcohol intake is defined as >1 units/dag for females and >2 units/day for males
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 2 Univariable analysis for ALT >1x ULN
OR (95% CI) p-value a
age (years)
age >60 years
0.98 (0.96-1.04)
0.96 (0.32-2.85)
0.91
0.94
female gender 1.42 (0.38-5.33) 0.60
BMI (kg/m2)
BMI >25 (kg/m2)
0.96 (0.86-1.07)
1.09 (0.35-3.39)
0.96
0.88
duration of symptoms (months) 1.01 (0.99-1.02) 0.23
alcohol (U/day)
increased alcohol intake b
0.79 (0.52-1.22)
0.45 (0.10-2.09)
0.29
0.31
DM type II 0.75 (0.16-3.54) 0.72
mesenteric artery stenosis
≥70% stenosis CA 
≥70% stenosis SMA 
≥70% stenosis both CA and SMA
0.59 (0.20-1.73)
0.66 (0.20-2.19)
0.84 (0.34-3.83)
0.34
0.49
0.84
presence of mucosal ischemia 2.69 (0.67-10.86) 0.17
a p-value <0.05 was considered significant
b increased alcohol intake is defined as >1 units/day for females and >2 units/day for males
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Conclusion
In this study, we show that liver injury is uncommon in CGI. The re-
sults of the current study shows that serum aminotransferases were 
very mildly raised in only 10% of the total cohort of 156 patients 
with well-defined CGI, which may have normalized after successful 
treatment of CGI.
The liver has a unique dial blood supply by both the hepatic 
artery (HA), which stems from the CA and provides up to 30% of the 
total blood supply to the liver, and the portal vein which provides 
the remaining 70-85% of blood to the liver 6. In contrast to most 
other organs, hepatic perfusion does not follow principles of supply 
and demand. Blood flow in the HA is inversely related to blood flow 
in the portal vein and is regulated by the presence adenosine, which 
is capable of controlling arterial tonus. In case of decreased portal 
flow, arterial blood flow increases due to dilation of the HA as a 
result of decreased washout of adenosine from the periportal space 
of Mall 7. This is not reciprocal in case of decreased arterial flow 
(such as in CGI) as the PV cannot control its blood flow (being the 
outflow tract of the extrahepatic splanchnic organs) 8. It is tempting 
to speculate that in CGI liver injury may be prevented by increased 
oxygen extraction and less by enhancement of portal blood flow 9.
Interestingly, although patients with CGI are known to have 
a high cardiovascular risk profile, no association could be found 
between elevated serum aminotransferases and risk factors for 
steatohepatitis. The observed BMI in this patient population might 
be beneficial and could be explained by involuntary weight loss 
due to CGI. However, no association could either be observed for 
BMI>25kg/m2.
In conclusion, in contrast to acute ischemic conditions, liver 
injury is not a common feature of CGI. Further studies need to the 
confirm the generalizability of this observation. 
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Abstract
Background
Gastrointestinal ischemia is a concerning 
complication of portal vein thrombosis 
(PVT). Minimally invasive techniques, 
such as visible light spectroscopy (VLS), 
have greatly improved the ability to 
diagnose gastrointestinal ischemia. 
The aim of this study was to assess the 
clinical presentation and characteristics 
of gastrointestinal ischemia in patients 
with PVT. 
Methods
Patients with non-cirrhotic, non-malig-
nant PVT were included in this prospec-
tive cohort study. Clinical symptoms of 
gastrointestinal ischemia were assessed 
by a structured questionnaire, VLS, and 
radiological evaluation of the mesenteric 
vasculature. VLS measurements were 
compared to those in patients with cir-
rhosis and a reference population. 
Results
We included 15 patients with chronic 
PVT and one patient with acute PVT (age 
46.1 [IQR 30.9-53.7] years; 44% male). 
Decreased mucosal oxygenation in at 
least one location of the gastrointestinal 
tract was found in 12/16 (75%) patients. 
Compared to the reference population 
(median 60.0 [56.2-61.7]), VLS measure-
ments were mostly decreased in the 
descending duodenum for patients with 
PVT (median 55.5 [52.3-58.8], p=0.02) 
and patients with cirrhosis (median 
52.0 [46.5-54.0], p=0.003). Symptoms 
typical for gastrointestinal ischemia, 
such as postprandial pain and exercise-
induced pain, were reported in 10/16 
(63%) patients with PVT. In patients 
with extension of thrombosis into the 
superior mesenteric vein and splenic vein 
and/or presence of hypercoagulability, 
decreased VLS measurements were 
observed compared to the historical 
controls. 
Conclusions
In patients with chronic PVT, gastrointes-
tinal ischemia is frequent. VLS enables 
objective and quantitative determination 
of gastrointestinal mucosal ischemia. 
Onset of abdominal symptoms such as 
postprandial pain should prompt the 
physician to re-evaluate extent, cause 
and treatment of PVT.
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Introduction
Portal vein thrombosis (PVT) is an infrequent vascular disorder 
that often leads to portal hypertension. Etiological factors include 
systemic and local prothrombotic factors 1. PVT can be classified 
as acute or chronic. The latter is characterized by the presence of 
portal cavernoma, which depends on the duration of existence of 
the thrombus in the portal vein (PV) 1-3.
Gastrointestinal ischemia is a concerning complication of PVT. It 
can result in intestinal infarction, a life-threatening complication 
that often requires immediate surgical intervention 2. Treatment 
of acute PVT therefore aims at vascular recanalization, preventing 
occurrence of gastrointestinal ischemia and portal hypertension 1. 
The actual prevalence of gastrointestinal ischemia in patients with 
PVT is unknown. Studies, mainly conducted in patients with acute 
PVT, report prevalences of intestinal infarction of 2%-32%, with 
mortality rates of 0%-20% 3-9. Regarding patients with chronic PVT, 
studies report conflicting results. As patients with chronic PVT 
often have an extensive venous collateral circulation, it is assumed 
that gastrointestinal ischemia is less likely to occur 2. However, in 
a large prospective study in splanchnic vein thrombosis, 26% of 
patients presented with intestinal infarction. In nearly half of these 
patients a portal cavernoma was detected, suggesting gastrointesti-
nal ischemia is also a frequent complication in chronic PVT 4. 
Typical complaints suggesting gastrointestinal ischemia are 
postprandial and/or exercise related abdominal pain, weight loss, 
and diarrhea. However, some patients present with more atypical 
symptoms, which limits the diagnosis of gastrointestinal ischemia 
based on clinical symptoms alone 10. In addition, clinical signs of 
gastrointestinal ischemia are often difficult to differentiate from 
symptoms due to PVT. Also, it has been suggested that signs of 
ischemia in patients with PVT depend largely on the extent of the 
occlusion, the size of the vein, and the involvement of the superior 
mesenteric vein (SMV) and/or splenic vein (SV) 2,11.
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With the development of minimally invasive techniques, such as 
visible light spectroscopy (VLS), the ability to diagnose gastrointes-
tinal ischemia has greatly improved 12. VLS enables direct measure-
ment of the adequacy of mucosal perfusion in the gastrointestinal 
tract 13. It is a new technique that non-invasively measures capillary 
hemoglobin oxygen saturation using white light delivered by a 
fiberoptic probe during gastroscopy 12,13. The oxygen saturation 
reflects the adequacy of mucosal perfusion. Therefore, venous 
occlusion, hampering oxygenation of the gastrointestinal mucosa, 
may result in lower mucosal hemoglobin oxygen saturations 12. VLS 
is a validated diagnostic method to detect gastrointestinal ischemia 
with a sensitivity and specificity of 90% and 60%, respectively 12,13.
Due to the rarity of the disease and lack of adequate diag-
nostic tools in the past, most data on gastrointestinal ischemia 
in patients with PVT stem from retrospective studies in selected 
patient populations 3-7. VLS enables us to directly quantify gastroin-
testinal ischemia in patients with PVT. Therefore, we performed a 
prospective cohort study in patients with PVT using VLS, radiologi-
cal examination, and questionnaires. The objective of this study 
was to assess the presence, clinical presentation and characteristics 
of gastrointestinal ischemia in patients with PVT.
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Methods
Study population 
Patients with non-cirrhotic, non-malignant PVT were studied in 
this single-center prospective cohort study in a tertiary care center. 
Patients aged 18 years and over with non-cirrhotic, non-malignant 
PVT were included in the study from 2009 until 2010. Acute and 
chronic PVT were defined according to Baveno V criteria as the 
presence of PVT with or without portal cavernoma and portal 
hypertension 14. Patients with isolated SV or SMV thrombosis were 
excluded. All patients underwent radiological evaluation within two 
months of the VLS measurements. All patients with PVT received 
scheduled visits at the out-patient clinic. For this cohort study, we 
adhered to the Strengthening the Reporting of Observational stud-
ies in Epidemiology (STROBE) initiative 15.
Patients with liver cirrhosis and portal hypertension with 
patent mesenteric vasculature were included as cirrhotic patient 
controls. Portal hypertension was defined as: presence of varices 
and/or splenomegaly and/or ascites and/or hepatic hydrothorax 
and/or increased hepatic venous pressure gradient (>12mm Hg) 
AND in the absence of an intrahepatic shunting stent (i.e. TIPS). 
For further comparison, VLS measurements of a historical 
reference population were used. These were participants in the 
original cohort of van Noord et al., of whom mucosal saturation 
measurements using VLS were obtained to establish the present 
cut-off values for gastrointestinal ischemia in the different loca-
tions in the gastrointestinal tract. These were consecutive patients 
referred for evaluation of possible chronic gastrointestinal ischemia 
who underwent the standard diagnostic work-up for gastrointes-
tinal ischemia consisting of evaluation of symptoms, radiological 
imaging, and gastrointestinal tonometry in addition to VLS. In all 
these patients, more common causes of upper gastrointestinal 
symptoms had been previously excluded. A diagnosis of chronic 
gastrointestinal ischemia was established if a patient fulfilled two of 
the three following criteria:
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1 distinct clinical presentation including presence of postpran-
dial pain and otherwise unexplained weight loss of >5% of the 
normal body weight.
2 significant stenosis of >50% of at least one of the mesenteric 
arteries.
3 functional signs of mucosal ischemia demonstrated by VLS. 
None of the historical controls fulfilled the required criteria. 
The VLS measurements were performed in identical fashion as in 
the previous study of the same group 12.
Informed consent was obtained from all patients. Approval 
for the study was obtained from the Institutional Review Board 
of the Erasmus MC University Medical Centre Rotterdam, the 
Netherlands. The study was registered at the ISRCTN registry 
(study ID ISRCTN14235960). 
Diagnostic work-up and data collection
All patients with PVT received the standard work-up. This consisted 
of screening for etiologic factors, laboratory testing, abdominal 
ultrasound, and gastroscopy.
Standardized abdominal ultrasound was performed to assess 
the liver parenchyma, PV, hepatic artery, hepatic veins, SV, SMV, 
and to exclude the presence of cirrhosis and assess features of 
portal hypertension. Gastroscopy was performed to determine the 
possible presence of varices.
Use of antithrombotic medication was evaluated for all 
patients. Antithrombotic medication was initiated at the discretion 
of the treating physician and/or according to standard care. Time 
of antithrombotic medication use was assessed from diagnosis of 
PVT to time of VLS measurements. For each patient, a covered time 
(in %) of antithrombotic use was calculated by dividing the time (in 
months) of antithrombotic medication use by time (in months) since 
diagnosis of PVT. 
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Assessment of gastrointestinal ischemia
Clinical symptoms of gastrointestinal ischemia were assessed by 
a structured questionnaire, VLS measurements and radiological 
evaluation of the mesenteric arteries. 
The questionnaire was specifically designed to collect rel-
evant medical and family history, medication use, and gastrointesti-
nal symptoms 10,16. To avoid missing data, medical history notes on 
gastrointestinal symptoms were also included. 
Radiological evaluation of the mesenteric vasculature was 
performed by CT- A, or MR-angiography (MR-A), with a maximum 
slice thickness of 3mm. Site and extension of the PVT, as well as 
involvement of the SMV and SV, were also evaluated. Stenosis of 
the mesenteric arteries of ≥70% of vessel lumen was considered 
significant. 
Mucosal saturation measurements 
Gastroscopy was performed in all patients. VLS measurements 
were performed during gastroscopy as described before 12,17. In 
short, cleansing of remnant bile, fluids or food remnants was 
done prior to measuring along with administration of butyl-
scopolamine 20 mg intravenously to halt upper gastrointestinal 
motility. Measurements were performed at three specific locations: 
descending duodenum, duodenal bulb and gastric antrum. We 
averaged three repeated readings per location, with every measure-
ment within 5% variation of panel read-out once a stable reading 
was obtained. This was considered the most accurate reflection 
of the mucosal saturation at that location. The sites of the VLS 
measurements per location were standardized in the way that in 
every patient the same anatomical regions were used. Peripheral 
oxygenation was kept above 94%. Mucosal ischemia was defined 
as: mucosal saturation <63%, <62% and <58%, for measurements 
in the gastric antrum, duodenal bulb, and descending duodenum, 
respectively 12. The physician performing the VLS measurements 
was not blinded to the patient characteristics. However, he was not 
the treating physician of the patient and was therefore not familiar 
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with the specifics of the radiological findings of these patients. At 
time of inclusion, only two physicians in our center were specialized 
in performing the VLS measurements. The second physician was 
trained by the other physician, limiting a possible inter-observer 
variability.
Statistical analysis
Baseline characteristics were calculated using descriptive statistics. 
Data were expressed as mean and standard deviation (SD), median 
and interquartile range (IQR) or count and percentage (%), when 
appropriate. Differences in VLS measurements per location in the 
GI-tract between the different groups were assessed with linear 
regression analysis. Statistical analysis was performed using SPSS 
21.0 program (SPSS Inc., Chicago, IL, USA). A two-sided p-value of 
<0.05 was considered statistically significant.
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Results
Study population
In this prospective cohort study, we included 16 patients with PVT 
(age 46.1 [30.9-53.7] years; seven patients were male). Baseline 
characteristics of these patients, at the moment of VLS measure-
ment, are displayed in  1. At diagnosis, five patients had an acute 
PVT and in 11 patients a portal cavernoma was observed. At the 
moment of VLS measurement, 15 patients (94%) had chronic PVT. 
In 14 patients (87%), at least one prothrombotic risk factor 
was present, including an inherited hypercoagulable risk factor in 
six patients of whom three with a factor V Leiden mutation. A local 
risk factor, such as inflammatory bowel disease or pancreatitis, was 
found in four patients. 
Treatment with heparin followed by oral anticoagulants (OAC) 
was administered in 12 patients (75%). In nine of these patients 
(75%), anticoagulants were started at diagnosis and was continued 
at least until the moment of VLS measurement (covered time 
99-100%). In two of these 12 patients, administration of OAC was 
delayed by 6 and 9 months respectively, which resulted in treat-
ment with anticoagulants with a covered time <99-100%. In the 
remaining patient, OAC was directly administered, but discontinued 
early because of an upper gastrointestinal bleeding, resulting 
in a covered time of 16.7%. The absolute length and percentage 
covered time of anticoagulation use is further described in  1. In 
two patients, acetylsalicylic acid was started because of presence 
of a myeloproliferative neoplasm (MPN). Before administering oral 
anticoagulants, thrombolysis was unsuccessfully attempted in one 
patient. All patients who initially presented with an acute PVT were 
treated with OAC from diagnosis until at least the moment of VLS 
measurement. 
To determine whether the VLS measurements in patients 
with PVT are affected only by presence and extent of the portal and 
mesenteric venous thrombosis or also by portal hypertension, we 
included a cirrhotic patient control group consisting of five patients 
124 Vascular diseases of the gastrointestinal tract
 1 Baseline characteristics
 PVT 
ID age sex site a presentation b
underlying 
liver disease
degree of 
occlusion
extrahepatic 
involvement
hyper-
coagulability c
Jak2 
mutation MPN d
anticoagulant time (%) e 
/ length (mon) f
anti- 
platelets varices g
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
30
38
48
34
53
62
26
53
54
30
48
43
53
20
19
54
F
M
F
F
F
M
F
F
M
F
M
F
F
M
M
M
3
2a
1
3
2b
3
1
3
3
2a
3
3
3
3
3
3
chronic
chronic
chronic
chronic
acute
chronic
chronic
chronic
chronic
chronic
chronic
chronic
chronic
chronic
chronic
chronic
none
none
none
none
none
none
none
none
none
none
none
none
none
none
none
none
complete
complete
complete
partial
partial
complete
complete
complete
complete
partial
complete
complete
complete
complete
complete
complete
SMV+SV
SMV+SV
SMV
SMV
SMV
None
None
SMV+SV
SMV+SV
SMV
SMV+SV
SMV+SV
SMV+SV
None
None
SMV+SV
–
–
FVL
APA
na
–
FVL
FVIII
PC
–
–
–
–
–
–
FVL
+
–
–
na
na
+
na
+
–
–
–
+
+
–
–
+
NOS
–
–
na
na
PV
na
ET
na
–
–
PV
ET
–
–
ET and PV
0/0
38.5/6
100/66
99/55
100/62
100/26
0/0
100/59
16.7/1
100/8
100/23
0/0
100/57
0/0
100/31
20.8/22
–
–
–
–
–
+
–
–
–
–
–
+
–
–
–
–
+
+
+
–
–
+
–
+
+
–
–
+
–
+
–
+
17
18
19
20
21
61
55
59
64
67
M
M
F
M
F
none
none
none
none
none
none
none
none
none
none
cirrhosis
cirrhosis
cirrhosis
cirrhosis
cirrhosis
none
none
none
none
none
none
none
none
none
none
na
na
na
na
na
na
na
na
na
na
na
na
–
na
na
–
–
–
–
–
–
–
–
–
–
+
+
+
+
+
a site of thrombotic involvement of the portal vein. Type 1=thrombosis of the trunk; type 
2a=thrombosis of one branch; type 2b=both branches; type 3=thrombosis of both portal trunk 
and branches
b presentation at moment of VLS measurement, as diagnosed by radiological imaging 
(CT or abdominal ultrasound)
c one patient (ID 4) had elevated antiphospholipid (anti-cardiolipin) antibodies and ID 8 had 
elevated levels of factor VIII. Three patients had an FVL mutation
d MPN NOS: an MPN is present, but the type could not be classified into more detail by 
histological examination of bone marrow
e amount of time on anticoagulants (oral anticoagulants and/or heparin) from diagnosis until VLS 
measurement divided by total amount of time from diagnosis until VLS measurement
f absolute length of anticoagulation use from moment of inclusion until end of follow-up, 
in months
g all patients with varices had oesophageal varices, except for ID 2, who was diagnosed with 
duodenal varices. ID 1 had both gastric (GOV-1) and oesophageal varices
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 1 Baseline characteristics
 PVT 
ID age sex site a presentation b
underlying 
liver disease
degree of 
occlusion
extrahepatic 
involvement
hyper-
coagulability c
Jak2 
mutation MPN d
anticoagulant time (%) e 
/ length (mon) f
anti- 
platelets varices g
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
30
38
48
34
53
62
26
53
54
30
48
43
53
20
19
54
F
M
F
F
F
M
F
F
M
F
M
F
F
M
M
M
3
2a
1
3
2b
3
1
3
3
2a
3
3
3
3
3
3
chronic
chronic
chronic
chronic
acute
chronic
chronic
chronic
chronic
chronic
chronic
chronic
chronic
chronic
chronic
chronic
none
none
none
none
none
none
none
none
none
none
none
none
none
none
none
none
complete
complete
complete
partial
partial
complete
complete
complete
complete
partial
complete
complete
complete
complete
complete
complete
SMV+SV
SMV+SV
SMV
SMV
SMV
None
None
SMV+SV
SMV+SV
SMV
SMV+SV
SMV+SV
SMV+SV
None
None
SMV+SV
–
–
FVL
APA
na
–
FVL
FVIII
PC
–
–
–
–
–
–
FVL
+
–
–
na
na
+
na
+
–
–
–
+
+
–
–
+
NOS
–
–
na
na
PV
na
ET
na
–
–
PV
ET
–
–
ET and PV
0/0
38.5/6
100/66
99/55
100/62
100/26
0/0
100/59
16.7/1
100/8
100/23
0/0
100/57
0/0
100/31
20.8/22
–
–
–
–
–
+
–
–
–
–
–
+
–
–
–
–
+
+
+
–
–
+
–
+
+
–
–
+
–
+
–
+
17
18
19
20
21
61
55
59
64
67
M
M
F
M
F
none
none
none
none
none
none
none
none
none
none
cirrhosis
cirrhosis
cirrhosis
cirrhosis
cirrhosis
none
none
none
none
none
none
none
none
none
none
na
na
na
na
na
na
na
na
na
na
na
na
–
na
na
–
–
–
–
–
–
–
–
–
–
+
+
+
+
+
a site of thrombotic involvement of the portal vein. Type 1=thrombosis of the trunk; type 
2a=thrombosis of one branch; type 2b=both branches; type 3=thrombosis of both portal trunk 
and branches
b presentation at moment of VLS measurement, as diagnosed by radiological imaging 
(CT or abdominal ultrasound)
c one patient (ID 4) had elevated antiphospholipid (anti-cardiolipin) antibodies and ID 8 had 
elevated levels of factor VIII. Three patients had an FVL mutation
d MPN NOS: an MPN is present, but the type could not be classified into more detail by 
histological examination of bone marrow
e amount of time on anticoagulants (oral anticoagulants and/or heparin) from diagnosis until VLS 
measurement divided by total amount of time from diagnosis until VLS measurement
f absolute length of anticoagulation use from moment of inclusion until end of follow-up, 
in months
g all patients with varices had oesophageal varices, except for ID 2, who was diagnosed with 
duodenal varices. ID 1 had both gastric (GOV-1) and oesophageal varices
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(age 61.0 [57.5-66.1] years (p=0.02 compared to patients with PVT), 
three patients were male (p=0.2)) with liver cirrhosis without PVT. 
All of these patients had Child-Pugh C cirrhosis and were screened 
for liver transplantation. In these five patients, liver cirrhosis was 
caused by hepatitis B virus infection (n=2), hepatitis C virus infec-
tion (n=2) or primary sclerosing cholangitis (n=1). All patients in the 
cirrhotic patient control group had oesophageal varices. There were 
no liver function abnormalities in all patients with PVT. 
 2 Clinical symptoms and risk factors for gastrointestinal  
  ischemia at time of VLS measurements
cases
(n=16)
cirrhotic patient 
controls (n=5)
historical
controls (n=29)
abdominal pain 
postprandial pain 
exercise-induced pain
weight loss 
weight loss (kg/month) a
loose stools
10 (63)
9 (56)
8 (50)
7 (44)
5 [2.0-6.7]
12 (75)
0
0
0
 1(20)
–
3 (60)
28 (97)
15 (52)
13 (45)
19 (66)
0.6 [0-1.1]
8 (28)
BMI (kg/m2) a
coronary and/or peripheral  
  arterial disease 
family history of CVD b
DM type II
hypertension c
hypercholesterolemia d
smoking
25.4 [21.9-26.8]
0
4(27)
1 (6)
9 (56)
4 (27)
3 (19)
28.4 [24.0-33.5]
1 (20)
5 (100)
2 (40)
1 (20)
1 (25)
1 (20)
20.9 [19.6-23.9]
7 (24)
12 (44)
3 (10)
10 (35)
6 (21)
13 (46)
mesenteric arterial stenosis e 0 0 4 (14)
values represent number of patients (percentage %), unless otherwise specified
a median, interquartile range
b positive family history is defined as first-degree relatives with history of coronary and/or 
peripheral arterial disease. Family history of cardiovascular disease was missing in one patient 
with PVT
c hypertension is defined as systolic blood pressure of >140mm Hg and/or diastolic blood 
pressure of ≥90mm Hg or use of anti-hypertensive medication
d hypercholesterolemia is defined as serum LDL cholesterol ≥190 mg/dl or use of statins. Serum 
LDL-cholesterol was missing in one cirrhotic patient control
e mesenteric arterial stenosis is defined as a significant stenosis of ≥70% of the vessel lumen of 
the celiac trunk (CT), superior mesentery artery (SMA) or inferior mesentery artery (IMA) on 
CT-angiography with maximum slice thickness of 3 mm
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Clinical features of gastrointestinal ischemia
Abdominal pain was reported by ten out of 16 (63%) patients with 
PVT  2. Postprandial pain, typical for gastrointestinal ischemia, 
was reported by nine out of 16 (56%). Furthermore, exercise-
induced pain and weight loss (median 5.0 [2.0-6.7] kg/month) were 
reported in eight (50%) and seven (44%) patients with PVT. None of 
the cirrhotic patient controls reported any presence of postprandial 
abdominal or exercise-induced pain. Of the 11 PVT patients with 
extension into the SMV and SV, eight reported postprandial or 
exercise-induced abdominal pain. None of the PVT patients without 
involvement of the SMV and SV reported abdominal pain. 
Abdominal pain was the presenting symptom and reason for 
referral in the vast majority of the 29 historical controls (38% male 
(p=0.09 and p=0.09 compared to patients with PVT and cirrhotic 
patient controls, respectively), age 56.5 [43.9-66.4] years (p=0.7 and 
p=0.4, respectively)). However, the occurrence of significant weight 
loss (median 0.6 [0-1.1] kg/month) and loose stools (28%) was signifi-
cantly lower in this group compared to patients with PVT (p=0.001 
and p=0.002, respectively). Mesenteric arterial stenosis was ruled 
out in the patients with PVT and the cirrhotic patient controls. Four 
historical controls were referred because of a stenosis of the mes-
enteric arteries, however the diagnosis of gastrointestinal ischemia 
was excluded during the diagnostic work-up.
Mucosal saturation measurements 
VLS measurements were performed in all patients with PVT and in 
the five patients with severe cirrhosis and portal hypertension. VLS 
measurements of the historical controls were used as reference 
population. Decreased VLS measurements in at least one location 
of the gastrointestinal tract were found in 12 out of 16 (75%) patients 
with PVT. Compared to the reference population (median 60.0 [56.2-
61.7]), mucosal saturation measurements were mostly decreased 
in the descending duodenum for both patients with PVT (median 
55.5 [52.3-58.8], p=0.02) and patients with cirrhosis (median 52.0 
[46.5-54.0], p=0.003)  1. The median VLS measurement of patients 
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with PVT (median 62.0 [60.0-65.8]) and cirrhosis (median 57.0 
[55.0-60.0]) were also significantly lower in the antrum compared to 
the historic reference population (median 65.9 [64.2-69.3], p=0.01 
and p<0.001, respectively). There was a significant difference in 
median VLS measurements in the duodenal bulb between patients 
with cirrhosis and portal hypertension (median 58.0 [50.5-61.0]) 
compared to the historic reference population (median 62.9 
[59.2-66.9], p=0.02), but not between patients with PVT (median 
60.5 [59.3-64.0]) and the reference population (p=0.5)). There 
 1 Visible light spectroscopy (VLS) measurements in patients  
  with portal vein thrombosis (PVT), cirrhotic patient controls  
  and in the reference population
  
 PVT n=16
 cirrhotic patient controls n=5
 historical controls n=29
VLS measurements performed at three locations in the gastrointestinal tract for all three groups 
of patients. VLS measurements were significantly decreased for patients with PVT compared 
to the reference population in the antrum and descending duodenum, but not in the duodenal 
bulb. Compared to the reference population, patients with portal hypertension had decreased 
VLS measurements in all locations, indicating mucosal ischemia. Boxes represent medians with 
interquartile range, whiskers extend to the most and least extreme scores respectively.
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seemed to be an association between presence of postprandial 
abdominal pain and/or exercise-induced abdominal pain and de-
creased VLS measurements in the descending duodenum. Patients 
with abdominal pain tended to have lower VLS measurements than 
patients without abdominal pain (median 54.0 [48.8-57.3] vs median 
58.5 [53.8-60.5], p=0.09). Of the ten patients with PVT with post-
prandial abdominal pain and/or exercise-induced abdominal pain, 
nine (90%) had decreased VLS measurements, of which six at more 
than one location in the gastrointestinal tract.
Characteristics of ischemic colitis
Colonoscopy was performed in three out of 16 patients with PVT 
at the moment of VLS measurements. Two patients had abnormal 
findings. In one patient, signs of ulceration and colitis were seen in 
the descending colon attributed to ischemia, which was confirmed 
by histological tissue evaluation. This patient (ID 2) was diagnosed 
with a complete occlusion of a side branch of the PV, SMV, and SV. 
This patient also had decreased VLS measurements in the descend-
ing duodenum. In the second patient (ID 3), colonoscopy revealed 
mucosal edema and erythema in the distal colon and sigmoid, sug-
gestive for colitis due to congestion. This patient had a complete 
occlusion of the PV and SMV, and decreased VLS measurements of 
the duodenum. None of the cirrhotic patients had signs of ischemic 
colitis during colonoscopy. 
Factors associated with VLS measurements 
Patients with an extension of the thrombus into the SMV and/or SV 
had significantly lower VLS measurements in the antrum and de-
scending duodenum compared to the reference population, indicat-
ing mucosal ischemia (p=0.01 and p=0.009, respectively)  2. There 
was no difference in VLS measurements between patients with PVT 
without extension compared to the historical controls. Furthermore, 
no difference in VLS measurements was observed in patients with 
extension of the PVT into the SMV and/or SV compared to patients 
without extension of thrombus outside the PV. 
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Patients who were treated with OAC had higher VLS measurements 
compared to those who were not or partly (covered time <99%) 
treated, (median 58.0 [53.5-59.5] vs 53.0 [49.0-57.0], p=0.096 in the 
descending duodenum)  3. Patients who were not or partly treated 
with OAC had significantly lower VLS measurements in the antrum 
and descending duodenum compared to the reference population, 
indicating mucosal ischemia (p=0.007 and p=0.003, respectively). 
The use of OAC in patients with PVT results in a relative risk differ-
ence of 19% in decrease of VLS measurements. Hence, the number 
needed to treat with anticoagulants to prevent decreased VLS 
measurements in one patient is 5.3. 
 2 VLS measurements and extent of venous thrombosis
  
 no involvement other veins n=4
 SMV and/or SV involvement n=12
 historical controls n=29
Patients with PVT with an extension of the thrombus into the superior mesenteric vein (SMV) and/
or splenic vein (SV) had significantly lower VLS measurements in the antrum and descending 
duodenum compared to the reference population, indicating mucosal ischemia. Boxes represent 
medians with interquartile range, whiskers extend to the most and least extreme scores 
respectively.
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Abdominal pain was reported in a lower proportion of patients 
using OAC compared to patients without anticoagulation, but this 
difference was not statistically significant (56% vs 71%, p=0.6). 
Presence of an inherited hypercoagulable risk factor resulted 
in decreased VLS measurements at all locations in three out of six 
(50%) patients. In two of the three remaining patients with an inher-
ited risk factor, decreased measurements in the descending duo-
denum – and antrum in one patient – were observed. One patient 
with an inherited risk factor did not have decreased VLS measure-
ments, however this patient had an incomplete occlusion of the PV. 
Patients with a known inherited hypercoagulable risk factor more 
 3 VLS measurements in relation to use of antithrombotic therapy
  
 no or partly treated with OAC (n=7)
 treated with OAC (n=9)
 historical controls (n=29)
Patients who were not or partly treated with oral anticoagulation (OAC) had significantly lower VLS 
measurements in the antrum and descending duodenum compared to the reference population, 
indicating mucosal ischemia. Boxes represent medians with interquartile range, whiskers extent to 
the most and least extreme scores respectively.
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often reported abdominal pain typical for gastrointestinal ischemia 
compared to patients without an inherited hypercoagulable risk 
factor (83% vs 44%, p=0.3). 
Follow-up after VLS measurements
After a median follow-up time of 51 (11-59) months, 15 of the 16 pa-
tients with PVT were still alive. One patient developed multi-organ 
failure due to renal insufficiency and died of pneumonia and sepsis. 
Ischemic events occurred in two patients. One patient (ID 13) 
presented with an acute small bowel ileus at time of diagnosis of 
PVT, which was treated conservatively. Four months after diag-
nosis, due to ongoing symptoms, an explorative laparotomy was 
performed which showed a complete stenosis of the jejunum as 
well as thrombosis of the draining mesenteric veins. A side-to-side 
jejuno-jejunostomy was performed proximally of the stenosis. The 
second patient (ID 2) presented with melena one month after the 
VLS measurements. Distal enteroscopy showed signs of ischemic 
colitis for which the patient was treated conservatively. In both 
patients decreased VLS measurements were observed in at least 
one location of the gastrointestinal tract. 
Gastrointestinal bleeding events occurred in three patients 
and were all related to variceal bleeding (ID 1, 2, and 9). One patient 
did not use OAC at time of bleeding. However, in the fourth year of 
follow-up, the patient developed deep vein thrombosis (DVT), for 
which OAC treatment was initiated. Two patients were using OAC at 
time of bleeding. In one of these patients, OAC had to be discontin-
ued, which resulted in a DVT five months later. 
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Discussion
Gastrointestinal ischemia is a concerning complication of PVT. The 
occurrence and risks of gastrointestinal ischemia have in particular 
been acknowledged in patients with acute PVT 1-3,5,6. The clinical 
spectrum of gastrointestinal ischemia in patients with chronic PVT 
is hitherto unknown. Therefore, we performed a unique prospective 
study in a well-characterized cohort of PVT patients in which clini-
cal symptoms for gastrointestinal ischemia were assessed using 
a structured questionnaire, imaging of the mesenteric vasculature 
and VLS measurements. The latter enabled us to objectively and 
quantitatively determine the presence and extent of gastrointestinal 
mucosal ischemia. Patients presenting with non-malignant, non-
cirrhotic PVT are quite rare, but we were able to include 15 patients 
meeting our inclusion criteria during a period of 24 months. The 
rarity of the disease made it difficult to compose a homogenous 
group. Therefore, we included patients with both acute and chronic 
PVT, patients on anticoagulation versus no anticoagulation, and 
complete versus partial occlusion of PV. 
Nevertheless, this is one of the few studies with prospective 
data on the occurrence of gastrointestinal ischemia in a population 
of patients with PVT. In our study, 15 out of 16 patients were known 
with chronic PVT at time of the VLS measurements. We found 
that postprandial abdominal pain and exercise-induced pain are 
common in patients with chronic PVT and that mucosal ischemia is 
often present in these patients, especially in the antrum and de-
scending duodenum. We also found that patients with a thrombus 
extending into the SMV and/or SV more often report abdominal 
pain than patients without extension of the thrombus. Also, patients 
with extension of the thrombus into the SMV and/or SV had sig-
nificantly lower VLS measurements in the antrum and descending 
duodenum compared to the reference population. 
The findings presented in this study warrant caution in the 
patient with PVT: onset of abdominal symptoms such as postpran-
dial pain should prompt the physician to re-evaluate extent, cause 
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and treatment of PVT. For instance, one should be vigilant of a pos-
sible thrombus extension into the SMV, as this is associated with 
worse outcome 18. The results of our study show that involvement 
of the SMV and/or SV in patients with PVT can be detected by VLS 
measurements, however this was not the case in patients with PVT 
without thrombus extension. This suggests that mucosal ischemia 
could be more prevalent in patients with PVT with thrombus exten-
sion. Also, one should be aware of presence of a systemic hyperco-
agulable state, as this is associated with thrombosis of the smaller 
venules. Hypercoagulability results in thrombosis beginning in the 
intramural venules, venous arcades, and vasa recta, often without 
involvement of the larger venous vessels. Occlusion of these small 
veins, easily missed on conventional CT-A or MR-A 19, results in 
compromised venous drainage and is associated with an increased 
risk of bowel infarction 2,11,20. Indeed, we found decreased VLS 
measurements in five out of six patients with an inherited hyperco-
agulable risk factor. Finally, we observed that VLS measurements 
were higher in patients treated with OAC compared to patients who 
were not or only partly treated, although this difference was not 
statistically significant, suggesting that there might be a positive 
effect of OAC on gastrointestinal ischemia in patients with chronic 
PVT. The reported NNT needs to be interpreted with caution given 
it is based on a very limited number of patients. Combined with the 
demonstrated beneficial effects of anticoagulation in chronic PVT 
in previous studies, showing a reduction in thrombotic events and 
splanchnic venous infarction without increasing the risk of gastro-
intestinal bleeding, it is tempting to advocate for a more prominent 
role of OAC in the treatment of patients with chronic PVT 21,22.
In order to extrapolate our findings into daily practice, it is 
important to address a few issues. First, patients with chronic PVT 
by definition have portal hypertension leading to venous conges-
tion, which may result in decreased VLS measurements. This 
might be attributed to the presence of portal hypertension, since 
decreased VLS measurements were also observed in patients with 
cirrhosis. Furthermore, patients with cirrhosis had even lower VLS 
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measurements than patients with PVT. Gastrointestinal ischemia 
in patients with portal hypertension might be attributed to the 
substantial circulatory imbalance between vasoactive mediators, 
such as endothelin and nitric oxide synthetase, due to the affected 
liver parenchyma in cirrhosis that may lead to vascular dysfunc-
tion in the gastric antrum 23,24. Nonetheless, intestinal infarction is 
not a common complication of cirrhotic portal hypertension. This 
suggests compensatory mechanisms in these patients, which are 
lacking in patients with non-cirrhotic portal hypertension such as 
PVT. However, an in-depth studiy of the differences between cir-
rhotic and non-cirrhotic portal hypertension was beyond the scope 
of this study. 
Second, we used historical controls as a reference group 
for VLS measurements as concurrent controls were not available. 
These controls were derived from the study by van Noord et al.12 
The VLS measurements in this group were performed in the same 
fashion as in the patients with PVT and cirrhotic patient controls, 
using the same protocol of measuring, devices, and equipment. 
Nevertheless, we cannot exclude the possibility that the inclusion of 
historical controls, instead of concurrent controls, might have led to 
a selection bias. Therefore, caution is needed in the interpretation 
of these results. 
Finally, cardiovascular risk factors for atherosclerosis, espe-
cially DM type II and obesity, are associated with occurrence of PVT 
and intestinal infarction 20,25,26. In our study, only one patient had 
diabetes. However, given the limited number of patients, we cannot 
exclude the possibility that cardiovascular risk profile is associated 
with PVT-related gastrointestinal ischemia. 
To our knowledge, this is the first study which quantitatively 
assessed the presence of gastrointestinal ischemia in patients with 
PVT. VLS measures capillary hemoglobin oxygen saturation and 
is a validated diagnostic method with a high sensitivity to assess 
the presence of gastrointestinal ischemia. The established cut-off 
values for each of the specific sites of the mesenteric tract were 
previously calculated by van Noord et al. These cut-off values were 
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based on a trainee data set obtained from patients diagnosed with 
gastrointestinal ischemia using gastric tonometry and the values 
were additionally validated in a confirmation cohort 12. Events 
that decrease the delivery of oxygen to the mesenteric mucosa 
(i.e. concomitant cardiopulmonary diseases) will result in lower 
mucosal hemoglobin oxygen saturations. Therefore, peripheral 
oxygen saturation and heart rate are continuously monitored during 
VLS measurements. In order to minimize the effect of modifying 
factors such as concomitant cardiopulmonary diseases, peripheral 
saturation is kept above 94% by administering oxygen (FiO2 21%), if 
necessary. Factors that may affect VLS measurements are luminal 
spasms and bile acid remnants. Therefore, butylscopolamine is 
administered intravenously prior to the start of VLS measurements 
and these measurements are performed after irrigation of the target 
area. There is no difference in VLS measurements between younger 
and older patients, as VLS measurements are known to be affected 
only by the above mentioned factors and by presence of a signifi-
cant stenosis of the mesenteric vasculature. As VLS measurements 
were performed at one time point only, it would be interesting to 
study the time course of gastrointestinal ischemia in patients with 
PVT, for instance before and after initiation of anticoagulation. 
Nonetheless, we were able to collect follow-up data in all patients, 
enabling us to assess occurrence of bleeding events, recurrent 
thrombosis, ischemic complications, and mortality. 
In future studies, it would be interesting to perform colonos-
copy in all patients with PVT to assess ischemic changes in the 
colonic mucosa. Because bloody diarrhoea is only rarely observed 
in gastrointestinal ischemic patients, colonoscopy is now only 
included in our standard work up of the patient in case of lower 
GI symptoms. Furthermore, we believe it would be interesting to 
quantify the potential presence of ischemia in the colon by colo-
noscopy and also by VLS in future studies. However, currently VLS 
measurements are only validated in the upper GI tract and have not 
yet been validated in the colon. 
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In addition, future studies should look into interactions between 
the factors associated with VLS measurements. Unfortunately, we 
were not able to look into this further due to the limited number of 
patients included in our cohort. 
In conclusion, gastrointestinal ischemia in patients with 
chronic PVT is more frequently encountered than previously as-
sumed. Albeit in a small cohort, mucosal ischemia was detected in 
75% of patients with PVT. Furthermore, two patients experienced an 
ischemic event. To increase generalizability, future studies assess-
ing patients with PVT should put more focus on the diagnosis and 
treatment of gastrointestinal ischemia. 
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Abstract
Background
Endoscopic variceal ligation (EVL) is the 
accepted first line therapy for the sec-
ondary prevention of gastroesophageal 
variceal bleeding (GEVB). Recent data 
suggest that transjugular intrahepatic 
portosystemic shunt (TIPS) is more effec-
tive and may become the preferred treat-
ment. However, the comparative costs of 
these treatment strategies have not been 
well defined. We aimed to compare the 
total health care costs of TIPS placement 
versus EVL + β-blocker for the second-
ary prevention of GEVB in the first year 
following the index bleeding. 
Methods
Health care consumption data were 
based on observed data in 52 patients 
(25 TIPS/27 endoscopy) surviving an 
acute first or second variceal bleeding 
due to liver cirrhosis-related portal hy-
pertension in a multicenter, randomized 
controlled trial. The primary endpoint 
of this study was defined as mean total 
health care costs per patient for the two 
treatment strategies. 
Results
Twenty-five patients (age 56 (IQR 49-60) 
years; 13 males) were randomized to 
TIPS placement versus 27 patients (age 
54 (IQR 49-63) years; 16 males) to treat-
ment with EVL. The mean total costs 
per patient were significantly higher in 
the TIPS group compared to the EVL 
group (€ 27.746 vs € 16.818, p=0.006). The 
highest cost category for the TIPS group 
were costs of the intervention (mean cost 
per patient € 8.673 for TIPS placement 
vs € 328 for EVL, p<0.001) and re-inter-
vention (mean cost per patient per TIPS 
revision were € 1.388). Intramural care, 
consisting of hospital admissions, ICU 
care, and treatment in daycare setting 
were the highest cost categories for the 
EVL treatment arm (mean total cost per 
patient € 5.612 and € 1.440 for patients 
treated with EVL for admission on ward 
in an academic hospital and community 
hospital, respectively  1). 
Conclusion
Treatment with TIPS after an acute 
episode of GEVB has significantly higher 
treatment costs in the first year after 
treatment compared to patients treated 
with EVL. This cost consideration should 
play a role in selection of the most 
optimal treatment. From an economic 
point of view, treatment with endoscopic 
variceal band ligation is recommended 
for the secondary prevention of gastro-
esophageal variceal rebleeding in 
patients with portal hypertension.
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Introduction
A severe complication of portal hypertension is gastroesophageal 
variceal bleeding (GEVB). There is a high chance of rebleeding in 
these patients, which is associated with high morbidity and mortal-
ity 1,2. Therefore, management should be directed at the prevention 
of rebleeding. Currently, the secondary prevention of GEVB is 
endoscopic treatment with variceal ligation [EVL] for esophageal 
varices and N-butyl cyanoacrylate injection for gastric varices, in 
combination with β-blocker therapy. When this fails, transjugular 
intrahepatic portosystemic shunt (TIPS) placement is the recom-
mended as the second-line therapy 3. 
Previous research showed that TIPS placement is an effective 
and safe treatment for variceal rebleeding in patients with portal 
hypertension due to cirrhosis 4. This was recently confirmed in a 
randomized controlled study compared TIPS placement versus EVL 
for the secondary prevention of gastroesophageal variceal rebleed-
ing 5. The latter study also showed that TIPS is more effective in 
reducing the risk of variceal rebleeding in cirrhotic patients with 
GEVB, but is associated with a higher risk of hepatic encephalopa-
thy and does not improve survival after a follow-up of two years 5. 
Thus, TIPS placement has shown to be more effective in 
the prevention of rebleeding in patients with a previous episode 
of GEVB than treatment with EVL. Yet, there was no difference in 
survival between both treatment groups. However, next to clinical 
effectiveness, it is important to evaluate costs in order to fully 
determine which treatment is more superior as a secondary preven-
tion therapy for variceal rebleeding. Health care costs associated 
with the treatment of variceal bleeding are significant as these 
patients need intensive and time-consuming treatments. EVL re-
quires multiple sessions to achieve successful eradication of varices 
and is associated with frequent rebleeding from varices or banding 
ulcers, and probably has thus higher hospitalization costs. TIPS on 
the other hand is an expensive procedure that carries a risk, albeit 
low, of severe complications including bleeding, liver injury, and 
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heart failure but is associated with a relatively high risk of hepatic 
encephalopathy (HE) 4,6. Hence it might be that TIPS has higher costs 
regarding complications due to hepatic encephalopathy. 
Up till now, only a few studies have focused on the costs for 
different treatment options in this patient group. However, these 
studies have primarily focused on the cost-effectiveness of TIPS vs 
surgical portacaval or splenorenal shunts. Therefore, we aimed to 
compare the total costs of TIPS placement versus EVL + β-blocker 
for the secondary prevention of gastroesophageal variceal bleeding 
in the first year following the index bleed by determining direct 
medical costs from a multicenter randomized trial.
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Methods
Study design and population
We performed an analysis of direct medical costs based on ob-
served data from a multicenter, randomized controlled trial compar-
ing long-term EVL or glue injection + β-blocker treatment with TIPS 
placement in patients with a first or second episode of gastric and/
or esophageal variceal bleeding 5. 
Health care consumption data were based on observed data 
in 52 patients (25 TIPS/27 endoscopy + β-blocker) surviving an acute 
first or second variceal bleeding due to liver cirrhosis-related portal 
hypertension. These 52 patients were included in one academic 
centre and its surrounding community hospital, and were therefore 
more uniform regarding their treatment plan. Details of patients 
selection are described previously 5. In summary, patients were 
eligible for the study if they were between 18-75 years and present-
ed with a first or second episode of endoscopically documented 
esophageal or gastric variceal bleeding 5,7. 
Exclusion criteria have been extensively described before 5. 
They mainly included a history of serious or refractory hepatic 
encephalopathy unrelated to gastrointestinal bleeding, a history of 
significant heart failure, portal hypertension due to other causes 
than liver disease (e.g. portal or splenic vein thrombosis), and previ-
ous TIPS placement. 
Costs of all patients were calculated from inclusion until 
twelve months after randomization, death, or moment of liver 
transplantation. In the first year after inclusion, patients were 
followed with 3-monthly intervals. The trial was performed in ac-
cordance with the provisions of the Declaration of Helsinki and local 
regulations. The institutional review board at each center approved 
the protocol, and written informed consent was obtained from all 
patients. 
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Treatment 
Endoscopic treatment of esophageal varices consisted of 
EVL (6-Shooter Saeed Multi-band Ligator®, Cook Medical, 
Winston-Salem, North Carolina, USA) in combination with a 
β-blocker. Gastric varices were injected with cyanoacrylate glue 
(HistoAcrylTM, B. Braun, Germany) with lipiodol (Lipiodol®, 
Guerbet, France). A non-selective β-blocker (preferably slow release 
propranolol, titrated to the maximum tolerated dose aiming to 
decrease the heart rate in rest by 25%, with a lower limit of 50 bpm) 
was started at day 5 after the index bleeding, unless a contraindica-
tion was present (severe arrhythmia, severe obstructive COPD or 
known intolerance). Elective EVL sessions started 2 weeks after 
the index bleeding and were performed every 2-4 weeks thereafter 
until eradication of varices. In patients allocated by randomization 
to endoscopic treatment, further endoscopic management occurred 
on site by gastroenterologists experienced in variceal ligation. 
TIPS placement was performed under general anesthesia 
after transhepatic portography. Polytetrafluoroethylene (PTFE)-
covered stents (Viatorr, W.L. Gore & Associates, Flagstaff, Arizona, 
USA) were used. Post-TIPS monitoring of shunt patency and func-
tion was done according to local guidelines. 
Outcome measurements 
Health care consumption data were compared between the two 
treatment arms; the endoscopy + β-blocker arm and the TIPS arm. 
The primary endpoint of this study was defined as mean total 
health care costs per patient for the two treatment strategies. Total 
costs included the costs for intervention as well as healthcare costs 
from the day of randomization until twelve months after randomiza-
tion, or until the occurrence of death, or moment of liver trans-
plantation. Costs of treatment failure of one arm (switch to other 
therapy arm) were calculated for the randomization arm. The costs 
for initial stabilization of the index bleeding were excluded, because 
they were assumed to be comparable in both arms. 
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The study was performed in accordance with the Dutch guidelines 
for economic evaluation studies 8. Direct healthcare costs (inpatient 
and outpatient costs) were calculated from a health care perspec-
tive. Data on health care consumption were obtained from the 
follow-up survey conducted until 24 months after randomization 
and was again inventoried in all participating centers.
Direct healthcare costs were calculated by multiplying the 
volumes of health care (e.g. length of stay) with the correspond-
ing unit costs (e.g. costs per day in hospital). All unit costs were 
estimated in agreement with national guidelines for health care 
costing 8 or a detailed inventory of all cost items, reflecting real 
resource use  1. Cost prices of the different treatment options 
(e.g. TIPS and EVL) were inventoried in one center (Erasmus MC) 
and used for all centers. All costs estimated were adjusted for infla-
tion with the use of the Dutch Consumer Price Index Statline CBS 
(Consumentenprijsindex Statline CBS, The Hague, the Netherlands). 
The costs applied to the financial year of 2014 and are in euros. 
Data on hospital costs consisted of intervention costs, hospi-
tal admissions, diagnostics and medication:
∙  Interventional costs consisted of all the costs associated with 
TIPS placement or EVL. The cost price per unit for the procedures 
consisted of detailed measurement of investments in manpower, 
equipment, material costs, maintenance, number of years of use 
and discounting the number of procedures per year, housing, 
personnel costs, and overhead. 
∙  Hospital stays included intensive care unit (ICU) ad,missions, 
non-ICU admissions, visits to the emergency department and visits 
to the outpatient clinic. The length of hospital stay was multiplied 
with the cost price with differentiation for admission to an academic 
medical center or to a community hospital. 
∙  Costs of laboratory testing and other diagnostics were also 
included, such as radiological imaging as well as ascites taps and 
aspirations.
∙  Medication costs were calculated for all relevant medication 
associated with portal hypertension (e.g. terlipressin, albumin), 
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 1 Unit costs
unit costs (€)
admissions
admission ward a
admission ward b
admission ICU
treatment in daycare setting
634
480
1.572
276
consultations
ER
outpatients clinic c
outpatients clinic d
telephone consulting
167
142
71
30
radiological imaging
chest X-ray
abdominal ultrasonography
abdominal ultrasonography ward
CT-scan
MRI
angiography
53
78
77
223
261
14.725
values represent full cost prizes in euro in financial year 2014
a admission to the ward of an academic medical center
b admission to the ward of a community hospital
c visit to the outpatients clinic in an academic medical center
d visit to the outpatients clinic in a community hospital 
e includes diagnostic gastroscopies without EVL 
f includes ascites aspirations as well as taps. 
g liver transplantation screening includes extensive laboratory testing, blood cultures, urine 
cultures, gastroscopy, colonoscopy, abdominal ultrasound, Dual Energy X-ray Absorption 
(DEXA) scan, CT-scan, dental and sinus X-ray, if needed a mammogram, as well as visits 
to the infectiologist, surgeon, orthognathic surgeon, otolaryngologist, social worker and 
hepatologist. It also includes an admission of 5 work days in an academic medical center. 
h percutaneous transhepatic balloon angioplasty with manometry in the portal vein
unit costs (€)
diagnostics
laboratory testing
gastroscopy e
colonoscopy
ascites puncture
liver biopsy
liver transplantation screening g
percutaneous manometry h
14
303
469
172
133
9.858
2.160
pleural puncture/aspiration
pulmonary function test 
electroencephalography 
electrocardiography 
cardiac ultrasonography
180
41
222
352
77
treatment 
EVL
TIPS placement
328
8.395
thrombocyte transfusion
red blood cells transfusion
plasma transfusion
502
216
186
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hepatic encephalopathy (e.g. lactulose syrup or enema, rifaximin) 
and complications related to portal hypertension such as infection 
or rebleeding (e.g. antibiotics, octreotide, but not β-blockers). It 
was calculated in Defined Daily Dose (DDD) and was multiplied 
by the cost per DDD. The cost per DDD was different for inpatient 
or outpatient use of medication  s1. The price for outpatient use 
of medicine was determined by calculating the mean price of the 
medicine 9. 
Statistical analysis
Baseline characteristics were calculated using descriptive statistics. 
Data were expressed as mean and standard deviation (SD), median 
and interquartile range (IQR) or count and percentage (%), when 
appropriate. Non-parametric tests were used to compare costs per 
patient in the TIPS treatment group versus the EVL treatment group. 
Data analyses were carried put using the SPSS v21.0 program 
(SPSS Inc., Chicago, IL, USA). A two-sided p-value of <0.05 was 
considered statistically significant.
150 Vascular diseases of the gastrointestinal tract
Results
Patient characteristics 
We used data of 52 patients (age at randomization 54 (interquartile 
range (IQR) 49-61) years; 29 males) with an acute first or secondary 
GEVB randomized to either TIPS (n=25, age 56 (IQR 49-60) years; 
13 males) or standard care with EVL + β-blocker (n=27, age 54 (IQR 
49-63) years; 16 males). Characteristics of these patients, at the 
moment of randomization, are displayed in  2. At randomization, 
14 patients (56%) in the TIPS group vs 10 patients in the EVL (37%) 
group were known with ascites (p=0.27). Two patients in the EVL 
group and none of the patients in the TIPS group had experienced 
a previous episode of hepatic encephalopathy (p=0.38).
 2 Characteristics of 52 patients randomized to either TIPS  
  placement or endoscopic therapy with EVL after an acute  
  first or second episode of GEVB after one year
TIPS placement 
n=25
EVL 
n=27
gender
male
female
13 (52)
12 (48)
16 (59)
11 (41)
age at randomization (years) a 56 (49-60) 54 (49-63)
etiology
alcohol
hepatitis B/C
auto-immune liver/biliary disease b
other c
8 (32)
2 (8)
9 (36)
6 (24)
12 (44)
1 (4)
7 (26)
7 (26)
Child-Pugh score at randomization d 7,8 ± 2,27 7,2 ± 1,99
pre-existent ascites 14 (56) 10 (37)
previous episode of HE 0 2 (8)
data is derived from Holster et al. 5, with the exclusion of one patient of which follow-up data 
was insufficient for this paper. Values represent number of patients and percentage (%), unless 
otherwise specified
a values represent median, IQR
b this includes primary biliary cirrhosis, primary sclerosing cholangitis and auto-immune hepatitis
c this includes NASH, combined alcoholic and viral hepatitis, and cryptogenic liver disease.
d the Child-Pugh score ranges from 5 to 15. Values represent mean ± standard deviation.
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Initial costs
The initial costs of the two treatments, including all personnel, 
equipment, material, housing, and overhead costs were € 8.395 for 
TIPS placement and € 328 for EVL + β-blocker . The higher costs 
for TIPS placement were mainly caused by the higher material 
costs e.g. purchase costs of the stent is € 3.228. Also, the costs for 
personnel, equipment, and other materials were significantly higher 
in the TIPS group. In addition, treatment with TIPS also requires a 
pre-TIPS computed tomography (CT-) angiography (€ 188), and a 
post-TIPS stay on the post-anesthesia care unit (€ 2.324), costs that 
are not involved in EVL. For a detailed overview of the costs per 
treatment see  3. 
 3 Full costs prices of the two treatments groups
TIPS placement 
n=25
EVL 
n=27
personnel a
equipment b
materials c
housing/overhead d
€ 921
€ 393
€ 4120
€ 2962
€ 87
€ 51
€ 130
€ 61
total costs € 8395 € 328
values represent full cost prizes in euro in financial year 2014 
a for TIPS placement personnel includes costs for interventional-radiologist, registered 
nurse, registered in anesthesiology, and medical clerk. For EVL treatment this includes a 
gastroenterologist, registered nurse, and medical clerk
b equipment for TIPS placement includes anesthesia equipment (breathing/ventilation support, 
monitoringsystem, two pumps, hotline, warm air, monoplane X-ray system, and Ultrasound 
Esaote Mylab Twice), and costs for pre-TIPS computed tomography (CT) angiography. 
Equipment for EVL treatment includes use of a gastroscope, processor, monitor, pulsoximeter, 
computer, and datascope
c materials for TIPS placement include use of PTFE Stent (€ 3228), pigtail catheter, cobra 
catheter, Amplatz wire, Terumo enter wire, TIPS needle and sheet, portal vein needles, coils, 
sterile and non-sterile cloths, and sterile and non-sterile gloves. Materials for EVL include iv 
catheters, six shooter, endoscopic injector needle, scalpel, cryanoactrylate glue, mouth guard, 
non-sterile cloths, suction reservoir and wire, gloves, and personal protective equipment 
d housing for TIPS placement includes post-TIPS admission on the post-anesthesia care unit. The 
overhead rate for both TIPS placement and EVL was 42%
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Total costs in the first year
The mean total costs per patient in the first year after index bleed-
ing were significantly higher in the TIPS group compared to the 
EVL + β-blocker group (€ 27.415 vs € 16.762, p=0.006). The highest 
cost categories for the TIPS group were costs of the intervention 
(mean cost per patient € 8.395 for TIPS placement vs € 803 for 
EVL, p<0.001) and re-intervention (mean cost per patient per TIPS 
revision € 1.343 for TIPS group vs € 0 for EVL + β-blocker group, 
p=0.07). Intramural care, consisting of hospital admissions, ICU 
care, and treatment in daycare setting were the highest cost catego-
ries for the EVL treatment arm (mean total cost per patient € 5.612 
and € 1.440 for admission on ward in an academic hospital and 
community hospital, respectively). However, patients in the TIPS 
group had significantly higher costs per admission when compared 
to patients in the EVL treatment group (mean total days of admis-
sion on an academic ward for the TIPS group 16 vs 9 days for the 
EVL + β-blocker group; mean total cost for admission on academic 
ward € 10.093 for the TIPS group vs € 5.612 for the EVL group, 
p=0.005). Costs for treatment in daycare setting were significantly 
higher in the EVL treatment group (mean total days of treatment 
in daycare setting for the EVL group 2 days vs 0 days for the TIPS 
group; the mean total cost per patient € 552 for the EVL group vs 
€ 0 for the TIPS group, p<0.001). There were no differences in costs 
in hospital consultations and radiological imaging between both 
groups. In the EVL group, more diagnostic gastroscopies were 
performed compared to the TIPS group (p<0.001). 
A detailed overview of the mean costs of treatment per 
patient per treatment group is shown in  4. For the distribution of 
the total costs per patient per treatment group see  s1.
Sensitivity analysis
The TIPS treatment arm and the EVL treatment arm were re-strat-
ified into patients with and without pre-existent ascites. Fourteen 
patients (56%) in the TIPS group were known with ascites against 
10 patients (37%) in the EVL + β-blocker group. The mean total cost 
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per patient with ascites in the TIPS group was € 35.581 vs € 26.623 
(p=0.5) in the EVL group  s2. The mean total cost per patient for 
both treatment groups was higher in patients with pre-existent 
ascites.
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 4 Mean costs of healthcare use per patient
TIPS placement 
n=25
EVL 
n=27
cost category volume a costs b (€) volume a costs b (€) p-value c
admissions
admission ward d
admission ward e
admission ICU
treatment in daycare setting
15,9
1,2
1,3
0,0
10.093
826
2.075
11
8,9
3,0
1,3
2,0
5.612
1.440
2.038
552
0.005
0.022
0.59
<0.001
consultations
ER
outpatients clinic f
outpatients clinic g
outpatients clinic and daycare h
telephone consulting
0,5
2,6
1,2
0,0
0,5
80
364
85
0
16
0,2
1,7
1,7
0,3
0,5
37
247
121
124
16
0.77
0.29
0.29
0.09
0.72
radiological imaging
chest X-ray 
abdominal ultrasonography
CT-scan
MRI
angiography
1,8
1,5
0,8
0,2
0
93
119
187
52
0
0,7
1,3
0,4
0,1
0,1
35
98
83
19
34
0.26
0.61
0.59
0.21
0.17
diagnostics
laboratory testing
gastroscopy i
colonoscopy
ascites puncture j
liver biopsy
liver transplantation screening k
percutaneous manometry l
pleural puncture/aspiration
pulmonary function test 
electroencephalography 
electrocardiography 
cardiac ultrasonography
16,7
0,1
0,1
0,6
0
0,1
0,1
0
0
0,2
0,3
0,2
234
24
56
96
5
789
173
7
2
44
99
12
10,5
1,4
0
0,4
0
0,1
0
0
0
0
0,2
0
147
438
0
64
0
1.095
0
0
0
8
65
3
0.08
<0.001
0.30
0.44
0.30
0.71
0.14
0.30
0.30
0.26
0.12
0.14
initial treatment
EVL
TIPS placement
0
1,0
0
8.395
2,4
0
803
0
<0.001
<0.001
other treatments
switch therapy m
TIPS revision n
thrombocyte transfusion
red blood cells transfusion
plasma transfusion
0,1
0,2
0,6
3,3
2,0
349
1343
301
708
365
0,2
0
0,5
4,7
2,9
1.555
0
260
1.016
537
0.11
0.07
0.81
0.79
0.69
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TIPS placement 
n=25
EVL 
n=27
cost category volume costs (€) volume costs (€) p-value
medication 
laxatives o
albumin p
terlipressin q
octreotide r
antibiotics s
936,8
9,8
122,0
0,1
13,2
237
40
23
89
20
42,9
26,5
0
223,5
21,8
43
27
0
223
29
0.07
0.79
0.07
0.80
0.54
total costs – 27.415 – 16.762 0.006
a values represent volume of admission days, visits to the outpatient clinic, ER visit, or number 
of times of radiological imaging, diagnostics, and treatment. In case of medication, volumes 
represent the amount of defined daily dose (DDD) unless otherwise specified
b values represent full cost prizes per patient in euro in financial year 2014
c p-value <0.05 was considered significant
d admission to the ward of an academic medical center
e admission to the ward of a community hospital
f visit to the outpatients clinic in an academic medical center
g Visit to the outpatients clinic in a community hospital
h combined visit to the outpatients clinic and treatment in daycare setting in an academic 
medical center
i includes diagnostic gastroscopies without EVL
j includes ascites aspiration as well as taps
k liver transplantation screening includes extensive laboratory testing, blood cultures, urine 
cultures, gastroscopy, colonoscopy, abdominal ultrasound, Dual Energy X-ray Absorption 
(DEXA) scan, CT-scan, dental and sinus X-ray, if needed a mammogram, as well as visits 
to the infectiologist, surgeon, orthognathic surgeon, otolaryngologist, social worker and 
hepatologist. It also includes an admission of 5 work days in an academic medical center
l percutaneous transhepatic balloon angioplasty with manometry in the portal vein.
m failure of the initial treatment arm for which switch therapy to the other treatment arm
n revision of the TIPS placement to rule out occlusion or stenosis of the stent
o includes the administration of lactulose as well as rifaximin in DDD used in the clinical setting 
and in the outpatient setting
p includes albumin supplementation used in the clinical setting in ml used
q includes terlipressin supplementation in DDD used in the clinical setting
r includes octreotide administration in DDD in the clinical setting
s includes the use of the following antibiotics in DDD in case of bleeding related infection: 
amoxicillin/clavulanic acid, cefotaxim, ceftriaxone, cefuroxim, cefazolin, ciprofloxacin, 
clindamycin, erythromycin, gentamycin, norfloxacin, meropenem, and piperacilline/
tazobactam
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Discussion
We aimed to compare the total costs of TIPS placement versus 
EVL + β-blocker for the secondary prevention of gastroesophageal 
variceal bleeding. We found that patients treated with TIPS after an 
acute episode of GEVB have significantly higher treatment costs in 
the first year after treatment compared to patients treated with the 
standard care EVL + β-blocker. 
In the current era with rapidly expanding healthcare costs and 
more focus on economic viability of new treatments, cost studies 
provide insight into the distribution of costs and may allow to iden-
tify cost reducing measures. This is the first detailed cost inventory 
based on a randomized clinical trial on the secondary prevention 
of variceal rebleeding by means of TIPS or EVL + β-blocker. Mean 
total costs per treatment arm varied between € 16.762 and € 27.415, 
and was significantly higher for patients with TIPS placement. This 
is the result of the significant higher intervention costs in the TIPS 
group, which also includes higher costs for personnel, material, and 
post-TIPS care at the post-anesthesia care unit, as well as higher 
costs for intramural care compared to patients with EVL + β-blocker. 
Up till now, no insight in the costs was involved when 
comparing the two treatment options, TIPS or EVL + β-blocker, for 
variceal rebleeding due to portal hypertension in patients with liver 
cirrhosis. Only a few studies aimed to determine the costs for differ-
ent treatment options in this patient group. These studies primarily 
focused on the cost-effectiveness of TIPS vs surgical portacaval or 
splenorenal shunts 10-12. The average costs per life year was between 
$17.771 and $35.691 11,12. However, these studies were limited by the 
use of bare stents during TIPS placement. One study provided the 
actual costs accounted for covered stent TIPS placement, including 
costs for personnel, medical supply, costs of anesthesia, hospital-
ization, and amortization expense 10. In this study, the costs for a 
mean of 1.1 stent per patient, was $12.211 and included $4.746 for a 
covered stent, $3.168 for medical supply, $1.119 for staff, $1.143 for 
a mean length of admission of 2,5 days, and $2.035 for amortiza-
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tion expense. When converted to the euro currency and adjusted 
for the use of 1 stent, the price for TIPS placement is similar to our 
study except for the price and length of stay of admission. A recent 
randomized clinical trial from the United States, the direct costs of 
endoscopic therapy versus portocaval shunts in the elective setting 
and TIPS placement versus portocaval shunts in the emergency set-
ting were calculated 13. In this study, the total charges were greater 
in patients treated with endoscopic therapy (mean total overall 
charges of $168.100) or TIPS compared to emergency portocaval 
shunt placement (mean total overall charges of $39.400). However, 
a factor that may hamper the generalizability of the study is that it 
focused on treatment of gastric varices only. Another study only 
focused on the outcomes of TIPS through the left branch vs the 
right branch of the portal vein 14.
Our study offers insight into the economic burden that is as-
sociated with GEVB treated with EVL + β-blocker or TIPS. The costs 
in this study are based on the direct costs of a randomized con-
trolled trial, which included patients with esophageal varices as well 
as gastric varices bleeding. Complete charges were obtained for 
every patient entered in the study. In addition, a detailed cost over-
view for inpatients as well as outpatient costs is considered. We 
also performed a sensitivity analysis for patients with pre-existent 
ascites. There were more patients known with ascites in the TIPS 
group than in the EVL + β-blocker group. However, this difference 
was not significant as the data is based on a randomized controlled 
trial. The mean costs per patient for both treatment groups were 
higher in patients with pre-existent ascites compared to patients 
without ascites. The mean costs per patients were higher in pa-
tients with pre-existent ascites receiving TIPS-placement, however 
this difference was not statistically significant compared to the 
mean costs per patient in the EVL-group. 
Our study had some limitations. Firstly, we calculated the 
direct costs for patients during the first 12 months after interven-
tion. The costs after the first year were not considered. 
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Secondly, direct non-healthcare costs (travel costs) and indirect 
costs (productivity loss) were not calculated. This may affect the 
total costs per treatment group as TIPS placement is only per-
formed in tertiary referral centers and EVL in almost all community 
hospitals. Consequently, this may result in higher travel expenses 
in the TIPS group. However, productivity loss may not have a large 
effect on the mean costs of treatment after a year since most of 
these patients were already known with severe liver cirrhosis that 
prevented them from employment early on before treatment with 
TIPS or EVL + β-blocker . 
Furthermore, the cost calculations were performed based on 
data in Dutch centers. Cost prices differ per country, but are prob-
ably comparable. 
In addition, the study is limited by the limited number of 
individuals. Inclusion of more patients might assure an even more 
precised cost overview by reducing the effect of outliers (four pa-
tients in TIPS group, highest total cost per patient € 114.392 and two 
patients in the EVL group, highest cost prize per patient € 94.505). 
TIPS placement is more effective in the prevention of rebleed-
ing in patients with a previous episode of GEVB than treatment with 
EVL + β-blocker, currently the standard care 4,5. However, there was 
no difference in survival between both treatment groups. In addi-
tion, TIPS placement led to higher prevalence of hepatic encepha-
lopathy in these patients. This study implies that TIPS placement 
has significant higher costs than EVL + β-blocker. Considering this 
finding, one should be vigilant to treat patients with GEVB with TIPS 
as standard care.
However, there are possibilities to overcome these issues. 
First, there is the possibility to perform TIPS by administration of 
conscious sedation with intravenous midazolam and fentanyl 15. 
Performing the TIPS procedure under conscious sedation rather 
than general anesthesia, considerably reduces the initial costs prize 
for treatment with TIPS, as conscious sedation is relatively cheap 
and does not require certified staff in anesthesiology and post-TIPS 
admission on the PACU is no longer needed. Second, studies have 
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shown that the placement of a TIPS stent in the left portal vein 
branch may be more reasonable for decreasing the development 
of hepatic encephalopathy 14. Patients undergoing TIPS through the 
left branch of the portal vein had lower incidence of encephalopa-
thy, less rehospitalization and lower costs after TIPS implantation 
compared with patients undergoing TIPS through the right branch 
of the portal vein.
In conclusion, treatment with TIPS after an acute episode of 
GEVB is significantly more costly in the first year after treatment 
compared to EVL treatment. Given the similar effectiveness of TIPS 
and EVL in combination with β-blocker in the secondary treatment 
of variceal rebleeding, cost consideration should play a role in 
selection of the most optimal treatment. Future studies should put 
more focus on full cost comparisons as well as data on quality of 
life in this patient group. 
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 s1 Costs per DDD of medication according to inpatient or  
  outpatient use and prescription in an academic or community  
  medical center
medication administration costs per DDD (€) a costs per DDD (€) b
cefuroxim
octreotide
octreotide
augmentin
augmentin
albumin
norfloxacin
ciprofloxacin
ciprofloxacin
erytromycin
lactulose
lactulose (enema)
clindamycin
rifaximin
terlipressin
gentamycin
cefotaxim
piperacilline/tazobactam
ceftriaxon
meropenem
cefazolin
IV
IV
SC
IV
O
IV
O
IV
O
IV
O
R
O
O
IV
IV
IV
IV
IV/P
P
P
2,04
4,45
6,44
2,46
0,40
27,30
0,30
3,00
0,34
13,65
0,074
0,0142
2,36
6,92
327,67
3,24
4,60
7,84
1,15
10,26
2,16
12,27
17,23
34,65
9,66
0,77
75,65
0,53
29,68
0,25
0,62
0,147
0,07
1,94
6,71
964,24
5,52
22,20
52,69
20,27
46,91
8,58
values represent cost prizes per DDD in euro in financial year 2014
a cost per DDD in an clinical setting
b cost per DDD prescribed in the outpatient clinic
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 s2 Mean costs of healthcare use per patient with ascites
TIPS placement 
n=14
EVL 
n=10
cost category costs a (€) costs (€)
admissions
admission ward b
admission ward c
admission ICU
treatment in daycare setting
14.174
1.474
3.481
20
8.879
1.296
5.030
552
consultations
ER
outpatients clinic d
outpatients clinic e
outpatients clinic and daycare f
telephone consulting
119
274
117
0
9
67
227
85
0
21
radiological imaging
chest X-ray 
abdominal ultrasonography
CT-scan
MRI
angiography
148
156
271
75
0
42
78
112
26
3.492
diagnostics
laboratory testing
gastroscopy g
colonoscopy
ascites puncture h
liver biopsy
liver transplantation screening i
percutaneous manometry j
pleural puncture/aspiration
pulmonary function test 
electroencephalography 
electrocardiography 
cardiac ultrasonography
329
43
101
160
10
704
309
13
0
79
126
22
197
394
0
103
0
986
0
0
0
0
141
8
initial treatment
EVL
TIPS placement
0
4.701
953
0
other treatments
switch therapy k
TIPS revision l
thrombocyte transfusion
red blood cells transfusion
plasma transfusion
349
1.007
538
987
545
2.519
0 
703
2.462
1.451
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TIPS placement 
n=14
EVL 
n=10
cost category costs a (€) costs (€)
medication 
laxatives m
albumin n
terlipressin o
octreotide p
antibiotics q
217
67
41
133
25
58
59
0
69
16
total costs 35.581 26.623
a values represent full cost prizes per patient in euro in financial year 2014
b admission to the ward of an academic medical center
c admission to the ward of a community hospital
d visit to the outpatients clinic in an academic medical center
e visit to the outpatients clinic in a community hospital
f combined visit to the outpatients clinic and treatment in daycare setting in an academic 
medical center
g includes diagnostic gastroscopies without EVL
h includes ascites aspirations as well as taps
i liver transplantation screening includes extensive laboratory testing, blood cultures, urine 
cultures, gastroscopy, colonoscopy, abdominal ultrasound, Dual Energy X-ray Absorption 
(DEXA) scan, CT-scan, dental and sinus X-ray, if needed a mammogram, as well as visits 
to the infectiologist, surgeon, orthognathic surgeon, otolaryngologist, social worker and 
hepatologist. It also includes an admission of 5 work days in an academic medical center
j percutaneous transhepatic balloon angioplasty with manometry in the portal vein
k failure of the initial treatment arm for which switch therapy to the other treatment arm
l revision of the TIPS placement to rule out occlusion or stenosis of the stent
m includes the administration of lactulose as well as rifaximin in DDD used in the clinical setting 
and in the outpatient setting
n includes albumin supplementation used in the clinical setting in ml used
o includes terlipressin supplementation in DDD used in the clinical setting
p includes octreotide administration in DDD in the clinical setting
q includes the use of the following antibiotics in DDD in case of bleeding related infection: 
amoxicilline, cefotaxim, ceftriaxone, cefuroxim, cefazolin, ciprofloxacin, clindamycin, 
erythromycin, gentamycin, norfloxacin, meropenem, and piperacilline/tazobactam
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 s1 Distribution of total costs per patient per treatment group  
  in euros (€) 
    
    TIPS EVL + β-blocker
boxes represent medians with interquartile range, whiskers extent to the most and least extreme 
scores respectively. Dots represent the outliers
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Introduction
Chronic gastrointestinal ischemia (CGI) results from insufficient 
blood supply to the gastrointestinal tract, in most cases caused 
by atherosclerotic stenosis of the supplying arteries 1 but may also 
be due to hypo-perfusion and/or hypo-oxygenation caused by an 
underlying cardiac or pulmonary disease 2,3. Three direct branches 
of the abdominal aorta are responsible for the blood supply of the 
gastrointestinal tract: the celiac artery (CA), the superior mesenteric 
artery (SMA) and the inferior mesenteric artery (IMA). 
Until recently it was thought that CGI could only occur in the 
presence of two or more occluded arteries, but recent studies using 
functional testing have shown that a significant stenosis of a single 
artery with insufficient collateral circulation can also lead to clini-
cally relevant gastrointestinal ischemia. 1,4-6. Functional testing such 
as gastric tonometry and visible light spectroscopy (VLS) have been 
incorporated in the standard work-up to optimize the diagnosis of 
CGI in patients with chronic abdominal symptoms. Both methods 
seem to be accurate for detection of gastrointestinal ischemia in 
combination with radiological imaging 1,4,7,8. 
Currently, the established approach for diagnosing CGI is 
based on three main components including assessment of medical 
history and clinical symptoms, radiological imaging of the mes-
enteric arteries and detection of mucosal ischemia by means of a 
functional test such as VLS 9,10. 
A definitive diagnosis of CGI is made after persistent relief of 
symptoms on follow-up after treatment. 
In chapter 1 an introductory summary on CGI and other 
vascular diseases of the gastrointestinal tract are provided.
Chapter 2 addresses the effect of caloric challenge on 
VLS measurements in patients with CGI and healthy controls. 
Consecutive patients with a diagnosis of CGI and healthy controls 
were prospectively included between September 2014 and August 
2015. All patients received the standard work-up for CGI, consist-
ing of assessment of medical history and symptoms, radiological 
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imaging of the gastrointestinal arteries, and VLS measurements. 
VLS measurements in postprandial state were compared to VLS 
measurements in fasting state. We performed 168 VLS measure-
ments in 12 patients with CGI (median age 63.2 (IQR 48.8-70.4) 
years, 67% male) and 16 controls (32.9 (IQR 27.7-39.8.2) years, 44% 
male). There was no significant increase between postprandial 
and baseline VLS measurements in CGI patients (baseline antrum 
median 58.5 (IQR 53.5-59.0) vs postprandial antrum median 57.5 
(IQR 54.0-60.8), p=0.25; baseline duodenal bulb median 53.0 (IQR 
48.8-54.0) vs postprandial duodenal bulb median 53.5 (IQR 50.3-
56.8), p=0.89; baseline descending duodenum median 49.5 (IQR 
45.3-52.8) vs postprandial descending duodenum median 54.0 
(IQR 47.3-57.8), p=0.33, respectively). In the healthy controls, there 
was a trend towards higher VLS measurements in the postprandial 
state. We found no difference in VLS measurements before and 
after caloric challenge in patients with CGI, however there was a 
trend in increase in VLS measurements in the healthy controls. The 
current results indicate that a caloric challenge does not improve 
the discrimination between patients with CGI and healthy controls. 
In chapter 3 we studied the sublingual microcirculation in 12 
patients with CGI using a hand-held microscope based on Incident 
Dark Field (Cytocam). The microcirculation was assessed before 
(T0) and 20 minutes after enteral feeding (T1). Total vessel density 
(TVD (mm/mm2)), perfused vessel density (PVD (mm/mm2), propor-
tion of perfused vessels (PPV (%)), and microvascular flow index 
(MFI (AU)), respectively, of small vessels and all vessels, and before 
and after a caloric challenge. There was a significant increase in 
the PVD of the small vessels and all vessels, and in the PPV of the 
small vessels after caloric challenge compared to baseline (PVDs 
median 16.3 (IQR 13.3-22.1) mm/mm2 vs 19.9 (IQR 14.2-26.2) mm/
mm2, p=0.008; PVDa median 19.1 (IQR 16.2-23.6) mm/mm2 vs 22.2 
(16.5-28.9) mm/mm2, p=0.02; PPVs median 84.8% (IQR 75.3-90.4) vs 
91.0% (80.1-93.8), p=0.01). We found that patients with CGI have a 
significant increase in the perfused vessel density and proportion of 
perfused vessels after stimulation with food and thus have a hy-
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peraemic response to ingestion of food. These findings may lead to 
development of more rapid, less-burdensome and more advanced 
diagnostic methods for the detection of CGI. Future studies with 
more patients and healthy are needed to increase the generaliz-
ability of our findings and to provide more discriminatory power for 
clinical use. 
In chapter 4 we present a prediction model to identify pa-
tients with CGI based on a large prospective study consisting of 
436 patients. Our study shows that advanced age, female gender, 
presence of nausea and weight loss, recent onset of symptoms, 
concomitant cardiovascular disease, positive family history for 
cardiovascular disease, and no use of analgetics are predictors 
for CGI. Our study confirms that the diagnostic value of clinical 
variables alone in the diagnosis of CGI is limited (c-statistic 0.62) 11. 
Combining clinical variables with presence of mesenteric arterial 
stenosis in a second model allows discriminating more accurately 
between patients with and without CGI (c-statistic of 0.76). A 
prediction model for CGI that takes into account clinical variables 
and radiological assessment of the mesenteric arteries may also 
be a useful tool for clinicians to assess the risk of CGI and to decide 
whether further diagnostic work-up and treatment is indicated. 
In chapter 5 we performed a pilot study to investigate the 
expression of HIF-1α in chronic ischemic tissue by immunohisto-
chemistry. Immunohistochemical expression of HIF-1α in the gastro-
intestinal tract was analyzed in 20 patients with CGI, nine patients 
with H. pylori-gastritis, nine patients with ischemic colitis (IC), 18 
patients with inflammatory bowel disease (IBD) and five patients 
with infectious colitis. Ten controls served for the upper GI-tract 
and 12 controls for the lower GI-tract respectively. In the upper 
GI-tract, HIF-1α expression was found in 5/20 CGI-patients, but not 
in controls (p=0.08). The sensitivity and specificity of HIF-1α expres-
sion for diagnosing CGI was 25% and 84%. In the lower GI-tract, in 
HIF-1α was expressed in all patients with IC, infectious colitis and in 
majority of IBD-patients. This was also in 7/12 controls. The sensi-
tivity and specificity of HIF-1α for diagnosing IC was 100% and 51%. 
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HIF-1α expression was more observed in patients with inflammation 
on histology (p=0.02) in the lower GI-tract. Therefore, HIF-1α is not a 
pathognomonic marker for the presence of ischemia.
In chapter 6 we aimed to determine the incidence of hypoxic 
hepatitis in a well-defined cohort of CGI patients. In total, 156 
patients were eligible for inclusion (median age 64.1 (IQR 53.1-73.6) 
years; 74% female, median ALT 0.49x ULN (IQR 0.36-0.67). The 
results of the current study shows that serum aminotransferases 
were very mildly raised in only 10% of the total cohort of 156 pa-
tients with CGI, which normalized after successful treatment of CGI. 
Elevated ALT >1x ULN was not significantly associated with pres-
ence of mucosal ischemia, significant stenosis of the CA, SMA, or 
both CA and SMA. Neither was there an association between ALT 
>1x ULN and presence of known predisposed conditions of steatotic 
liver injury such as body mass index (BMI), alcohol consumption 
and diabetes mellitus (DM) type II, nor between ALT >1x ULN and 
increasing age. Twelve of these 15 patients received treatment 
(endovascular, surgical or medical treatment according to cause of 
CGI). At follow-up (median 17.6 months), only 2 of these patients 
kept ALT >1x ULN (mean 75 IU/ml). Both patients were diagnosed 
with NOMI and were irresponsive to treatment. Therefore, liver 
injury is not a common feature of CGI. When present, it is mild and 
mostly normalizes after appropriate treatment of CGI. 
In chapter 7 we describe the clinical presentation and char-
acteristics of gastrointestinal ischemia in patients with portal vein 
thrombosis (PVT). We performed a prospective cohort study in 
which patients with non-cirrhotic, non-malignant PVT were includ-
ed. Clinical symptoms of gastrointestinal ischemia were assessed 
by a structured questionnaire, VLS, and radiological evaluation of 
the mesenteric vasculature. VLS measurements were compared 
to those in patients with cirrhosis and a reference population. We 
included 15 patients with chronic PVT and one patient with acute 
PVT (age 46.1 [IQR 30.9-53.7] years; 44% male). Decreased mucosal 
oxygenation in at least one location of the gastrointestinal tract 
was found in 12/16 (75%) patients. Compared to the reference 
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population (median 60.0 [56.2-61.7]), VLS measurements were 
mostly decreased in the descending duodenum for patients with 
PVT (median 55.5 [52.3-58.8], p=0.02) and patients with cirrhosis 
(median 52.0 [46.5-54.0], p=0.003). Symptoms typical for gastroin-
testinal ischemia, such as postprandial pain and exercise-induced 
pain, were reported in 10/16 (63%) patients with PVT. We also found 
that patients with a thrombus extending into the SMV and/or SV 
more often report abdominal pain than patients without extension 
of the thrombus. Also, patients with extension of the thrombus into 
the SMV and/or SV had significantly lower VLS measurements in 
the antrum and descending duodenum compared to the reference 
population. In addition, we found decreased VLS measurements 
in five out of six patients with an inherited hypercoagulable risk 
factor. Finally, we observed that VLS measurements were higher in 
patients treated with OAC compared to patients who were not or 
only partly treated, although this difference was not statistically sig-
nificant, suggesting that there might be a positive effect of OAC on 
gastrointestinal ischemia in patients with chronic PVT. Therefore, 
in patients with PVT gastrointestinal ischemia is frequent. Onset of 
abdominal symptoms such as postprandial pain should prompt the 
physician to re-evaluate the extent, cause and treatment of PVT.
In chapter 8 we aimed to compare the total costs of TIPS 
placement versus EVL for the secondary prevention of gastro-
oesophageal variceal bleeding in the first year following the index 
bleed by determining direct medical costs from a multicenter 
randomized trial in which EVL was compared with TIPS placement. 
We performed a post-hoc analysis of direct medical costs of 52 
consecutive patients (25 TIPS/27 endoscopy) surviving an acute 
first or second variceal bleeding due to liver cirrhosis-related portal 
hypertension. The primary endpoint of this study was defined 
as mean total health care costs per patient for the two treatment 
strategies. Total costs included the costs for intervention as well as 
healthcare costs from the day of randomization until twelve months 
after randomization, or until the occurrence of death, or moment of 
liver transplantation. 
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The cost prizes of the two treatment groups, including all personnel, 
equipment, material, housing, and overhead costs were € 10.589 
and € 385 for TIPS placement and EVL, respectively. The mean total 
costs per patient were significantly higher in the TIPS group com-
pared to the EVL group (€ 27.746 vs € 16.818, p=0.006). Therefore, 
from an economic point of view, treatment with endoscopic variceal 
band ligation is recommended for the secondary prevention of 
gastro-oesophageal variceal rebleeding in patients with portal 
hypertension. 
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Conclusions
The diagnosis of chronic gastrointestinal ischemia (CGI) is a chal-
lenge. Currently, there is no single test with high sensitivity and 
specificity to diagnose or exclude this condition. Therefore, a 
diagnostic approach combining assessment of clinical symptoms, 
radiological imaging of the mesenteric arteries and functional 
testing using VLS is recommended in the work-up of CGI suspected 
patients 9. However, a definitive diagnosis of CGI is only to be made 
after persistent relief of symptoms on follow-up after treatment. 
This is not the ideal reference standard, however given the absence 
of any other generally accepted reference standard, it is currently 
the only reliable way to diagnose true CGI. Therefore, further stud-
ies should focus on improvement of the pre-treatment diagnosis of 
CGI. VLS appears to be of value as a minimal invasive diagnostic 
tool in patients suspected of CGI 5. It has a high sensitivity and spec-
ificity for the diagnosis of CGI. Currently, VLS measurements are 
performed when patients are in a fasting state. Postprandial VLS 
measurements after 60 minutes of caloric intake did not improve 
the discrimination between patients with CGI and healthy controls. 
Finding a correlation between sublingual microcirculation altera-
tions and presence of CGI could also lead to a change in approach 
in patients clinically suspected for CGI prompting more institutions 
and gastroenterologists to consider and test for CGI. A prediction 
model for CGI that takes into account clinical variables and radio-
logical assessment of the mesenteric arteries may also be a useful 
tool for clinicians to assess the risk of CGI and to decide whether 
further diagnostic work-up and treatment is indicated. Studies on 
the value of HIF-1α as a marker for ischemia remains to be further 
investigated as HIF-1α is expressed in ischemic tissue, but also in 
normal colon tissue, and various inflammatory disorders. 
We have also shown that the effect of CGI on the liver is mild 
and that in contrast to acute ischemic intestinal conditions, liver 
injury is not a common feature of CGI. When present, it is mild and 
mostly normalizes after appropriate treatment of CGI. In patients 
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with PVT however, gastrointestinal ischemia is frequent. Albeit 
in a small cohort, mucosal ischemia using VLS was detected in 
75% of patients with PVT. Onset of abdominal symptoms such as 
postprandial pain should prompt the physician to re-evaluate the 
extent, cause and treatment of PVT. We also compared the total 
costs of TIPS placement versus EVL for the secondary prevention 
of gastro-oesophageal variceal bleeding. The highest costs were 
found in the TIPS group, due to higher personnel, equipment, mate-
rial, and housing costs. From an economic point of view, treatment 
with endoscopic variceal band ligation is recommended for the 
secondary prevention of gastro-oesophageal variceal rebleeding in 
patients with portal hypertension. 
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Discussion and future directions
This thesis has some limitations. Firstly, all studies in this thesis 
were conducted in a single center setting. The Erasmus MC is one 
of the two referral centers in the Netherlands with a dedicated CGI 
program. To increase power of our studies and generalizability of 
our findings, further collaboration between the two referral centers 
should be explored. 
This also applies to the studies regarding the VLS. With the 
current cut-off values and the high sensitivity of 90%, no patient 
with CGI should be missed 5. However, this high sensitivity is at 
the expense of a low specificity and thus results in a higher rate 
of false-positives. In addition, the mean of mucosal saturation 
measurements in patients with CGI shows substantial variation and 
the range of measurements within an individual patient is large. 
Furthermore, there are small small changes in the position of the 
probe during the measurements which can elicit the possibility 
of not acquiring the actual mucosal oxygen saturation. Also, the 
performance of VLS are based on data from only one large cohort 
study and has not yet been reproduced by other groups 5. This 
illustrates the necessity for prospective validation of the established 
cut-off values in a new cohort of patients with the suspicion of 
CGI. Improved VLS measurements can be observed in patients 
with CGI after successful intervention 5. However, repeated upper 
endoscopy including VLS measurements, was performed in only a 
small number of patients. Therefore, future studies should focus on 
the role of repeated VLS measurements in the follow up of patients 
with CGI after treatment. 
Another limitation of the VLS is that the current technique 
causes restrictions regarding the place and time of the measure-
ments. Mucosal ischemia might be patchy and because VLS is 
limited to point measurements, it could be that mucosal ischemia 
might be missed with VLS. Continuous measurement of the mu-
cosal oxygen saturation using VLS could overcome this problem. 
Moreover, the time-dependent relationship of VLS measurements 
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and gastrointestinal blood flow can be further investigated by direct 
cessation of blood flow in the celiac artery and superior mesenteric 
artery in animal models. In addition, there might be a time-depen-
dent relation between mucosal ischemia and oral caloric stimula-
tion. In our study, repeated VLS measurements were performed 
after 60 minutes after caloric stimulation. We found that there is no 
significant increase or decrease in VLS measurements after stimula-
tion with food in patients with CGI whereas in healthy controls VLS 
measurements in the duodenal bulb rose significantly after food 
stimulation. Although these observations seem to confirm our 
initial hypothesis that indeed the physiological hyperemic response 
induced by food stimulation is impaired in patients with CGI, it 
currently provides too little discriminatory power for clinical use. 
Modifications of the VLS assessment protocol, in particular the tim-
ing of postprandial measurements, may improve its applicability. 
Furthermore, portal vein flow measurement using phrase 
contrast, with and without caloric stimulation, might also provide 
additional information on the time-dependent relationship between 
caloric intake, gastrointestinal arterial blood flow, and mucosal 
ischemia. 
Several studies have shown that microcirculatory alterations 
are related to hemodynamic changes which have been reported to 
impair gastrointestinal perfusion 12-14. In these patients, the sublin-
gual capillary perfusion seems well correlated to the hypoxic state 
of the gastric mucosa 15. Further research is required to illustrate 
and to validate the hypothesis that there is a correlation between 
impaired sublingual microcirculation and decreased endoscopic 
VLS measurements in patients with CGI. Although VLS is minimally 
invasive and can be performed in almost all patients, sublingual 
VLS measurements are less invasive, more patient-friendly and 
less time consuming than endoscopic VLS and therefore have the 
potential to be of great value in diagnosing patients with CGI 5,9. 
We established a prediction model for CGI based on clinical 
symptoms and radiological evaluation of the mesenteric arteries. 
However, a possible limitation of this study is incorporation bias 
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which may have led to overestimation of the accuracy of the stud-
ied variables for the prediction model for CGI 17,18. This illustrates 
the necessity for prospective, external validation of our model in a 
new cohort of patients. However, this is expected to be difficult as 
large well-defined cohorts are lacking and these studies will also be 
limited by the absence of a golden standard for CGI. 
Another point of focus for future studies should be the further 
elucidation of gastrointestinal ischemia in patients with PVT. It 
would be interesting to perform VLS measurements to study the 
time course of gastrointestinal ischemia in patients with PVT, for 
instance before and after initiation of anticoagulant therapy. In ad-
dition, colonoscopy is now only included in our standard work up of 
the patient in case of lower gastrointestinal symptoms. It would be 
interesting to perform colonoscopy in patients with PVT to assess 
ischemic changes in the colonic mucosa. 
The use of endovascular techniques for revascularization of 
chronic stenosis and occlusions of the gastrointestinal arteries has 
rapidly evolved and endovascular therapy with stenting has become 
the most common method in the treatment of CGI. Nowadays, 
use of bare metal stents is the standard care although the patency 
of these stents is limited. According to retrospective data the 
patency of covered stents is significantly higher compared to bare 
metal stents. It would be interesting to compare the outcome of 
revascularisation of the gastrointestinal arteries using covered 
stents compared to bare-metal stents in patients with CGI. Of great 
interest would also be to assess the role of fractional flow reserve 
(FFR) for the detection of significant stenosis in the gastrointestinal 
arteries. FFR is a technique used in coronary catheterization to 
measure pressure differences across a coronary artery stenosis to 
determine the likelihood that the stenosis impedes oxygen delivery 
to the organ. This could lead to a new approach in that only in 
case of high FFR patients with the suspicion of CGI would receive 
endovascular treatment. Another way of correctly identifying a 
significant stenosis of the gastrointestinal arteries would be using 
direct upper gastrointestinal sonography.
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A point of discussion has always be the treatment of single vessel 
CGI. Studies using functional testing in the diagnosis of CGI have 
shown that a significant stenosis of a single artery with insufficient 
collateral circulation can lead to clinically relevant gastrointestinal 
ischemia 4,6. However, a randomized controlled trial including inter-
vention by means of endovascular treatment, or a release operation 
in case of the celiac artery compression syndrome (CACS), and a 
sham procedure will present concrete evidence that patients with 
single vessel CGI would benefit from treatment. Future studies 
should also focus on the follow-up of these patients, especially 
regarding anti-coagulation. Nowadays, the use of anticoagulation 
consist of lifelong use of platelet aggregration inhibitor, such as 
aspirine, in combination with an oral, thienopyridine-class antiplate-
let agent such as clopidogrel. However, no sound scientific evidence 
existent on the duration of use of the latter in patients with CGI. 
In addition, studies on cost-effectiveness and quality of life in 
patients with CGI are lacking. Future studies on these topics should 
be performed to elucidate these issues further. 
Cost studies in patients with portal hypertension has shown 
that early TIPS placement has higher costs than EVL in the preven-
tion of rebleeding in patients with portal hypertension. However, 
data on quality of life in these patients are lacking. Future research 
should focus on the cost-effectiveness and quality of life in this 
patient population. 
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Het stellen van de diagnose chronische gastrointestinale ischemie 
(CGI) is een klinische uitdaging. Er bestaat geen enkel- en eenvoudig 
onderzoek waarvan de sensitiviteit hoog genoeg is voor het stellen 
van de diagnose. Daarom wordt evaluatie van de combinatie van 
klinische symptomen, radiologische beeldvorming van de mesente-
riale slagaders en functionele testen aanbevolen in de diagnostiek 
van CGI verdachte patiënten 1. Echter een definitieve diagnose van 
CGI kan pas gesteld worden nadat de patiënt aanhoudend verlicht-
ing van symptomen ondervindt na de behandeling. Dit is niet de 
ideale gouden standaard voor het stellen van de diagnose, maar 
gezien het ontbreken van een andere aanvaarde standaard, het is 
momenteel de meest betrouwbare manier om de diagnose van 
CGI te bevestigen. Daarom moet verder onderzoek zich richten op 
verbetering van de diagnose van CGI.
Hoofdstuk 1 geeft een korte inleiding en doelen van dit 
proefschrift weer. 
Hoofdstuk 2 richt zich op het effect van calorische intake 
op VLS metingen bij patiënten met CGI en gezonde controles. 
Opeenvolgende patiënten met de diagnose van CGI en gezonde 
controles werden prospectief geïncludeerd tussen september 2014 
en augustus 2015. Alle patiënten kregen de standaard diagnostische 
work-up voor CGI, bestaande uit uitvoerige anamnese en medische 
voorgeschiedenis, radiologische beeldvorming van de gastrointes-
tinale bloedvaten en VLS metingen. VLS metingen na calorische 
intake, oftewel postprandiale VLS waarden, werden vergeleken met 
VLS metingen in nuchtere toestand. We voerden 168 VLS metingen 
uit bij 12 patiënten met CGI (gemiddelde leeftijd 63,2 (IQR 48,8-70,4) 
jaar, 67% mannen) en 16 controles (32,9 (IQR 27.7-39.8.2) jaar, 44% 
mannen). Er was geen significante toename in postprandiale VLS 
metingen en VLS metingen in nuchtere toestand in patiënten met 
CGI (nuchter antrum mediaan 58,5 (IQR 53,5-59,0) versus postpran-
diale antrum mediaan 57,5  (IQR 54,0-60,8), p=0,25; nuchter bulbus 
duodeni mediaan 53,0 (IQR 48,8 -54,0) versus postprandiale bulbus 
duodeni mediaan 53,5 (IQR 50,3-56,8), p=0,89; nuchter duodenum 
descendens mediaan 49,5 (IQR 45,3-52,8) versus postprandiale 
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duodenum descendens mediaan 54,0 (IQR 47,3-57,8), p=0,33, 
respectievelijk). We vonden geen verschil in VLS metingen vóór en 
na calorische intake bij patiënten met CGI, maar er was een trend in 
toename VLS metingen in de gezonde controles. De huidige resul-
taten tonen onvoldoende onderscheid tussen patiënten met CGI en 
gezonde controles.
Hoofdstuk 3 beschrijft de sublinguale microcirculatie in 
12 patiënten met bewezen CGI. Beoordeling van de sublinguale 
microcirculatie gebeurde met behulp van een handmicroscoop 
(Cytocam). Patiënten met CGI hadden een toename in het aantal 
kleine bloedvaten en een toename in de perfusie van deze kleine 
bloedvaten na calorische intake. 
In hoofdstuk 4 presenteren we een predictiemodel voor 
patiënten met een klinische verdenking op CGI. Het predictiemodel 
is gebaseerd op een grote prospectieve studie bestaande uit 436 
patiënten met de verdenking op CGI en die verwezen zijn naar 
ons centrum voor nadere analyse. Onze studie toont aan dat toen-
emende leeftijd, vrouwelijk geslacht, misselijkheid, gewichtsverlies, 
recent begin van de symptomen, belaste cardiovasculaire voorge-
schiedenis alsook een positieve familie anamnese voor cardiovascu-
laire ziekten sterke voorspellers zijn voor het ontwikkelen van CGI. 
Daarentegen pleit het gebruik van analgetica tegen het krijgen van 
CGI. Onze studie laat zien dat de diagnostische waarde van klinische 
variabelen alleen in de diagnose van CGI beperkt is (c-statistic 0,62), 
maar dat een combinatie van klinische variabelen en radiologische 
evaluatie van de mesenteriale vaten een nauwkeurigere voorspell-
ing kan doen voor het krijgen van CGI (c-statistic van 0,76). Op basis 
hiervan ontwikkelden we een eenvoudige vragenlijst die voor clinici 
een nuttig hulpmiddel kan zijn om het risico van CGI in te schatten 
en om te beslissen of verdere diagnostiek en behandeling van deze 
patiënten geïndiceerd is.
Hoofdstuk 5 laat de resultaten zien van een studie waarin de 
expressie van HIF-1α is onderzocht in het gastrointestinale stelsel. 
Immunohistochemische expressie van HIF-1α werd geanalyseerd in 
20 patiënten met CGI, 9 patiënten met H. pylori-gastritis, 9 patiënten 
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met ischemische colitis (IC), 18 patiënten met inflammatoire dar-
mziekte (IBD), 5 patiënten met infectieuze colitis en 22 controles. 
In de bovenste tractus digestivus werd HIF-1α expressie in 5/20 
CGI-patiënten gezien, maar niet in de controlegroep (p=0,08). De 
sensitiviteit en specificiteit van HIF-1α expressie voor de diagnose 
CGI was 25% en 84%, respectievelijk. In de lage tractus digestivus 
werd HIF-1α expressie gezien in alle patiënten met IC, infectieuze 
colitis, in de meerderheid van de IBD-patiënten en in een gedeelte 
van de controles. De sensitiviteit en specificiteit van HIF-1α voor 
de diagnose IC was 100% en 51%, respectievelijk. HIF-1α expressie 
werd sterk waargenomen in patiënten met histologische inflam-
matie van de lage tractus digestivus (p=0,02). Onze resultaten tonen 
aan dat HIF-1α expressie aanwezig is in ischemisch weefsel, maar 
bij inflammatie en in normaal colon weefsel. 
In hoofdstuk 6 geeft de resultaten weer van de frequentie van 
leverschade in een welomschreven cohort van 156 patiënten met 
CGI. In slechts 10% van de patiënten was een zeer mild verhoogde 
serum transaminasestijging te zien. Verhoogde ALT> 1 x ULN was 
niet significant geassocieerd met de aanwezigheid van mucosale 
ischemie, significante stenose van de CA, SMA of van zowel CA 
als de SMA. Evenmin was er geen associatie tussen ALT> 1x ULN 
en verhoogde BMI, alcoholconsumptie, DM type II en toenemende 
leeftijd. Na behandeling van CGI, normaliseerde de ALT in 10/12 
(83%) patiënten. In tegenstelling tot acute ischemische aandoenin-
gen, komt leverschade in slechts 10% van de patiënten met CGI 
voor. De leverschade is mild en normaliseert na een goede en 
passende behandeling van CGI.
In hoofdstuk 7 worden de resultaten beschreven van een 
prospectieve cohort studie waarin de klinische presentatie en 
kenmerken van gastrointestinale ischemie in patiënten met vena 
porta trombose (PVT) wordt beschreven. In deze studie werden 15 
patiënten met chronische PVT en een patiënt met acute PVT geïn-
cludeerd. Klinische symptomen van ischemie werd beoordeeld met 
behulp van een gestructureerde vragenlijst, radiologische evaluatie 
van de mesenteriale vaten en VLS metingen. De VLS metingen 
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werden vergeleken met een historische controlegroep en met een 
groep patiënten met levercirrose. Symptomen typisch voor isch-
emie, zoals postprandiale pijn en inspannings-geïnduceerde pijn, 
werd in 10/16 (63%) patiënten met PVT waargenomen. Verlaagde 
VLS metingen in ten minste één plaats in het bovenste tractus di-
gestivus werd 12/16 (75%) patiënten gezien. Patiënten met PVT had-
den met name verlaagde VLS metingen in het duodenum vergele-
ken met de controlegroep en patienten met levercirrose(mediaan 
55,5 [52,3-58,8] vs mediaan 60,0 [56,2-61,7], p=0,02 en mediaan 52,0 
[46,5-54,0], p=0,003, respectievelijk). Gastrointestinale ischemie 
is frequent aanwezig in patiënten met chronische PVT. Mucosale 
ischemie werd in 75% van de patiënten met PVT gedetecteerd. VLS 
maakt objectieve en kwantitatieve bepaling van mucosale ischemie 
mogelijk.
De huidige maatschappij vraagt om slimme en betaalbare 
behandelmogelijkheden. In hoofdstuk 8 hebben we de totale kosten 
van een transjugulaire intrahepatische portosystemische shunt 
(TIPS) plaatsing versus endoscopische rubberbandligatie (EVL) 
vergeleken in de secundaire preventie van gastro-oesofageale 
bloedingen. Directe medische kosten van 52 opeenvolgende 
patiënten (25 TIPS / 27 EVL) in het eerste jaar na de eerste bloeding 
werden berekend. De hoogste kosten werden gevonden in de TIPS 
groep (gemiddelde kosten per patiënt € 27.746 vs € 16.818 voor de 
EVL groep), als gevolg van hogere personeelskosten, uitrusting-, 
materiaal- en huisvestingskosten. 
In het laatste hoofdstuk 9 worden de belangrijkste bevindin-
gen uit de voorgaande hoofdstukken in dit proefschrift samengevat 
en worden aanbevelingen voor toekomstig onderzoek beschreven.
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